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Summary 
Human T-lymphotropic virus Type 1 (HTLV-1) is a retrovirus that persists lifelong in the 
host. In ~4% of infected people, HTLV-1 causes a chronic disabling neuroinflammatory 
disease known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). 
The pathogenesis of HAM/TSP is unknown and treatment remains ineffective.  In this study 
we aimed to identify patterns in frequencies of peripheral leukocyte populations and blood 
gene expression profiles of HTLV-1 carriers that suggest new hypotheses as to the 
mechanisms of HTLV-1 persistence and HAM/TSP pathology. 
Flow cytometric immunophenotyping of peripheral blood leukocytes revealed abnormal 
activation and maturation profiles of effector T cells but not antigen-presenting cells. High 
frequencies of circulating granzyme and perforin-rich CD8
+
 T cells were associated with an 
increased probability of HAM/TSP. However, the cytolytic capacity of these T cells is not 
known as although they accumulated cytolytic proteins, granzyme mRNA levels were down-
regulated in patients with HAM/TSP. Furthermore, presence of HAM/TSP was associated 
with an expansion of CD56-negative NK cells, which are thought to have decreased cytolytic 
functions.  
Blood gene expression profiles identified perturbations of the p53 signalling pathway as a 
hallmark of HTLV-1 infection. In contrast, a subset of interferon (IFN)-stimulated genes was 
over-expressed in patients with HAM/TSP but not in asymptomatic HTLV-1 carriers or 
patients with the clinically similar disease multiple sclerosis. The IFN-inducible signature was 
present in all circulating leukocytes and its intensity correlated with the clinical severity of 
HAM/TSP. Leukocytes from patients with HAM/TSP were primed to respond strongly to 
stimulation with exogenous IFN. However, while type I IFN suppressed expression of the 
HTLV-1 structural protein Gag it failed to suppress the highly immunogenic viral 
transcriptional transactivator Tax.  
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Based on our findings we hypothesise that impaired NK cell and T cell-mediated immune 
responses result in high HTLV-1 proviral loads but that the over-expression of a subset of 
IFN-stimulated genes contributes to the development of HAM/TSP.  
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Chapter 1 – Introduction 
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In 1980 the human T lymphotropic virus type 1 (HTLV-1) was isolated as the first human 
retrovirus by R. C. Gallo and colleagues (Poiesz et al, 1980). Due to the absence of viral 
particles in the plasma of infected individuals, HTLV-1 was long assumed to reside latent in 
the host (Cavrois et al, 1996; Etoh et al, 1997; Eiraku et al, 1998). However, evidence now 
points towards a highly dynamic interaction between the virus and the host immune system 
that determines the risk of HTLV-1-associated diseases (Bangham, 2003). 
 
1.1 Epidemiology and Transmission 
 
Persistent infection with the human T lymphotropic virus type 1 (HTLV-1) is widespread in 
the tropics and subtropics, i.e. south western Japan, the Caribbean, Central and South 
America and intertropical Africa (De The & Bomford, 1993; Proietti et al, 2005). The current 
global burden of HTLV-1 infection is unknown as the widely cited estimate of 10 to 20 
million infected people worldwide dates back to studies that are now more than 25 years old 
(Hlela et al, 2009). In mainland UK about 20,000 individuals carry the virus and most HTLV-
1 diagnoses are associated with the Caribbean by birthplace or ethnicity (Dougan et al, 2004; 
Payne et al, 2004; Davison et al, 2009). 
Diagnosis of HTLV-1 infection is based on Western blots for HTLV-1-specific antibodies 
and the presence of the virus is subsequently confirmed and the proviral load measured by 
quantitative polymerase chain reaction (Davison et al, 2009). Screening for HTLV-1 in blood 
donations at UK blood centres was introduced in 2002 and the risk of an infected donation 
entering the blood supply was estimated at 0.11 per million donations (Davison et al, 2009). 
HTLV-1 is transmitted between individuals via breast milk, semen or blood (Zaninovic, 1986; 
Osame et al, 1987; Gout et al, 1990; Stuver et al, 1993). While the majority of infected 
individuals remain disease-free asymptomatic carriers (AC), approximately 2-3% develop a 
fatal adult T cell leukaemia/lymphoma (ATLL) and another 2-3% chronic progressive 
 21 
encephalomyelopathy termed HTLV-1-associated myelopathy/tropical spastic paraparesis 
(HAM/TSP) (Nagai & Osame, 2003). Usually, HAM/TSP or ATLL develop after a long 
clinically asymptomatic latency. In Japan, the mean onset of ATLL was 60 years and it has 
been proposed that the decline of the immune system with age contributes the onset of 
HTLV-1-associated diseases (Nakagawa et al, 1995; Arisawa et al, 2000).  
It is not understood how the virus causes the onset of such diverse diseases. In the early 90s 
extensive sequencing efforts have been made to associate distinct strains of HTLV-1 with 
each of the diseases (Daenke et al, 1990; Komurian et al, 1991; Ono et al, 1994; Beby-Defaux 
et al, 1999; Sambor et al, 1999). There are three genotypes of HTLV-1: Melanesian, Central 
African and Cosmopolitan with four subtypes of the Cosmopolitan group: Transcontinental, 
Japanese, Western African and North African (Knipe et al, 2007). Furukawa and colleagues 
found that individuals infected with the Cosmopolitan subgroup A variant of HTLV-1 had a 
slightly higher risk of HAM/TSP; however, no definite strain has been exclusively associated 
with the neurological disease (Furukawa et al, 2000). 
There is currently no HTLV-1 vaccine available and therapy does not extend beyond the 
treatment of disease-related symptoms. 
 
1.2 Molecular virology 
 
HTLV-1 is a complex retrovirus with a diploid, positive-sense RNA genome (reviewed in 
(Kashanchi & Brady, 2005). With only 9 kb the HTLV-1 genome is relatively small; 
however, the virus encodes multiple proteins by using both RNA strands and accessing 
several open reading frames (ORFs).  
HTLV-1 gene products have been demonstrated to regulate viral as well as host gene 
expression and contribute to viral persistence and most likely pathogenesis in HTLV-1 
infection. Similar to other retroviruses, HTLV-1 encodes a series of structural (Gag, Env) and 
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enzymatic proteins (reverse transcriptase, integrase, protease) flanked by long terminal 
repeats (LTRs). Located between Env and the 3’LTR the HTLV-1 genome comprises a 
unique pX region that encodes the regulatory genes Tax and Rex as well as the accessory 
proteins p12
I
, p13
II
 and p30
II
. In 2002, Gaudray and colleagues identified an additional open 
reading frame located in the pX region of the complementary RNA strand (Gaudray et al, 
2002). Its protein product comprises a C-terminal basic leucin zipper (bZIP) and was 
therefore named HTLV-1 bZIP factor, abbreviated as HBZ. Thus, while all other viral 
proteins are under the control of a promoter located at the 5’ LTR end, HBZ is controlled by a 
promoter comprising the 3’LTR and is therefore transcribed in antisense. 
 
 
 
 
 
Figure 1. Organisation of the HTLV-1 genome.  
Figure from (Boxus & Willems, 2009). 
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1.2.1 Gag 
The classical retroviral proteins Gag, Pro and Pol are translated from a primary full length 
mRNA transcript and ribosomal frameshifts result in the production of Gag-Pro and Gag-Pro-
Pol fusion proteins, which are then subject to proteolytic cleavage (Nam et al, 1993). Gag 
encodes the structural proteins Matrix, Capsid and Nucleocapsid that form the structural core 
of the HTLV-1 virion. 
1.2.2 Env 
HTLV-1 Env protein is transcribed as a singly spliced transcript. It is a heterodimer of 
transmembrane and surface subunit proteins, which assemble to the outer capsid of the 
HTLV-1 particle (Delamarre et al, 1996). Similar to other retroviral Env proteins, HTLV-1 
Env enhances viral infectivity by mediating receptor binding and membrane fusion of the 
viral particle with the cellular membranes.  
1.2.3 Tax 
HTLV-1 Tax is a pleiotropic transactivator that is essential to the viral life cycle and the best 
studied of all HTLV-1 proteins. Tax regulates viral transcription by interacting with triplicate 
enhancer elements in the viral genome (TxRE; Tax-responsive element) (Tan et al, 1989). 
However, Tax does not bind directly to specific DNA sequences but instead initiates the 
transcription by recruiting various transcription factors to the LTR or promoters in the host 
genome (reviewed in (Grassmann et al, 2005; Marriott & Semmes, 2005)). For example, Tax 
has been shown to interact with cellular pathways involving nuclear NF-B (factor-kappa B), 
AP1 (activator protein 1) and CREB/ATF2 (cyclic AMP-responsive element-binding factor/ 
activating transcription factor).   
Tax functions range from triggering of multiple signaling pathways to overriding of cell cycle 
check points and inhibition of DNA repair. Tax expression promotes cell proliferation and its 
oncogenic potential was demonstrated by its ability to immortalize cell lines in vitro 
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(Grassmann et al, 1989) and to promote the growth of tumours in mice in vivo (Pozzatti et al, 
1990).  
It has been hypothesised that Tax exerts all of these diverse functions by interacting with 
hundreds of cellular proteins (Boxus et al, 2008). Indeed, several Tax-binding partners have 
been reported and a series of studies demonstrated that Tax is subject to post-translational 
modification including sumoylation, poly-ubiquitination, phosphorylation and acetylation, 
each of which alters its binding affinities and functions (reviewed in (Shembade & Harhaj, 
2010)). However, a caveat of these studies is that they mostly relied on in vitro models 
involving over-expression of Tax from plasmids in transfected cell lines. It is therefore likely 
that a number of these studies report in vitro artefacts of potential Tax-protein-complexes that 
may never occur under physiological condensations when there is competition for a limited 
number of Tax molecules. 
1.2.4 Rex 
HTLV-1 Rex is a second positive regulator of viral expression (reviewed in (Baydoun et al, 
2008)). In contrast to Tax, Rex acts at the post-transcriptional level by binding to specific cis-
regulatory sequences in viral mRNAs (Seiki et al, 1988). The Rex protein is able to shuttle in 
and out of the nucleus and Rex function stabilises mRNAs, stimulates the export of viral 
mRNAs and ultimately controls the ratio of spliced to non-spliced viral mRNAs.  
1.2.5 HBZ 
The HBZ gene is consistently transcribed in primary ATL cells; in contrast Tax is only 
detected in 40% of leukaemic cells (Takeda et al, 2004; Satou et al, 2006). Experiments with 
non-functional HBZ mutants demonstrated that although HBZ is dispensable for T cell 
transformation in vitro, cells lacking functional HBZ have a low proliferative capacity in vivo 
(Arnold et al, 2006). Similarly, suppression of HBZ expression by small interfering RNAs 
inhibited the proliferation of infected T cell lines (Satou et al, 2006). Thus, HBZ has been 
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suggested as a key player in ATLL. However, HBZ may also contribute to pathology in 
HAM/TSP: HBZ mRNA abundance was reported to correlate with HTLV-1 proviral load and 
the disease severity in patients with HAM/TSP (Saito et al, 2009).  
Via its bZIP domain the HBZ protein interacts with several transcription factors, e.g. AP1, 
JunD and JunB; which depending on the binding partner results in activation or inhibition of 
cellular gene transcription (reviewed in (Matsuoka, 2010)). Furthermore, HBZ acts as a 
counterpart to Tax and can suppress Tax-mediated gene expression by preventing the CREB-
2 from binding to the TxRE in the HTLV-1 LTR region (Gaudray et al, 2002). 
In 2006, Satou et al. demonstrated that HBZ mRNA rather than protein mediates the growth-
promoting effect observed in vitro (Satou et al, 2006). They introduced codon mutations in 
the HBZ gene that retained the amino acid sequence of the wild type protein but significantly 
altered the mRNA structure. This mutant did not induce proliferation of transfected cells 
suggesting that the secondary structure of HBZ mediated the effect on cell growth.  
1.2.6 p30II 
In contrast to Tax and Rex, HTLV-1 p30
II
 is a negative transcriptional and post-
transcriptional regulator of viral expression. It has been suggested that the function of p30
II
 is 
dependent on its concentration, i.e. at high concentrations p30
II
 prevents viral replication by 
binding to Tax-Rex mRNAs and retaining them in the nucleus (Nicot et al, 2004); at low 
concentration p30
II
 functions as a transcription factor by modulating CREB-responsive 
promoters, and is critical for maintenance of proviral loads in rabbits (Zhang et al, 2000). 
1.2.7 p12I 
HTLV-1 p12
I
 expression has been demonstrated to increase the proliferative capacity of 
infected cells. Binding of p12
I
 to the IL-2 receptor enhances the recruitment and activation of 
downstream signaling molecules, which in turn reduces the threshold for T cell proliferation 
in response to IL-2 stimulation (Mulloy et al, 1996; Nicot et al, 2001). Furthermore, HTLV-1 
 26 
p12
I
 has been suggested to contribute to immune evasion of infected cells by binding to 
MHC-I heavy chains and targeting them for proteasomal degradation (Johnson et al, 2001).  
1.2.8 p13II 
HTLV-1 p13
II
 can be detected in the nucleus of infected cells but is primarily targeted to 
mitrochondria (Koralnik et al, 1993; Ciminale et al, 1999). Mitochondria have important 
function in cellular energy production, cell death and calcium homeostasis. Expression of 
p13
II
 in vitro is associated with alterations in mitrochondrial morphology and metabolism 
(Ciminale et al, 1999). Thus, it has been suggested that p13
II
 has a role in apoptosis and 
activation of calcium-dependent transcription factors (D'Agostino et al, 2002; Silic-Benussi et 
al, 2004).  
 
1.3 Molecular Basis of Infection and Viral Spread 
 
HTLV-1 is an exogenous retrovirus that upon cellular entry integrates itself into the host 
genome. No free HTLV-1 viral particles are detected in patient serum and about 90–95% of 
the proviral load, i.e. the percentage of circulating peripheral blood mononuclear cells 
(PBMCs) that carry the provirus, is carried by CD4
+
 and 5–10% by CD8+ T cells (Richardson 
et al, 1990; Hanon et al, 2000). The proviral load ‘set point’ within one individual remains 
relatively stable over time but varies greatly between infected individuals (Matsuzaki et al, 
2001). A high proviral load is associated with an increased risk of HTLV-1-associated 
diseases such as HAM/TSP (Nagai et al, 1998). 
To persist within the host lymphocytes, the virus pursues two strategies: (i) proliferation of 
infected cells, therefore passing on the provirus to all daughter cell generations or (ii) 
infectious spread via the virological synapse resulting in de novo infection of lymphocytes 
(Cavrois et al, 1996; Igakura et al, 2003). In the latter case up-regulation of cell adhesion 
molecules (ICAM-1) facilitates and prolongs cell-cell contact which triggers the reorientation 
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of the microtubule organizing centre of the HTLV-1 infected cell toward the cell-cell junction 
into which virus particles are secreted (Fukudome et al, 1992; Nejmeddine et al, 2005). 
Indeed, in an in vitro model of cell-to-cell spread, Mazurov and colleagues demonstrated that 
co-culture of HTLV-1-transfected T cells with target CD4
+
 T cells enhanced infection rates 
by ten thousand fold, demonstrating that HTLV-1 has developed efficient molecular 
mechanisms that allow rapid cell-to-cell spread (Mazurov et al, 2010). In comparison, in the 
same in vitro model HIV infection rates only doubled.  
It is thought that the bulk of HTLV-1 proviral is maintained via the mitotic route (Wattel et al, 
1995) but the expression of viral proteins is required for both actively driving the proliferation 
of infected cells and HTLV-1 spread via the virological synapse (Asquith & Bangham, 2008).  
In 2007, Meekings et al. demonstrated an association between proviral expression and 
genomic location of the viral integration site (Meekings et al, 2008). In individuals with high 
rates of proviral expression, HTLV-1 was frequently integrated in transcriptionally active 
units of the genome. Indeed, the size of an HTLV-1 clone increased with its proximity to CpG 
islands, host genes, and activating epigenetic marks (Gillet et al, 2011). In ACs the provirus 
was predominantly integrated in transcriptionally silenced parts of the genome, while 
integration into transcriptionally active units and subsequently increased expression of the 
provirus was associated with HAM/TSP. 
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1.4 Immune response to HTLV-1 infection 
 
HTLV-1 infection is characterised by a strong humoral and cellular immune response against 
the virus. High titres of HTLV-1-specific antibodies are detected in ACs and patients with 
HAM/TSP, however, their relative contribution to the immune control of the infection is not 
known (Jacobson et al, 1990a; Nagasato et al, 1991; Kira et al, 1992; Nagai et al, 1998b)  
HTLV-1-specific CD8
+
 T cells are highly abundant and chronically activated in ACs and 
patients with HAM/TSP (Jacobson et al, 1990b; Kannagi et al, 1991). The Tax protein is the 
immunodominant antigen recognised by CD8
+
 T cells in HTLV-1 carriers (Goon et al, 2004). 
However, despite their ability to kill HTLV-1-infected target cells ex vivo they fail to 
eradicate the virus (Parker et al, 1992; Parker et al, 1994). The finding that the frequency of 
these HTLV-1-specific T cells positively correlates with proviral has led to the suggestion 
that these cytotoxic T cells (CTLs) are not able to limit HTLV-1 replication and may in fact 
be responsible for the tissue damage observed in HAM/TSP (see models of HAM/TSP 
pathogenesis below) (Kubota et al, 2000a; Kubota et al, 2000b; Jacobson, 2002). 
However, several lines of evidence suggest that a strong CTL response controls HTLV-1 
proviral and can decrease the risk of disease:  
(i) the MHC class I genotypes HLA-A*02 and –Cw*08 confer protection from HAM/TSP in 
a population with endemic HTLV-1 infection in southern Japan (Jeffery et al, 1999); 
(ii) high mRNA levels of cytotoxic genes in CD8
+
 T cells are associated with a low HTLV-1 
proviral load (Vine et al, 2004); 
(iii) CTLs spontaneously kill autologous HTLV-1-expressing cells ex vivo (Hanon et al, 
2000a; Asquith et al, 2005); 
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(vi) Tax coding sequences are more variable in ACs than HAM/TSP suggesting that CTLs 
exert a strong selection pressure on the viral genome at least in ACs (Niewiesk et al, 1994; 
Kubota et al, 2007). 
However, a beneficial role of an efficient CTL response in ACs does not exclude a 
detrimental effect of HTLV-1-specific CTLs in HAM/TSP pathogenesis. Indeed, a 
simultaneously protective role and a pathogenic role of CTL-mediated immune responses has 
been recognized for other viral infections (Klenerman & Zinkernagel, 1997).  
 
1.5 Associated diseases 
1.5.1 HTLV-1-associated myelopathy 
In 1888 Strachan first described a neurological disorder prevalent in the West Indies, which 
was initially attributed to dietary deficiencies. In 1956 Cruickshank revised the existing 
evidence of the disorder and renamed it “tropical spastic paraparesis” (TSP) based on its 
neurological symptoms and the geographic distribution of known cases (Cruickshank, 1956) .  
Following the discovery of HTLV-1 as the etiological agent of ATLL in 1981, Gessain and 
colleagues identified antibodies against the virus in plasma samples from patients with TSP 
from Martinique (Gessain et al, 1985). Shortly thereafter Osame and colleagues linked 
HTLV-1 infection to a neurological syndrome prevalent in south-western Japan and termed it 
HTLV-1-associated myelopathy (HAM) (Osame et al, 1986). In 1988 the World Health 
Organisation recognized both diseases as the same and subsequently published guidelines for 
HAM/TSP diagnosis (Osame, 1990). 
HAM/TSP is a chronic, progressive inflammatory disease of the CNS that usually develops 
only after decades of clinical latency. Patients most commonly present with paraparesis of the 
lower limbs, lumbar pain, sensory losses and disturbances of bladder or bowel function 
(Nagai & Osame, 2003; Hauser & Oksenberg, 2006). The clinical phenotype of HAM/TSP 
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resembles that of primary progressive multiple sclerosis and the patient’s health declines 
gradually without remission. The major initial symptom is gait disturbance (63% of patients), 
followed by urinary dysfunction (33% of patients) (Nakagawa et al, 1995); however, the 
clinical severity of HAM/TSP and pace of disease progression can vary significantly between 
individuals.  
The lifetime risk for developing HAM/TSP is between 0.25-4% (Kaplan et al, 1990). A 
comprehensive study by Nakagawa et al. of clinical and laboratory findings in a cohort of 231 
individuals with HAM/TSP from Kagoshima, Japan, reported a relationship between certain 
clinical features and age of onset and mode of transmission. The mean age of onset was 
reported to be 44  17 years and individuals who had been infected with HTLV-1 by blood 
transfusion progressed more rapidly.  
Neuropathological findings in autopsied cases of patients with HAM/TSP revealed a severe 
involvement of the thoracic spinal cord, where mononuclear cell infiltration was accompanied 
by myelin and axonal destruction (Akizuki et al, 1987; Aye et al, 2000). These thoracic spinal 
cord lesions contain perivascular cuffs of inflammatory cells, comprising CD4
+ 
cells, CD8
+
 T 
cells and monocytes (Moore et al, 1989; Umehara et al, 1993). The distribution and activity of 
these cells appears to change with disease duration. Early, active lesions are characterised by 
the presence of both CD4
+
 and CD8
+
 T cells and high levels of pro-inflammatory cytokines 
such as TNF-α, IL-1β and IFN-γ (Iwasaki et al, 1992b; Umehara et al, 1993; Umehara et al, 
1994). In contrast, lesions in patients with prolonged duration of HAM/TSP had an increased 
CD8
+
 to CD4
+
 T cell ratio and low expression levels of pro-inflammatory cytokines (Iwasaki 
et al, 1992b; Umehara et al, 1993; Umehara et al, 1994). HTLV-1 proviral DNA was detected 
in the lesions and correlated with the frequency of infiltrating CD4
+
 T cells (Hashimoto et al, 
1994; Kubota et al, 1994). There is no in vivo evidence for HTLV-1 infection of neurons or 
astrocytes.  
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Clinical management of HAM/TSP is challenging because there is currently no proven 
effective or curative treatment available (reviewed in (Martin & Taylor, 2011)). Development 
of therapeutic strategies is hindered by our lack of understanding of HAM/TSP pathogenesis. 
Over the past three decades a variety of interventions have been tried; however, the majority 
of the evidence remains anecdotal due to small sample sizes and lack of appropriate clinical 
controls.  
Observational studies with corticosteroids reported some short-term relief in patients with 
early disease (Nakagawa et al, 1996). Some success was reported in treatment with the 
nucleoside reverse transcriptase inhibitor zidovudine; however, the results were not 
reproducible (Matsushita et al, 1987; Gout et al, 1991; Sheremata et al, 1993; Taylor et al, 
2006). Monoclonal antibody therapy targeting CD25 that is strongly up-regulated HTLV-1-
expressing cells and anti-CD122 (the IL-15 receptor ) show some promise (Lehky et al, 
1998; Oh et al, 2009). A recent small-scale trial with cyclosporine A reported a reduction in 
HTLV-1 proviral load that correlated with clinical improvement in 5 out of 7 patients (Martin 
et al, 2009). Therapy with type I interferon resulted in mild improvement in some patients 
(Izumo et al, 1996; Yamasaki et al, 1997; Saito et al, 2004). However, a recent study 
assessing the safety and efficacy of the treatment in Japan reported that although the response 
rate was good (after four weeks 66% of patient mildly, moderately or markedly improved) the 
frequency of adverse events was very high (536 events reported in 46 patients, 46 classified 
as severe) (Arimura et al, 2007).  
 
1.5.2 Adult T cell leukaemia/lymphoma  
ATLL is an aggressive malignancy of HTLV-1-infected peripheral CD4
+
 T-cells (reviewed in 
(Goncalves et al, 2010). HTLV-1 Tax is a powerful transactivator that interferes with many 
signaling pathways that control gene transcription and cell cycle progression. In some cells 
the molecular actions of Tax can override cell cycle arrest and promote proliferation even in 
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the presence of chromosomal abnormalities.  This can result in the accumulation of genomic 
abnormalities that result in cell transformation and the emergence of a malignant clone. 
Abnormal lymphocytes can present with characteristic multilobular nuclei termed “flower 
cells”. 
The lifetime risk of ATLL is estimated between 2-5% in HTLV-1 carriers (Kondo et al, 
1989). The majority of patients with ATLL present with lymphadenopathy, 
hepatosplenomegaly, osteolytic bone lesions due to hypercalcaemia and skin involvement 
(Shimoyama, 1991). There are four clinical subtypes of ATLL: acute, lymphomatous, 
chronic, and smouldering (Shimoyama, 1991). Patients with chronic ATLL and smouldering 
subtypes have a relatively good prognosis while for acute ATLL the median survival time 
after diagnosis is only 6 months (Yamaguchi & Watanabe, 2002). However, some treatment 
progress has been made recently with a combination of IFN- plus zidovudine, supplemented 
with arsenic trioxide and (Kchour et al, 2009). 
 
1.5.3 Other inflammatory diseases 
HTLV-1 infection has been associated with a variety of minor inflammatory diseases: uveitis 
(Mochizuki et al, 1992a; Mochizuki et al, 1992b; Sato et al, 1994a), polymyositis (Morgan et 
al, 1989) and Sjögren’s syndrome (Vernant et al, 1987). Moreover, HTLV-1 carriers are more 
susceptible to certain opportunistic bacterial and helminth infections (reviewed in (Marsh, 
1996)); i.e. tuberculosis (infection with Mycobacterium tuberculosis; (Tachibana et al, 1988; 
Hanada et al, 1989; Murai et al, 1990; Welles et al, 1994)), strongyloidiasis ( infection with 
Strongyloides stercoralis; (Nakada et al, 1984; Hanada et al, 1989; Sato et al, 1994b) ) and  
infectious dermatitis (superinfection with Staphylococcus and Streptococcus species; 
(LaGrenade et al, 1990)). 
 
 33 
1.6 Models of HAM/TSP pathogenesis 
 
To date the best predictor of HAM/TSP is a high HTLV-1 proviral load (Nagai et al, 1998). 
Indeed, the risk of HAM/TSP rises exponentially after the proviral load reaches a threshold of 
1% of PBMCs. Thus, factors that control HTLV-1 proviral load are of central interest to 
investigations into HAM/TSP pathogenesis. However, there are two major caveats arising 
from the association between HTLV-1 proviral load and HAM/TSP: (i) there is a significant 
overlap between proviral loads in ACs and patients with HAM/TSP, suggesting that there are 
other factors in addition to proviral load that contribute to HAM/TSP pathogenesis; (ii) 
experimental studies have to be normalised for differences in proviral loads between patients 
to avoid biasing results towards factors that just passively follow proviral load.  
Despite significant research efforts in the past 30 years many questions in HAM/TSP 
pathogenesis remain open. For example, it is not known why HTLV-1-infected T cells in 
certain infected individuals cross the blood-brain-barrier, where they are presumed to cause 
the tissue damage observed in HAM/TSP. Furthermore, the sequence and nature of events 
that lead to the observed inflammation and neuronal damage are not clear. Several models 
were postulated to explain how HTLV-1 infection could trigger inflammatory processes in the 
CNS (reviewed in (Takenouchi et al, 2004; Lepoutre et al, 2009)): 
(i) Direct damage model. HTLV-1-specific CD8
+
 T cells follow infected CD4
+
 T cells and 
infiltrate the CNS. Here, targeted lysis of infected CD4
+
 T cells or infected CNS cells results 
in axonal damage (Levin et al, 1995). 
(ii) Bystander damage model. Secretion of pro-inflammatory cytokines by activated CTLs or 
HTLV-1 infected CD4
+
 T cells increases local cytokine concentrations in the CNS. This may 
activate other either resident or infiltrating cell populations in the vicinity, thus further 
augmenting immune responses that damage neurons (Jacobson, 2002).  
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(iii) Autoimmunity due to molecular mimicry. Levin and colleagues demonstrated that serum 
IgG isolated from patients with HAM/TSP but not ACs bound to the heterogeneous nuclear 
ribonuclear protein A (hnRNP-A1) on neurons and antibodies to hnRNP-A1 were found to be 
cross-reactive with HTLV-1-Tax protein (Levin et al, 2002). This has led to the hypothesis 
that Tax-specific autoantibodies disrupt neuronal function in the CNS.   
While there is evidence for all models, their relative contribution to HAM/TSP pathogenesis 
is not known. Furthermore, they fail to explain why only a minority of infected individuals 
develop HAM/TSP and why the disease emerges often only after many years of clinical 
latency. Thus, despite our deepening understanding of the immune control of HTLV-1 
replication, our knowledge about the mechanism of HAM/TSP pathogenesis remains 
fragmented.  
A global approach that documents the anti-HTLV-1 immune responses in ACs and patients 
with HAM/TSP could help to link existing findings as well as provide crucial insights into the 
mechanisms that determine the outcome of HTLV-1 infection. 
 
1.7 Animal model for HAM/TSP 
 
In the past 30 years several attempts have been made to generate suitable animals models for 
HTLV-1 infection and associated diseases (reviewed in (Lairmore et al, 2005)). Experimental 
infection with HTLV-1 was successful in rabbits (Akagi et al, 1985; Lairmore et al, 1992), 
some non-human primates (Nakamura et al, 1987; Murata et al, 1996) and rats (Suga et al, 
1991; Ibrahim et al, 1994). However, establishing an animal model that mirrors the clinical 
phenotype of human HTLV-1-associated diseases has been problematic: although all animal 
models can become persistently infected with HTLV-1 they do not reliably develop disease 
following infection. 
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So far only one specific strain of rats, the Wistar-King-Aptekman-Hokudai (WKAH) strain, 
develops a neurological disorder, when infected with HTLV-1-producing cells, which 
resembles HAM/TSP in some respects (Ishiguro et al, 1992; Kushida et al, 1993; Ibrahim et 
al, 1994). Onset of spastic paraparesis in infected animals is evident after 7 months when 
apoptosis of oligodendrocytes in the thoracic spinal cord coincides with an increase of TNF 
in the CNS and peaking expression levels of HTLV-1 pX region (Ohya et al, 1997; Ohya et 
al, 2000). After 15 months post infection animals have developed chronic progressive 
paraparesis of the hind legs. Although the neurological symptoms developed by WKAH-rats 
are similar to that of HAM/TSP, there are extensive histological differences in the cellular 
composition of the thoracic lesions. The T lymphocytic infiltrates observed in humans are 
markedly absent in rats (Yoshiki, 1995; Jacobson, 2002); instead, apoptosis of 
oligodendrocytes is followed by infiltration of activated macrophages (Yoshiki, 1995). Also, 
it should be noted that whilst T lymphocytes are the main cellular reservoir of HTLV-1 in 
humans; in rats macrophages and microglia carry the majority of the proviral load (Kasai et 
al, 1999).  
These fundamental differences between HTLV-1-induced myelopathy in rats and humans 
suggest different molecular origins of the diseases; thus, observations made in the rat model 
may not be applicable to the human system. 
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1.8 Hypotheses and aims  
 
The central aim of this study was to identify molecules, pathways and cell types that are 
associated with HAM/TSP pathology to fuel new hypotheses as to the pathogenesis of the 
inflammatory disease. 
More specifically, we aimed to test the hypotheses that: 
 The frequency of total, mature and/or activated monocytes, neutrophils, dendritic 
cells, B cells, T cells and NK cells is altered in HTLV-1 infection and further 
distinguishes patients with HAM/TSP from HTLV-1 asymptomatic carriers.   
 The frequency of perforin-, granzyme A- and granzyme B-expressing T cells is a 
factor that determines the probability of HAM/TSP. 
 HTLV-1 infected asymptomatic carriers, patients with HAM/TSP and uninfected 
individuals can be distinguished at the transcriptional level by gene expression 
patterns in their whole blood immune cells.  
 Variances in the transcriptional profiles of these individuals are related to HTLV-1 
infection and differences in clinical disease status. 
 The expression levels of a subset of genes that differ between HAM/TSP patients and 
HTLV-1 asymptomatic carriers are independent of HTLV-1 proviral load. These 
genes may be cause or consequence of HAM/TSP disease manifestation. 
 The thereby identified genes are involved in pathways that counteract HTLV-1 
replication and/or are associated with HAM/TSP pathology and pathogenesis.  
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Chapter 2 – Materials & Methods 
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2.1 Enrolment criteria, sample collection and disease severity score 
2.1.1 Enrolment criteria 
Ethical approval for this study was obtained as follows: IRB approval numbers: St Mary’s 
NHS Trust Local Research Committee EC no. 02.31 (27.06.2002); National Research Ethics 
Service, Oxfordshire REC C no. 09/H0606/106 (16.11.2009). 
A total of 74 subjects consisting of 57 HTLV-1-positive and 17 uninfected control subjects 
were recruited for this study. All patients attended the HTLV-1 clinic at St Mary's Hospital, 
London, UK and had given their written informed consent. Patients had previously tested 
negative for co-infections with HCV, HBV and HIV and did not receive pharmaceutical 
treatment for HTLV-1-related diseases for at least 6 months prior to sample collection. 
HAM/TSP in HTLV-1 carriers was diagnosed according to the criteria specified in the World 
Health Organisation (WHO) guidelines (Osame, 1990). 
For the purpose of this study, individuals were grouped according to their HTLV-1 status and 
clinical profile into 3 categories: uninfected subjects, patients with HAM/TSP and ACs 
(healthy carriers). For microarray analysis patients were divided into training and test set 
cohorts (Figure 2). 
For further analysis ACs were subdivided according to their level of HTLV-1 proviral load in 
peripheral mononuclear cells (PBMCs) into ACs with high proviral load (≥ 1% PBMCs) or 
low proviral load (< 1% PBMCs).  
  
 39 
 
Figure 2. Participant recruitment for the microarray training and test set.  
Study participants were recruited at the National Centre for Human Retrovirology at St Mary’s 
Hospital in London, UK. All subjects had to meet the following criteria: confirmed HTLV-1 
seropositive or seronegative status, received no pharmaceutical treatment for HTLV-1-related diseases 
for at least 6 months, had no known inflammatory comorbidities and tested negative for co-infections 
with HCV, HBV and HIV. Blood samples from patients in the (A) training and (B) test set were 
collected sequentially and processed independently. 
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2.1.2 Sample collection 
A total of 52 ml of blood was donated by each individual:  3 ml of blood were drawn directly 
into each of 2 Tempus vacutainer tubes (Applied Biosystems, Foster City, CA, USA) 
containing an RNA stabilization solution. Samples were mixed by vigorously shaking the 
tubes for 15 sec and stored at -80°C before RNA extraction for the microarray. A total of 10 
ml heparin-coagulated blood was used for flow cytometric analysis and separation of serum 
by centrifugation. PBMCs were purified by density centrifugation on Histopaque (Sigma, 
Poole, UK) from a further 25 ml of EDTA-coagulated blood and subsequently cryopreserved 
in liquid nitrogen.  
 
2.1.3 Clinical severity of HAM/TSP  
Clinical records of patients with HAM/TSP documented patients’ performance in the 10 
Meter Timed Walk Test on the day of blood sampling. This test documents the time taken by 
patients to walk 10 m on a flat, clear surface, with or without a walking aid (Martin et al, 
2010). Healthy individuals aged 50-79 years are able to complete the course in under 8 
seconds (Bohannon et al, 1996). Consequently the extent of deterioration of mobility in 
patients with HAM/TSP was categorized as ‘mild’ (8-15 s; n=5), ‘moderate’ (16-30 s; n=6) or 
‘severe’ (>30 s or use of a wheelchair; n=6). 
 
2.2 HTLV-1 proviral load measurement 
 
DNA was extracted from 2 x 10
6 
PBMCs and eluted in 100 l PCR-grade H2O using a Qiagen 
DNAeasy Tissue kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany). 
DNA concentration was measured on a NanoDrop 100 (ThermoScientific, NJ, USA) and 
quantitative real time PCR was performed on 1 g DNA. DNA was amplified for HTLV-1 
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and genomic DNA using primers specific to HTLV-1 Tax and -actin and in two separate 
reactions (Tosswill et al, 1998). Amplified DNA was detected using a Roche light cycler 
measuring SYBR Green I incorporation (Roche, Mannheim, Germany). Standard curves were 
generated using the rat cell line Tarl2, which contains 1 copy per cell of HTLV-1 provirus 
(Nagai et al, 1998). The sample copy number was estimated from by interpolation from the 
standard curve and expressed as percentage of PBMCs, assuming one copy of HTLV-1 
provirus per cell. 
 
2.3 Flow Cytometric immunophenotyping of peripheral leukocyte 
populations 
 
2.3.1 Staining of peripheral blood leukocytes 
A total of 200 µl of fresh heparinised blood was incubated with a mix of monoclonal 
antibodies corresponding to well-characterised markers of antigen-presenting and effector cell 
populations (Table 1). Samples were incubated for 15 min at room temperature (RT) in the 
dark. Erythrocytes were lysed with 2 ml BD FACS
TM
 Lysing solution (BD Biosciences, 
Breda, The Netherlands) following the manufacturer’s instructions. Cells were fixed with 
0.5% paraformaldehyde (PFA) and kept at 4°C in the dark until analysis on a CyAn
TM
 ADP 
flow cytometer (Beckman Coulter, Marseille, France).  
An intracellular staining step was required for granzyme A (GrzA), B (GrzB) and perforin 
(Per) staining. After the lysis of red blood cells, samples were fixed with the Cytofix-
Cytoperm kit (BD Biosciences,) and stained intracellularly with the monoclonal antibodies 
following the manufacturer’s protocol. 
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Table 1. List of monoclonal antibodies. 
Fluorophores Blood 
DCs 
Monocytes & 
Neutrophils 
B Cells & 
NK cells 
T cell subsets 
FITC Lin1* CD86 IgD --- Perforin 
PE CD123 --- CD56 --- GrzA 
ECD --- CD14 CD19 CD45RA CD4 
PerCP-Cy5.5 --- CD62L CD20 CD62L --- 
APC/A647 DCIR CD16 CD27 γδ TCR GrzB 
PE-Cy7 PD-L1 CD11b CD16 CCR7 CD3 
APC-
H7/A647 
HLA-DR HLA-DR CD3 CD8 --- 
PacOrange CD45 CD45 CD45 CD3 CD45 
PacBlue/V450 CD11c --- CD8 CD4 CD8 
*Lineage marker: CD3, CD14, CD16, CD19, CD20, CD56 
 
2.3.2 Gating strategies 
We employed a CD45 gating strategy to separate leukocytes from debris. CD45 is a member 
of the tyrosine phosphatase family of molecules and is expressed on the surface of all 
leukocyte populations. Thus, the number of CD45
+
 cells can be used as a common 
denominator: subsequent cell populations can be expressed as percentage of CD45
+
 
leukocytes, i.e. percentage of all white blood cells. Individual gating strategies are illustrated 
as follows: DCs (Figure 3), monocytes and neutrophils (Figure 4), B cells and NK cells 
(Figure 5), T cell maturation (Figure 6) and cytotoxic T cells (Figure 7). 
2.3.3 CD8
+
 T cell depletion and intracellular staining of Tax and GrzA 
To detect Tax and GrzA proteins in HTLV-I infected CD4
+
 T cells, whole PBMCs were first 
depleted of CD8
+
 T cells using CD8
+
 -antibody-coupled magnetic microbeads (Miltenyi 
Biotec) and then incubated in vitro for 18 h. The cells were then surface-stained with 
monoclonal antibodies to CD45, CD3 and CD4 (BD Biosciences, USA) for 15 min at RT in 
the dark. Cells were then fixed and permeabilized with a commercial kit (Insight 
Biotechnology, Wembley, UK). Finally, cells were stained intracellularly with the FITC-
conjugated anti-Tax protein antibody Lt-4 (Lee et al, 1989a) (diluted 1/100) and GrzA 
following the manufacturer's protocol.  
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Table 2. Flow cytometric definition of peripheral blood leukocyte populations. 
 Cell populations Flow cytometric markers Figure 
Plasmacytoid DCs CD45
+
Lin
-
HLA-DR
+
CD123
+
 Figure 3 
Myeloid DCs CD45
+
Lin-HLA-DR
+
CD11c
+
 Figure 3 
Monocytes CD45
+
CD14
+
 Figure 4 
Neutrophils CD45
+
CD16
+
 Figure 4 
B cells CD45
+
CD3
+
CD19
+
CD20
+
 Figure 5 
CD4
+
 T cells CD45
+
CD3
+
CD4
+
 Figure 6, Figure 7 
CD8
+
 T cells CD45
+
CD3
+
CD8
+
 Figure 6, Figure 7 
NK cells CD45
+
CD3
+
CD56
+
CD16
+
 Figure 5 
 
 
 
Figure 3. Flow cytometric gating strategy for blood dendritic cells. 
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Figure 4. Flow cytometric gating strategy for blood monocytes and neutrophils. 
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Figure 5. Flow cytometric gating strategy for blood B cells and NK cells. 
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Figure 6. Flow cytometric gating strategy for naïve and mature T cells and  T cells. 
 
 47 
 
 
 
 
Figure 7. Flow cytometric gating strategy for granzyme and perforin in T cells. 
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2.3.4 Quantification of CD64 and FAS expression by flow cytometry.  
Fresh blood was stained with monoclonal antibodies for population-specific markers 
(neutrophils: CD45
+
CD14
+
CD16
+
, monocytes: CD45
+
CD14
+
CD16
+
, B cells: 
CD45
+
CD19
+
CD20
+
, T cells: CD45
+
CD3
+
CD4
+
 or CD8
+
, NK cells: 
CD45CD3
+
CD56
+
CD16
+
) and anti-CD64 or anti-FAS antibodies for 15 min at RT. Following 
lysis of erythrocytes with BD FACS Lysing solution (BD Biosciences, Franklin Lakes, NJ, 
USA), data were acquired on a CyAn ADP flow cytometer (Beckman Coulter, Marseille, 
France) and analysed using FlowJo software (TreeStar, Ashland, USA). All antibodies were 
purchased from eBioscience, Beckman Coulter, BD Pharmingen and Miltenyi Biotec.  
 
2.4 Microarray procedure and analysis 
2.4.1 mRNA preparation and microarray data acquisition 
A total of 74 subjects who satisfied the study entry criteria were selected for the microarray 
training and test set (Figure 2). The sample preparation and microarray procedure was carried 
out by Quynh-Anh Nguyen and Jason Skinner at the Baylor Research Institute for 
Immunology in Dallas, TX, USA. Total RNA was extracted using the Tempus Spin Isolation 
kit (Applied Biosystems) according to the manufacturer’s instruction. The RNA quality was 
assessed on an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA); all samples scored 
integrity values ≥ 9 (scale: 0-10) and were retained for further processing.  
A globin mRNA reduction step was performed using the GLOBIN-clear
TM
-Human kit 
(Ambion, Austin, TX, USA). The globin-reduced mRNA was subsequently amplified and 
labelled using the Illumina TotalPrep RNA Amplification kit (Ambion). Following the 
manufacturer’s protocol, cRNA was hybridized overnight to Human HT-12 V3 or WG6 V3 
expression BeadChip arrays (chips have identical probes but allow for multiplexing of 6 or 12 
patients per chip, Illumina, San Diego, CA, USA). Following a series of washing and 
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blocking steps according to the manufacturer’s protocols, the arrays were scanned on an 
Illumina BeadStation 500.  
 
2.4.2 Microarray data extraction  
Microarray signal intensity values were acquired with BeadStudio version 2.0 software 
(Illumina). By default this software package applied 2 data processing steps to probe signal 
intensity values prior to data extraction: (i) an automated background signal subtraction 
followed by (ii) re-scaling each probe’s average intensity value in a particular sample to the 
probe’s median average intensity value for all samples across multiple chips. The extracted 
probe signal intensities were treated as raw gene expression values.  
 
Table 3. Illumina Human HT-12 and WG6 V3 BeadChip content. 
Probes Description Probes* 
NM Coding transcript, well-established annotation 27,455 
XM Coding transcript, provisional annotation 7,870 
NR Non-coding transcript, well-established annotation 446 
XR Non-coding transcript, provisional annotation 196 
UniGene (Build 199) Experimentally confirmed mRNA sequencies that align to 
EST clusters 
12,837 
TOTAL  48,804 
*Human RefSeq Build 36.2 Rel 22 
 
2.4.3 Supervised non-parametric data analysis 
The supervised analysis of microarray data is a standard approach for identifying genes that 
are differentially expressed between study groups and thus might serve as group classifiers 
(Figure 8). For this, raw gene expression values were normalised and analysed with 
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GeneSpring GX7.3.1 software (Agilent Technologies). Normalization followed a standard 2-
step procedure for one-colour arrays: first, BeadStudio raw gene expression values were 
transformed by setting signal values <10 to 10, then per-gene normalisation was applied by 
dividing each probe’s intensity by the median intensity value for all samples (Pankla et al, 
2009). 
We then filtered for genes that were present in a minimum of 10% of all samples by 
excluding transcripts that had a BeadStudio detection P-value of more than 0.01 (GeneSpring 
GX 7.3.1: data file filter)(Figure 8). From the resulting gene list (14,392 genes) we selected 
transcripts that varied more than 2-fold from the median gene expression value of all samples 
(7,205 genes). Genes that were differentially expressed between a minimum 2 of the 4 study 
groups were identified by a non-parametric Kruskal-Wallis test (542 genes). To identify genes 
that were differentially expressed between ACs and patients with HAM/TSP, we performed 
Mann-Whitney tests between patients with HAM/TSP and ACs with high or low proviral 
loads, and selected genes that were present in both gene lists (80 genes).  
To identify the genes most strongly associated with HAM/TSP, we selected genes that were 
>1.5-fold differentially expressed versus ACs in >50% of patients with HAM/TSP (11 genes).  
Microarray data was deposited in the Gene expression Omnibus database (accession number 
GSE29312). 
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Figure 8. Data dimension reduction by supervised non-parametric analysis of the microarray 
training set. 
 
2.4.4 Hierarchical clustering 
To visualize transcriptional patterns, an iterative agglomerative clustering method 
(hierarchical clustering) was applied to gene lists (algorithm: Pearson correlation). The 
resulting gene trees were used to organize samples based on their differences in gene 
expression (algorithm: Spearman correlation) in condition trees.  
 
2.4.5 Biological interpretation of the HAM/TSP transcriptional signature 
The transcriptional module-based approach was developed by Damien Chaussabel and 
colleagues to facilitate the biological interpretation of microarray data (Chaussabel et al, 
2008). Gene expression profiles derived from blood leukocyte microarrays of patients 
suffering from systemic (e.g. lupus erythematosus) and acute diseases (e.g. tuberculosis) were 
used to identify clusters of co-regulated genes (8 diseases in total). Transcripts that clustered 
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together across the tested diseases were grouped to form a set of modules (algorithm: K-
Means, software: GeneSpring Version 7.1 from Agilent), starting with the largest identified 
gene cluster. In a first round only transcripts that clustered across all 8 diseases were grouped 
into modules (e.g. M1.1) and the stringency was decreased in a second (7 out of 8 diseases) 
and third round (6 out of 8 diseases) to identify transcripts that belong to similar K-mean 
clusters. A total of 28 modules were identified and a biological interpretation was derived by 
literature profiling of the genes in each module. For an in-depth description of the method see 
(Chaussabel et al, 2010). 
Modular transcriptional fingerprints for ACs and patients with HAM/TSP were generated by 
comparing BeadStudio raw gene expression values to baseline median expression values of 
uninfected controls for all genes present in a module (Mann Whitney, P<0.05). Significant 
differences in gene expression were displayed on a gridline plot with the intensity of the dot 
representing the percentage of differentially genes in a module and the colour indicating the 
directionality of this change, with red depicting over-expression blue under-expression of 
genes relative to control samples. 
Canonical pathway analysis was performed using the web-based Ingenuity Pathway Analysis 
software (Ingenuity Systems Inc.).  
IFN-inducible transcripts in the 80-gene blood transcriptional signature were identified using 
the Interferome database (www.interferome.org) (Samarajiwa et al, 2009). 
 
2.4.6 Weighted molecular distance to health analysis 
The weighted molecular distance is a metric that quantifies global transcriptional changes 
relative to a pre-determined baseline value. First, the mean and standard deviation (referred to 
as mean and S.D. in the formula) of the baseline per-gene expression value was calculated 
from BeadStudio raw gene expression values of uninfected control subjects. Then, for each 
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gene in a given sample we noted the raw gene expression value and the standardized normal 
deviate (Z). This is by definition the standardized normal deviate, i.e.     
 
A filter was applied to select genes whose raw expression value was greater than 200 (call: 
genes present) and whose value of Z >2 (call: genes differentially expressed). The number of 
standard deviations of the genes that passed the filter was added to yield the weighted 
molecular distance to health (WMDH). 
 
2.4.7 Class prediction algorithms 
Class prediction was performed within GeneSpring using the k-nearest neighbor algorithm 
(neighbors=10; P-value ratio cut off =0.65) (Gandhi et al, 2010) or the support vector 
machine package in R (DiagnosisMed package, Gaussian radial basis, diagonal scaling =3). 
 
2.5 Mathematical Modelling 
The significance of an association between the frequency of a specific cell population 
(continuous variable) and disease status (response variable) was analysed using the “stats” 
software package in R (Team, 2009). The disease status of patients was classified as either 
AC or HAM/TSP (binomial). Generalized linear models (GLM) support the strictly bounded 
error structure of binomial response values (errors vary between AC=0 and HAM/TSP=1). 
The structure of the model relates each observed y value (disease status) to a predicted value μ 
(predicted disease status). The predicted value is obtained by transformation of the value 
emerging from the linear predictor η (frequency of one cell population) with the canonical 
logit function: 
 

Z 
observed mean 
SD 
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For GLMs with binary response variables a binomial distribution is assumed in which the 
interpretation of μ is then the probability (p) of the outcome (Y) being on the value one.  
 
In R the significance of the association between a given cell population frequency (e.g. 
CD8
+
GrzB
+
 T cells) and risk of HAM/TSP (Disease) was then computed as: 
>glm (Disease ~ CD8GrzB, family=binomial) 
For graphical tests of the fit of the logistic to the experimental data see reference (Crawley, 
2007). 
2.6 Functional experiments 
2.6.1 Isolation of separated cell populations, RNA extraction and quantitative Real-
Time PCR.  
 
Neutrophils (defined as CD15
+
) followed by CD8
+
 T cells or monocytes (CD14
+
) followed by 
CD4
+
 T cells were isolated from whole blood using antibody-coupled magnetic whole blood 
beads (Miltenyi Biotec, Bergisch Gladbach, Germany). RNA from blood and isolated cell 
populations was purified using the QIAamp RNA Blood Mini Kit (QIAGEN, Hilden, 
Germany).   
Total cDNA was generated from 1 µg of RNA using the SuperScript III First-Strand 
Synthesis Supermix (Invitrogen, Paisley, UK). Custom Taqman Low Density Array cards 
(Applied Biosystems, Carlsbad, CA, USA) comprised probes for the top 11 genes associated 
with HAM/TSP (Supplementary material) and six reference genes for normalization (B2M, 
ACTB, HMBS, GNB2L1, RPLP0, 18S). qRT-PCR was performed on a 7900HT fast real-time 
 
 
e
1e 
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system (Applied Biosystems). Ct values were extracted and analysed using SDS2.3 software 
according to the method published by Vandesompele and colleagues (Vandesompele et al, 
2002)(Applied Biosystems)  
2.6.2 Quantification of IFN concentrations in plasma.  
Plasma concentrations of IFNs were measured by Luminex using a LEGENDplex assay kit 
according to the manufacturer’s instructions (Bioplex, Biolegend, San Diego, USA). 
Bioactivity of Type I and III IFNs in plasma samples was assessed using the iLite Human 
Interferon Alpha Kit (Neutekbio, Galway, Ireland). 
 
2.6.3 Detection of IFN-α secretion and IFN-γ production in whole blood by flow 
cytometry.  
To measure IFN-α secretion by pDCs, blood samples were stimulated with 10 M R-848 
(TLR-7/8 agonist; Insight Biotech, Wembley, UK) for 3 h at 37C. We used the Miltenyi 
Human IFN-α Secretion Assay Detection Kit to detect IFN-α captured and bound to the 
surface of pDCs (defined as BDCA-2
+
CD123
+
). 
To quantify intracellular IFN-γ production by CD8+ T cells blood samples were stimulated 
with 10 ng/ml PMA, 0.5 g/ml calcimycin (Sigma, Gillingham, UK) in the presence of 
monensin (eBioscience, San Diego, CA, USA) for 4 h at 37C. After erythrocyte lysis using 
the BD FACS Lysing solution (BD Biosciences) cells were permeabilized with BD 
Cytofix/Cytoperm (BD Biosciences), stained with monoclonal antibodies for CD3, CD8 and 
IFN-γ for 30 min at 4aC nd analysed by flow cytometry. 
2.6.4 Quantification of IFN receptor surface expression in whole blood by flow 
cytometry.  
Fresh whole blood samples were incubated with IFNGR2-Fluorescein (R&D Systems, 
Minneapolis, MN, USA), IFNGR1-PE (eBioscience) or IFNAR1-Fluorescein and IFNAR2-
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PE (PBL Interferon Source, Piscataway, NJ, USA) and immune cell population markers for 
25 min at RT. Following lysis of erythrocytes with BD FACS Lysing solution (BD 
Biosciences), samples were acquired on a CyAn ADP flow cytometer (Beckman Coulter) 
and analyzed using FlowJo software (TreeStar). 
 
2.6.5 Detection of basal STAT1 protein levels and IFN-induced STAT1 
phosphorylation by flow cytometry.  
 
Heparinized whole blood was treated with 1000 IU/ml of recombinant IFN-α2a or IFN-γ 
(PBL Interferon Source) for 20 min at 37°C. Detection of STAT1 phosphorylation by flow 
cytometry was adapted for whole blood following the specifications refined by Chow and 
colleagues (Chow et al, 2005). In brief, blood samples were fixated with 10% PFA for 10 
min at RT, erythrocytes were lysed with Triton-X 100 for 30 min, followed by a 10 min 
incubation with 50% methanol in PBS at 4°C. Samples were stained with flow cytometric 
markers of peripheral leukocyte populations, STAT1 and STAT1p(Y701) (BD Biosciences), 
and analysed by flow cytometry. 
 
2.6.6 Effect of exogenous IFN on Tax and Gag protein and HBZ mRNA expression.  
CD8
+
 T cells were depleted from PBMCs by positive selection using antibody-coated 
magnetic microbeads (Miltenyi Biotec) to prevent cytotoxic T cell-mediated killing of HTLV-
1 expressing cells. Cells were incubated in the presence of 100 IU/ML IFN-α, 100 IU/ml IFN-
γ or PBS in RPMI 1640 medium (Sigma) supplemented with 10% FCS, 2 mM L-Glutamine, 
100 U/ml Penicillin and 100 μg/ml Streptomycin (Life Technologies) at 37°C in 5% CO2. 
For HBZ and Tax mRNA expression cells were harvested after 0, 2, 4, 8, and 16 h and RNA 
extracted using the RNeasy kit (QIAGEN, Hilden, Germany) according to the manufacurer’s 
instructions. The cDNA was produced using the QuantiTect Reverse Transcription kit 
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(QIAGEN) and qRT-PCR was performed in 96-well plates on a 7900HT fast real-time system 
(Applied Biosystems). Primer sequences detected spliced HBZ mRNA: forward primer 5’-
GGACGCAGTTCAGGAGGCAC-3’, reverse primer 5’-CCTCCAAGGATAATAGCCCG-
3’. Ct values were extracted and analysed using SDS2.3 software (Applied Biosystems). 
Primer sequences for spliced Tax mRNA: forward  5’- CCGGCGCTGCTCTCATCCCGGT -
3’, reverse 5’-GGCCGAACATAGTCCCCCAGAG-3’. HBZ and Tax mRNA levels were 
normalised to endogenous GAPDH levels, primers: forward 5’-
CTTTGGTATCGTGGAAGGACTC-3’, reverse 5’-GTAGAGGCAGGGATGATGTTCT-3’. 
For Tax and Gag protein detection cells were fixed and permeabilized after 16 h using the 
FoxP3 staining buffer set from eBioscience and stained for CD3, CD4, CD8, HTLV-1 Tax 
(LT4 antibody) (Lee et al, 1989b) and HTLV-1 Gag (Gin7 antibody) (Tanaka et al, 1986) and 
analyzed by flow cytometry. 
 
2.7 Statistical analysis.  
 
Correlations were tested by Spearman’s rank-order and differences between two study groups 
by Mann-Whitney U test. Pairwise comparisons were tested using the Wilcoxon signed-rank 
test. All tests were two-tailed and P-values<0.05 were considered as significant. Box plots are 
depicted as median with error bars within the 1.5 interquartile range (IQR); bar graphs depict 
median with error bars representing the standard error of the mean (SEM). Statistical 
programs used included SPSS version 17; Microsoft Excel 2007; GeneSpring GX7.3.1 and 
the DiagnosisMed package in R. 
  
 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
 
 
 
 
 
 
 
 
Chapter 3 
 
Immunophenotyping of peripheral 
blood leukocytes in HAM/TSP 
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3.1 Introduction 
Pathological conditions can arise from – or result in – altered frequencies of peripheral blood 
immune cells. Abnormal blood profiles can feature (i) differences in the frequencies of 
normal cell populations, e.g. the selective loss of CD4
+
 T cells in Human immunodeficiency 
virus (HIV) infection (Fahey et al, 1990), or (ii) the appearance of an unusual cell type in 
blood, e.g. the emergence of atypical T lymphocytes with multilobulated nuclei in ATLL 
patients (Shimoyama et al, 1983). Hence, immunophenotyping of peripheral blood cell 
populations can provide useful information on dynamic changes in immune responses, which 
can then be related to pathological processes.  
 
3.1.1 Dendritic cells 
Dendritic cells (DCs) are a heterogeneous cell population of antigen presenting cells whose 
primary function is to stimulate and regulate immune responses (reviewed in (Banchereau et 
al, 2000; Liu, 2001)). The majority of DCs reside in tissues and the lymphoid organs, and 
circulating DCs represent less than 1% of peripheral mononuclear cells (Savary et al, 1998). 
Two major DC subsets, plasmacytoid DCs (pDCs) and myeloid DCs (mDCs), can be 
identified by their differential expression of surface markers: mDCs are defined by their 
surface expression of CD11c (Integrin-X); in contrast, pDCs do not express CD11c but high 
levels of CD123, the  chain of the IL-3 receptor. Both types of DCs have the ability to 
promote adaptive immune responses by processing and presenting antigen to T cells on major 
histocompatibility complex (MHC) class II. However, only pDCs can rapidly secrete large 
amounts of type I interferons (IFNs) in response to foreign nucleic acids and thereby create a 
link between innate and adaptive immune responses (Siegal et al, 1999). 
It has been demonstrated that DCs can be infected with HTLV-1 in vitro (Ali et al, 1993; 
Jones et al, 2008) and HTLV-1 provirus was detected in circulating DCs in patients with 
HAM/TSP, although infection rates were low with only 0.5-4% of blood DCs being HTLV-1-
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positive (Macatonia et al, 1992). DCs seem to play an ambiguous role in HTLV-1 infection 
and there is evidence that DCs are crucial both in combating and in propagating the infection. 
In a murine model of HTLV-1 infection using chimeric HTLV-1 carrying the envelope 
protein of the Moloney murine leukemia virus, systemic depletion of CD11c
+ 
mDCs strongly 
increased the mice’s susceptibility to infection with cell-free HTLV-1 (Rahman et al, 2010). 
Furthermore, DCs were central to mounting appropriate innate and adaptive immune response 
against HTLV-1 by producing pro-inflammatory cytokines, type I IFNs and stimulating 
proliferation of CD8
+
IFN-+ T cells (Rahman et al, 2011). These findings suggest that DCs 
are crucial to generating early immune responses in HTLV-1 infection.  
In contrast, it has been demonstrated that HTLV-1-infected DCs might enhance the spread of 
the infection by transmitting the virus to CD4
+ 
T cells (Jones et al, 2008; Jain et al, 2009). 
Furthermore, it has been suggested the DCs contribute to immunopathology in HTLV-1 
infection by stimulating and sustaining the expansion of potentially detrimental Tax-specific 
CD8
+
 T cells (Manuel et al, 2009).  
Most likely DCs play a role in both the initiation of beneficial as well as detrimental immune 
responses to HTLV-1 and are thus central to HTLV-1 persistence and pathogenesis. 
 
3.1.2 Monocytes 
Monocytes are circulating leukocytes of myeloid origin that can further differentiate into 
tissue macrophages and DCs (reviewed in (Murray & Wynn, 2011)). Monocytes, 
macrophages and monocyte-derived DCs are professional phagocytes that sense pathogens 
via pattern recognition receptors on the cell surface, phagocytose infectious particles and 
present pathogen-specific antigens on their cell surface. In addition, they stimulate and 
regulate immune responses by secreting a vast array of cytokines and chemokines, e.g. 
interleukin (IL) 1, IL-6, IL-8, tumor necrosis factor  (TNF), CCL22 and IL-10. 
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HTLV-1 provirus was detected in a small proportion of circulating monocytes in HTLV-1 
carriers (Koyanagi et al, 1993); however, it is not known whether viral genes are actively 
transcribed in these cells in vivo. Indeed, it has been demonstrated expression of the provirus 
in an HTLV-1-transfected monocytic cell line was only initiated during phorbol-ester-induced 
monocytic differentiation (Grant et al, 2006). Thus, it was hypothesized that HTLV-1 is latent 
in monocytes but expressed during their differentiation into macrophages or DCs.  
Only few studies have explored a potential role of infected monocytes in HTLV-1-associated 
diseases. Datta et al. found that expression of HTLV-1 p30 in monocytes interferes with 
transcription factor PU.1-dependent expression of toll-like receptor 4 (TLR4), which senses 
lipopolysaccharides (LPS) from Gram-negative bacteria (Datta et al, 2006). An impaired 
capacity of HTLV-1-infected monocytes to respond to bacterial antigens may provide a 
molecular explanation for the increased susceptibility of ATLL patients to opportunistic 
bacterial infection (Marsh, 1996). 
Furthermore, HTLV-1-infected monocytes have been demonstrated to stimulate IFN- 
production and subsequent degranulation of autologous CD8
+
 T cells in vitro (Enose-Akahata 
et al, 2008). This interaction is mediated by IL-15, a cytokine that can be induced by HTLV-1 
Tax (Azimi et al, 1998). Indeed, increased levels of surface-bound IL-15 were detected on 
monocytes from patients with HAM/TSP suggesting that HTLV-1-infected or activated 
monocytes can augment CD8
+
 T cells-mediated immune responses to the virus (Enose-
Akahata et al, 2008). 
 
3.1.3 Neutrophils 
Neutrophils are granular leukocytes of myeloid origin that constitute an essential first line of 
defense against invading bacteria, fungi and protozoa (reviewed in (Nathan, 2006)). HTLV-1 
infection is associated with an increased susceptibility to opportunistic bacterial and parasitic 
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infections (Marsh, 1996), and an impaired neutrophil function has been reported in other 
chronic viral infections, e.g. Human immunodeficiency virus (HIV) and hepatitis C (HCV) 
(Elbim et al, 1995; Pawlowska et al, 2000; Wisniewska-Ligier et al, 2006).   
Few studies have explored neutrophil function in the context of HTLV-1 infection. Guerreiro 
et al. reported preliminary evidence for spontaneous neutrophil activation in HTLV-1 
infection using a nitroblue tetrazolium assay that measures the production of reactive oxygen 
species (Guerreiro et al, 2005). Whilst a subsequent study by Bezerra et al. confirmed the 
findings of the nitroblue tetrazolium assay, the author’s did not obtain evidence for impaired 
neutrophil function in HTLV-1 infection: in response to LPS stimulation neutrophils from 
HTLV-1 carriers produced normal levels of peroxynitrite, CXCL8 and CCL4; and retained 
their ability to kill Leishmania amazonensis in an in vitro assay (Bezerra et al, 2011). 
 
3.1.4 B cells 
B cells are leukocytes of lymphoid origin that mediate humoral immune responses against 
pathogens (reviewed in (Dorner & Radbruch, 2007)). B lymphocytes can differentiate either 
into plasma cells capable of antibody secretion or memory B cells that can provide long-lived 
protection against secondary infection. Antibodies function by recognizing and binding to 
distinct epitopes on pathogens thereby (i) preventing pathogens from interacting with host 
cells, (ii) marking them for phagocytosis and degradation, and (iii) activating the complement 
system. 
Nakamura et al. reported high frequencies of B cells producing immunoglobulin (Ig) G and 
IgA in response to recombinant HTLV-1 Gag and Env proteins (Nakamura et al, 1992). 
Patients with HAM/TSP were found to have higher levels of circulating anti-HTLV-1 
antibodies than ACs with comparable HTLV-1 proviral loads (Osame et al, 1986; Gessain et 
al, 1988; Kira et al, 1992; Burbelo et al, 2008). In addition to IgG, IgM anti-HTLV-1 
antibodies were detected in 50% of HTLV-1 carriers and were particularly abundant in 
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carriers with high proviral loads (Nagasato et al, 1991; Ishihara et al, 1994). Epitope mapping 
analysis revealed that whilst antibody reactivity to the HTLV-1 envelope protein was 
comparable between patients with HAM/TSP and ACs, reactivity to the immunodominant 
epitopes of Tax and Rex was higher in patients with HAM/TSP (Lal et al, 1994).  
Previously, Levin et al. reported that anti-Tax antibodies produced by patients with 
HAM/TSP are cross-reactive with the host protein heterogeneous nuclear riboprotein 
(hnRNP)-A1 (Levin et al, 2002). Usually, hnRNP-A1 is located in the nucleus where it 
shuttles eukaryotic mRNAs from the active site of transcription to that of translation and is 
therefore inaccessible to antibodies in intact cells. However, tissue damage as seen in 
HAM/TSP may be associated with a release of hnRNP-A1, which may then augment ongoing 
inflammatory processes.  
 
3.1.5 Natural killer cells 
Natural killer (NK) cells are leukocytes of lymphoid origin that participate in tumour 
surveillance and immune responses against microbial infections (reviewed in (Vivier et al, 
2008)). NK cells are classified as part of the innate immune system because of their ability to 
recognize and directly kill their target cells without the need for prior antigen-specific 
stimulation by antigen presenting cells. The cytolytic function of NK cells is regulated by the 
balance of activatory and inhibitory signals received through a variety of cell surface 
receptors. In addition to their cytolytic capacity, NK cells regulate immune responses by 
secreting an array of pro- and anti-inflammatory cytokines, e.g. TNF and IL-10. 
Although NK cells can be infected with HTLV-1 in vitro (Lo et al, 1992), there is no evidence 
for infection of NK cells by HTLV-1 in vivo (Richardson et al, 1990). In the host, NK cells 
are able to detect and kill cells that lack surface expression of MHC class I (MHC-I) 
molecules (Karre et al, 1986). Down-regulation of MHC-I complexes is a classical strategy 
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employed by many viruses to evade class I-restricted killing by CTLs. Likewise, HTLV-1 
infection results in reduced levels of surface MHC-I molecules; however, Banerjee and 
colleagues showed that NK cells have a limited ability to kill primary infected CD4
+
 T cells in 
vitro (Banerjee et al, 2007). They found that HTLV-1 p12 protein down-regulates surface 
expression levels of the intracellular adhesion molecules (ICAM) 1 and 2; thereby preventing 
NK cell docking and subsequent killing of infected cells. 
However, several lines of evidence point towards a role of NK cells in the control of HTLV-1 
infection: (i) low frequencies and reduced activity of NK cells was reported for patients with 
HAM/TSP but not ACs (Fujihara et al, 1991; Yu et al, 1991a; Saito et al, 2003; Azakami et 
al, 2009); (ii) in vitro incubation of PBMCs from HTLV-1 carriers resulted in spontaneous 
proliferation of the CD56
+
-NK cells (Norris et al, 2010); and (iii) a preliminary clinical trial 
investigating the therapeutic benefit of the Lactobacillus casei strain Shirota in patients with 
HAM/TSP resulted in increased NK cells activity that was associated with a relief in clinical 
severity of HAM/TSP (Matsuzaki et al, 2005). 
 
3.1.6 CD4+ T cells 
An important role of CD4
+ 
T cells is to orchestrate B cell and CD8
+
 T cell-mediated immune 
responses. In HTLV-1 infection, CD4
+
 T cells are the major reservoir of the virus in blood 
(Richardson et al, 1990). Infected CD4
+
 T cells express high levels of surface CD25, the alpha 
chain of the IL-2 receptor, which is thought to sustain their increased proliferative capacity 
(Inoue et al, 1986; Cross et al, 1987). Furthermore, HTLV-1
+
CD4
+
 T cells are chronically 
activated and produce IFN- that may induce immune activation and associated tissue damage 
in the CNS (Hanon et al, 2001). A proportion of infected CD4
+
 T cells present with a memory 
effector phenotype (CD45RA
-
CCR7
-
), which may allow them to migrate to peripheral tissues 
including the CNS (Hanon et al, 2001). Indeed, the level of HTLV-1 provirus detected in 
early CNS lesions from patients with HAM/TSP positively correlated with the number of 
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infiltrating CD4
+
 T cells (Kubota et al, 1994). Thus, it has been hypothesized that HTLV-1-
infected CD4
+
 T cells are able to cross the brain-blood-barrier and cause initial tissue damage 
that is then exacerbated by the subsequent influx of virus-specific CTLs.  
Regulatory CD4
+
 T cells are characterized by the expression of the transcription factor FoxP3 
and have been shown to dampen immune responses, thus counterbalancing inflammatory 
stimuli. In 2008, Toulza et al. reported an increased abundance of CD4
+
FoxP3
+
 T cells on 
patients with HAM/TSP (Toulza et al, 2008). High frequencies of these HTLV-1-negative 
CD4
+
FoxP3
+
 T cells were associated with reduced CTL activity and increased HTLV-1 
proviral loads, suggesting that regulatory T cells impair the CTL response against HTLV-1. 
Nevertheless, anti-viral CD4
+
 T cells can also contribute to the control of HTLV-1 infection. 
The dominant antigen recognized by HTLV-1-specific CD4
+
 T cells is Env, followed by Gag, 
Pol and the regulatory proteins (Kitze et al, 1998; Goon et al, 2004a). Frequencies of HTLV-
1-specific CD4
+
 T cells are 25-fold higher in patients with HAM/TSP than in ACs with 
similar proviral loads (Goon et al, 2004a; Nose et al, 2007). The majority of these cells have a 
TH1 phenotype and produce IFN-, TNF and IL-2 (Goon et al, 2002; Goon et al, 2003); 
however, their increased frequencies in patients with HAM/TSP suggest that CD4
+
 T cell-
mediated anti-viral immune responses are not sufficient to control the infection and may 
contribute to an increased risk of HAM/TSP.  
 
3.1.7 CD8+ T cells 
CD8
+
 T lymphocytes recognize pathogen-derived peptides presented on MHC-I molecules on 
the surface of infected cells. Activated cytotoxic T cells are able to directly kill infected cells 
by targeted secretion of cytolytic molecules, e.g granzymes and perforin. Although HTLV-1 
preferentially infects CD4
+
 T cells, a significant proportion of CD8
+
 T cells are infected in 
vivo and can be killed by HTLV-1-specific CTLs (Hanon et al, 2000b).  
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Chronically activated Tax-specific CD8
+
 T cells are abundant in HTLV-1 carriers 
independently of disease status; however, they are particularly frequent in blood and CNS 
from patients with HAM/TSP (Greten et al, 1998; Nagai et al, 2001). It has been proposed 
that CTL quality rather than quantity is a critical factor that determines the outcome of 
HTLV-1 infection (Bangham et al, 1996; Nowak & Bangham, 1996; Jeffery et al, 1999; 
Asquith & Bangham, 2000; Asquith et al, 2005; Bangham, 2009). Indeed, two recent studies 
demonstrated differences between HTLV-1 carriers in the ability of their CTLs to recognize 
and respond to HTLV-1-antigens (Kattan et al, 2009). MacNamara et al. found that whilst 
Tax is the immunodominant antigen recognized by HTLV-1-specific CD8
+
 T cells, 
individuals whose HLA alleles strongly bind to the HBZ protein have lower proviral loads 
and are more likely to be asymptomatic (Macnamara et al, 2010). In a second study, Kattan et 
al. demonstrated that CTLs from ACs secreted IFN-γ when stimulated with even a low 
concentration of HTLV-1 antigens, while the majority of CTLs from patients with HAM/TSP 
required high antigen concentrations (Kattan et al, 2009). Thus, an efficient CTL-response to 
HTLV-1 is characterised by recognition of HBZ not Tax and sustained CTL activity even at 
low antigen concentrations. 
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3.1.8 Aims 
The aim of this chapter was to identify immunophenotypic markers on peripheral blood 
leukocytes in HTLV-1 carriers that are associated with HAM/TSP. For this we measured the 
frequencies of total, mature and/or activated monocytes, neutrophils, dendritic cells, B cells, T 
cells and NK cells in ACs, patients with HAM/TSP and uninfected control subjects.  
 
 69 
3.2 Results 
 
3.2.1 HTLV-1 infection does not alter the frequency of major blood cell populations  
 
To identify changes in blood cell populations that are characteristic of HTLV-1 infection and 
HAM/TSP, we quantified the relative abundance of peripheral blood leukocytes in HTLV-1 
carriers and uninfected controls by flow cytometry. We found no significant differences in the 
frequencies of either antigen-presenting or effector cell populations between the study groups 
(Figure 9). Although the difference in NK cell frequencies between ACs and patients with 
HAM/TSP was statistically significant, this amounted to a mere 1.3-fold increase of NK cell 
numbers in ACs. Thus, the relative abundance of major cell populations was comparable 
between all study groups. 
 
In a subsequent detailed flow-cytometric analysis of blood samples from HTLV-1 carriers, we 
investigated changes in the expression patterns of known markers for cell maturation and 
activation of DCs, monocytes, neutrophils, B cells, NK cells and T cells.  
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Figure 9. Relative frequencies of peripheral blood cell populations in HTLV-1 infection. 
Cells from heparinised blood were stained with monoclonal antibodies corresponding to well-
characterised markers of antigen-presenting and effector cell populations. Following lysis of red blood 
cells using the BD FACS lysis solution, the samples were analysed by flow cytometry; WBC = white 
blood cells, DC = dendritic cells. P-values were calculated using a two-tailed Mann-Whitney test; Ctrl: 
n≤6, AC: n≤9, HAM/TSP: n≤9.  
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3.2.2 Frequencies of mature pDCs and mDCs in HTLV-1 infection 
 
Dendritic cells promote adaptive immune responses by processing and presenting antigens. 
To assess the maturation state of DCs in HTLV-1 infection, we quantified the surface 
expression levels of the dendritic cell immune receptor (DCIR) on plasmacytoid and myeloid 
DCs (Figure 10 A, C).  DCIR is a C-type lectin immunoreceptor that mediates endocytosis, 
thus facilitating antigen presentation and controlling DC expansion (Bates et al, 1999; 
Fujikado et al, 2008; Meyer-Wentrup et al, 2008). Maturation and activation of DC is 
associated with a loss of cell surface DCIR; however, we did not detect significantly reduced 
levels of surface DCIR on DCs from HTLV-1 carriers (Figure 10 A, C). 
In HIV infection recognition of viral products by toll-like receptors (TLRs) on DCs enhanced 
expression of the programmed death ligand 1 (PD-L1) (Meier et al, 2008). PD-L1 is a 
negative regulator of immune responses and inhibits T cell proliferation even in the presence 
of antigen; thus, increased levels of PD-L1 on DCs have been associated with T cell 
exhaustion and disease progression in chronic viral infections (Trabattoni et al, 2003). To test 
whether increased PD-L1 levels are associated with negative outcomes in HTLV-1 infection, 
we quantified PD-L1 levels on mDCs and pDCs from HTLV-1carriers. However, we found 
that HTLV-1 infection was not associated with increased levels of PD-L1 on peripheral blood 
DCs (Figure 10 B, D). 
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Figure 10.  Expression levels of DC activation and maturation markers in HTLV-1 infection.  
Heparinised blood was stained with monoclonal antibodies corresponding to well-characterised 
markers for DCs: pDCs were defined as CD123
+
HLA-DR
+
, mDCs were defined as CD11c
+
HLA-DR
+
. 
Following lysis of red blood cells using the BD FACS lysis solution, the samples were analysed by 
flow cytometry. pDCs = plasmacytoid dendritic cells; mDCs = myeloid dendritic cells; DCIR = 
dendritic cell immune receptor; PD-L1 = programmed death ligand 1. Box plot represent median ± 1.5 
IQR.  A two-tailed Mann-Whitney test was used to determine significant differences in expression 
patterns of cell surface markers between study groups. Ctrl: n=10, AC: n=10, HAM/TSP: n=9.  
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3.2.3 Frequencies of activated and inflammatory monocytes in HTLV-1 infection 
 
Monocytes are circulating phagocytes which, depending on the stimuli, can differentiate into 
tissue macrophages or myeloid-derived DCs. To investigate the maturation and activation 
state on circulating monocytes in HTLV-1 infection, we quantified cell surface expression 
levels of the following markers on peripheral monocytes in HTLV-1 carriers and uninfected 
controls: 
(i) CD16 (Figure 11 A): Monocytes are characterized by the expression of the CD14 receptor 
and a less frequent subset of monocytes can be identified by the co-expression of the Fc-
receptor IIIb (CD16) (Fingerle et al, 1993). This subset of ‘inflammatory’ CD14+CD16+ 
monocytes secretes large quantities of proinflammatory cytokines and is expanded in patients 
with severe infection (Fingerle et al, 1993; Belge et al, 2002).  
(ii) HLA-DR (Figure 11 B): Monocytes present extracellular antigens on the major 
histocompatibility complex (MHC) class II molecule human leukocyte antigen (HLA)-DR. 
Monocytic expression of HLA-DR is strongly up-regulated an activated monocytes and 
diminished levels of HLA-DR are associated with reduced antigen-presentation capacity 
(Hershman et al, 1990; Wakefield et al, 1993). 
(iii) CD86 (Figure 11 C): Monocytes and other antigen presenting cells constitutively express 
CD86, which is a member of the immunoglobulin superfamily (Azuma et al, 1993). CD86 is 
up-regulated on activated monocytes and regulates immune responses by interacting with 
receptors on T cells, i.e. the interaction between CD86 and CD28 stimulates T cell 
proliferation whilst ligation of CD86 with CTLA4 (Cytotoxic T-lymphocyte antigen 4) 
inhibits T cell proliferation (Azuma et al, 1993). 
(iv) CD62L (Figure 11 D): L-selectin (CD62L) is an adhesion molecule that is expressed on 
monocytes and facilitates homing to the secondary lymphoid organs and sites of inflammation 
(Siegelman & Weissman, 1989; Griffin et al, 1990). CD62L mediated monocyte tethering to 
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and rolling on endothelial cells and is down-regulated on activated monocytes (McEver et al, 
1995). 
Flow cytometric quantification of CD16, HLA-DR, CD86 and CD62L by flow cytometry 
revealed no significant differences in the expression patterns of these markers on peripheral 
monocytes in HTLV-1 carriers and uninfected controls. 
 
 
 
 
Figure 11. Activation status of peripheral monocytes in HTLV-1 infection. 
Whole blood was stained with anti-CD14-ECD to identify monocytes. Frequencies of (A) 
inflammatory monocytes were determined by co-expression of CD16 on the cell surface. Expression 
levels of (B) HLA-DR, (C) CD86 and (D) CD62L were quantified on peripheral monocytes and 
expressed as mean fluorescence intensity (MFI). Box plot represent median ± 1.5 IQR. A two-tailed 
Mann-Whitney test was used to determine significant differences in expression patterns of cell surface 
markers between study groups. Ctrl: n=5, AC: n=10, HAM/TSP: n=9.  
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3.2.4 Frequencies of activated and apoptotic neutrophils in HTLV-1 infection 
 
Next, we investigated maturation and activation states of peripheral neutrophils in HTLV-1 
infection. Neutrophils are part of the innate immune system and combat pathogens by 
secreting granules containing antimicrobial and cytotoxic substances. Neutrophils have a very 
short half-life in blood (6-12 h) and are committed to the apoptotic pathway. Apoptotic 
neutrophils are characterized by reduced surface expression of CD16 and display only low 
cytotoxic activities (Moulding et al, 1999). Activated neutrophils over-express the 2-integrin 
CD11b, which supports both rapid migration to and immobilization at sites of inflammation 
(Hughes et al, 1992; Sheikh & Nash, 1996). We determined the maturation and activation 
states of neutrophils in HTLV-1 infection by examining CD16 and CD11b surface expression 
levels by flow cytometry. We did not detect significant differences in either the frequencies of 
apoptotic or activated neutrophils between the HTLV-1 carriers and uninfected controls 
(Figure 12). 
 
 
Figure 12. Frequencies of apoptotic and activated neutrophils in HTLV-1 infection. 
Blood samples were analysed by flow cytometry. Neutrophils were identified based on size, granularity 
and expression of CD16. (A) Apoptotic neutrophils were defined as CD14
-
CD16
low
. (B) The activation 
status of neutrophils was determined by quantifying surface expression levels of CD11b. MFI = Mean 
fluorescence intensity. Box plot represent median ± 1.5 IQR. A two-tailed Mann-Whitney test was used 
to determine significant differences in expression patterns of cell surface markers between study 
groups. Ctrl: n=5, AC: n=10, HAM/TSP: n=9.  
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3.2.5 Altered ratios of naïve to unswitched B cells in HTLV-1 infection  
Maturing B cells undergo immunoglobulin class switching that is characterized by loss of 
surface IgD and gain of CD27 expression. Relative quantification of B cell subpopulations 
revealed an altered ratio of naïve to unswitched memory B cells in HTLV-1-positive 
individuals (Figure 13A). Because the overall B cell frequency in the patients did not differ 
significantly from healthy controls, this finding reflects a true accumulation of naive B cells 
and a reduced frequency of mature B cells. However, within patients with HAM/TSP the 
percentage of naïve B cells negatively correlated with HTLV-1 proviral load, suggesting that 
at least in the context of the inflammatory disease a potential inhibition of B cell activation 
and/or maturation can be overcome by increased levels of antigen (Figure 13 B). 
 
 
 
 
Figure 13. Frequencies of naïve and mature B cells in HTLV-1 infection. 
Fresh whole blood samples were stained with multicolour antibodies corresponding to B cells 
(CD19
+
CD20
+
) and their maturation states (IgD, CD27). Red blood cells were lysed and samples 
analysed by flow cytometry. (A) HTLV_1 infection was characterized by an increased naïve/memory 
B cell ratio. Box plot represent median ± 1.5 IQR. P-values were determined using a two-tailed Mann 
Whitney test. (B) In patients with HAM/TSP the percentage of naïve B cells declined with increasing 
proviral load (Spearman correlation). Ctrl: n=10, AC: n=10, HAM/TSP: n=9.  
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3.2.6 Increased frequencies of CD56+CD16+ NK cells in ACs    
 
NK cells can be separated in three functionally distinct subsets based on their expression 
levels of CD56 and CD16: highly cytotoxic CD56
+
CD16
+
NK cells, CD56
+
CD16
- 
NK cells 
with diminished lytic activity, and CD56
-
CD16
+
 NK cells which have been shown to be over-
abundant in HIV-viraemic patients (Mavilio et al, 2005).
 
   
The previously observed increase in NK cell numbers in ACs corresponded to an increase in 
CD56
+
CD16
+
 NK cells (Figure 14 A). Interestingly, the CD56--negative NK cell 
compartment was expanded in patients with HAM/TSP but not in ACs. Indeed, with 
increasing proviral load the frequency of these CD56
-
CD16
+
 NK cells declined in ACs 
(Figure 14). 
 
 
 
 
 
Figure 14.  Frequencies of NK cell subsets in HTLV-1 infection. 
(A) NK cells subsets were identified in fresh whole blood samples based on their expression levels of 
CD56 and CD16. Box plot represent median ± 1.5 IQR. P-values were determined using a two-tailed 
Mann Whitney test. (B) CD56
-
CD16
+
 NK cells were frequent in patients with HAM/TSP but not in 
ACs in whom the frequency of these cells is negatively correlated with HTLV-1 proviral load 
(Spearman correlation). Ctrl: n=10, AC: n=10, HAM/TSP: n=9.  
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3.2.7 HAM/TSP disease is characterised by an increased frequency of terminally 
differentiated CD8+ and double-negative but not CD4+ T cells 
 
CD4
+
 T cells constitute the major viral reservoir in the circulation. Presumably, these HTLV-
1- expressing CD4
+
 T cells are continuously killed by HTLV-1-specific CD8
+
 T cells 
(Bangham, 2003). We therefore hypothesised that HTLV-1-positive individuals have 
increased frequencies of mature circulating CD8
+
 T cells. 
We analysed the frequency of naive and memory T cell subpopulations based on their 
expression of the CD45RA and CD62L markers. The maturation patterns of CD8
+
 and 
double-negative (DN) T cells were remarkably similar: frequencies of terminally 
differentiated effector memory T cells (TEMRA) were greater than 2-fold higher in patients 
with HAM/TSP compared to ACs and healthy controls. Interestingly, the naive CD8
+
 and DN 
T cell pools were not depleted but frequencies of central memory T cells in the CD8
+
 and DN 
T cell populations were significantly decreased (Figure 15 B, C). This suggests that the 
observed terminally differentiated T cells were the progeny of re-stimulated circulating 
memory T cells. 
In contrast to CD8
+
 and DN T cells, frequencies of naïve and memory CD4
+
 T cell 
populations were not significantly altered in HTLV-1 infection (Figure 15 A). 
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Figure 15. Frequencies of naïve and memory T cell populations in HTLV-1 infection.  
Fresh blood from HTLV-1-infected und uninfected donors was stained with a multicolour antibody 
panel for T cell markers, CD45RA and CD62L. After lysis of red blood cells samples were analysed by 
flow cytometry. (A) CD4
+
 T cells maturation was not significantly affected by HTLV-1 infection. 
Patients with HAM/TSP had significantly elevated frequencies of terminally differentiated (B) CD8
+
 
and (C) DN T cells. Box plot represent median ± 1.5 IQR. P-values were determined using a two-tailed 
Mann Whitney test. Ctrl: n=10, AC: n=10, HAM/TSP: n=10.  
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3.2.8 Elevated frequencies of granzyme and perforin-rich T cells in HAM/TSP  
 
To estimate the cytotoxic and pro-inflammatory potential of the T cell populations, we stained 
for intracellular granzyme A (GrzA), granzyme B (GrzB) and perforin (Per). The frequencies 
of perforin and granzyme B-producing T cells were significantly increased in patients with 
HAM/TSP (Figure 16 A, B). Again, CD8+ and DN T cells appeared to vary in a similar way: 
comparable proportions of both T cell populations expressed GrzA, GrzB and Per (Figure 16 
A-C). While some CD8+ and DN T cells contained GrzA only, GrzB expression was 
restricted to cells that co-expressed GrzA (Figure 16 E-F). 
The mRNA levels of Per, GrzA and GrzB did not necessarily correspond to the observed 
protein levels. Indeed, GrzB mRNA was significantly under-expressed in patients with the 
inflammatory disease compared with ACs (Figure 16 D). 
Interestingly, while GrzA protein was constitutively expressed in the majority of CD8
+
 and 
DN T cells, it was detected in only ~6% of CD4
+
 T cells from healthy controls (Figure 16 C). 
However, in patients with HAM/TSP the percentage of GrzA positive CD4
+
 T cells increased 
by 2-fold, suggesting that GrzA production is inducible in CD4
+
 but not in CD8
+
 or DN T 
cells. Even though the absolute frequencies of granzyme- and perforin-expressing CD4
+
 T 
cells were much lower than that of CD8
+
 and DN cells’, the proportional increase in 
expression of these proteins was much greater in CD4
+
 than in other T cells (Table 4).  
 
Table 4.  Increased expression of perforin and granzymes A and B in HTLV-1 infection. 
T cell subset CD4
+
  CD8
+
  CD4
-
CD8
-
 
 AC HAM/TSP  AC HAM/TSP  AC HAM/TSP 
Perforin 7.6 6.6  1.9 4.6  0.9 4.5 
Granzyme A 1.1 2.2  1.1 1.4  1.0 1.2 
Granzyme B 3.0 4.8  1.9 2.6  1.0 1.8 
Depicted are fold changes compared to the median of healthy control subjects. 
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Figure 16. Granzyme and perforin expression in T cells from HTLV-1 infection.  
Fresh blood from, HTLV-1-infected and control donors was stained with CD45, CD3, CD4 and CD8 T 
cell markers. Red blood cell lysis was flowed by intracellular staining for perforin (Per), granzyme A 
(GrzA) and granzyme B (GrzB) and samples were analysed by flow cytometry. HAM/TSP was 
associated with high frequencies of (A) Per and (B) GrzB expression CD4
+
 and CD8
+
 and double-
negative T cells. (C) GrzA expression was induced in CD4
+
 but not other T cells. (E-G) GrzB 
expression was limited to cells that co-expressed GrzA. (D) Blood Per, GrzA and GrzB mRNA 
expression levels as determined by microarray. Box plot represent median ± 1.5 IQR. P-values were 
determined using a two-tailed Mann Whitney test. Ctrl: n=10, AC: n=10, HAM/TSP: n=10.  
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Granzyme A has been shown to stimulate pro-inflammatory cytokine production in 
macrophages (Metkar et al, 2008), thus, CD4
+
GrzA
+
 T cells could contribute to the 
exacerbated cytokine response associated with HAM/TSP. To test whether HTLV-1-infected 
CD4
+
 T cells constituted the majority of GrzA-producing CD4
+
 T cells, we co-stained CD4
+
 T 
cells for expression of GrzA and Tax. We did not observe significant differences in the 
frequency of GrzA
+
 Tax-positive or Tax-negative CD4
+
 T cells (Figure 17 C). Moreover, 
frequencies of CD4
+
GrzA
+
 T cells did not correlate with PVL (Figure 17 B). Thus, GrzA 
expression in CD4
+
 T cells was not limited to infected cells but rather a general feature of the 
inflammatory disease. 
 
Figure 17. Granzyme A expression is not limited to HTLV-1 positive CD4
+
 T cells. 
CD8
+
 T cell-depleted PBMCs from ACs and HAM/TSP patients were incubated for 18 h without any 
stimuli to allow expression of the viral protein Tax in infected cells. Cells were then stained with CD3 
and CD4 followed by intracellular staining for Tax and GrzA. (A) Flow cytometric staining of Tax-
FITC and GrzA-PE in CD4
+
 T cells. (B) The frequency of CD4
+
 GrzA
+
 T cells did not correlate with 
HTLV-1 proviral load (Spearman correlation). (C) There were no significant differences in the 
frequencies of GrzA
+
 cells in Tax
+
 or Tax
-
 CD4
+
 T cells. P-values were determined using a two-tailed 
Mann Whitney test; AC=4, HAM/TSP: n=4. 
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3.2.9 High frequencies of perforin and granzyme B containing CD8+ and double-
negative T cells increase the probability of HAM/TSP 
 
We then wished to examine whether the frequency of one particular perforin- or granzyme-
containing T cell population is associated with disease status. For this, we tested the 
relationship between each individual cell population and disease status in a series of 
generalized linear models (see methods, Software: R). We found that high frequencies of 
CD8
+
Per
+
, CD8
+
GrzB
+
 and CD4
-
CD8
-
Per
+
 T cell populations were significantly associated 
with an increased probability of HAM/TSP (Figure 18, Table 5), with the strongest 
association being demonstrated for CD4
-
CD8
-
Per
+
 T cells (P=0.0251). 
 
 
 
   
 
 
Figure 18. High frequencies of CD8
+
Per
+
, CD8
+
GrzB
+
 and CD4
-
CD8-Per
+
 T cells are associated 
with an increased probability of HAM/TSP.  
To visualize the goodness of the fit for each model, theoretical values (black line) were superimposed 
on experimental data (blue dots). The rug pattern on the x-axis indicates the experimentally determined 
frequencies of CD8
+
Per
+
, CD8
+
GrzB
+
 or CD4
-
CD8
-
Per
+ 
T cells for each AC or HAM/TSP patient in 
the data set. We then split the data set into 4 sections and plotted the average and standard deviation 
(blue dots and lines) of the cell population frequency and probability of HAM/TSP for the patients in 
each of the 4 sections. AC= 9, HAM/TSP: n=9. 
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Table 5. Frequency of Grz
+
 and Per
+
 containing T cells and probability of HAM/TSP. 
Protein Cell population P-value 
 CD4
+
 0.2530 
Perforin CD8
+
 0.0359* 
 CD4
-
CD8
-
 0.0251* 
   
 CD4
+
 0.1950 
Granzyme A CD8
+
 0.0819 
 CD4
-
CD8
-
 0.539 
   
 CD4
+
 0.2370 
Granzyme B CD8
+
 0.0497* 
 CD4
-
CD8
-
 0.104 
               *Analysis of variance: P-value calculated using a Chi-squared test. 
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3.3 Discussion 
3.3.1 Normal frequencies of DCs, monocytes and neutrophils in HTLV-1-positive 
individuals  
 
We found no significant differences in the frequencies or maturation states of DCs, 
monocytes and neutrophils between HTLV-1 carriers and uninfected control subjects. This 
finding was unexpected: there is ample evidence for a strong humoral and cellular immune 
response to HTLV-1 suggesting that viral antigens are abundant in vivo, which in turn should 
be reflected in increased monocytic activation and dendritic cell maturation. A recent study 
by Nascimento and colleagues may provide an explanation for our observation: they 
demonstrated that monocytes from HTLV-1 carriers had a reduced capacity to differentiate 
into DCs (Nascimento et al, 2011). Their findings confirmed and extended two previous 
studies by Makino and Al-Dahoodi, which had provided evidence for impaired monocytic and 
DC maturation in HTLV-1 infection (Makino et al, 2000; Al-Dahoodi et al, 2003). If these in 
vitro observations indeed translate into a reduced differentiation potential of these cell 
populations in vivo, it would explain the absence of increased frequencies of activated and 
matured monocytes and DCs in our study.  
A previous study on HTLV-1 positive patients in Peru has reported a decreased frequency of 
myeloid DC in patients with HAM/TSP but we were unable to confirm this finding in our 
cohort (Best et al, 2009). The frequencies of circulating DCs in the blood are very low, 
making their detection by flow cytometry challenging. Thus, differences between staining of 
DCs in whole blood (our study) versus PBMCs (Best et al, 2009) may result in different 
measurements. We therefore believe that this discrepancy is due to differences in staining 
technique and perhaps sample sizes and does not represent a biological difference between the 
cohorts. However, staining of DCs in fresh whole blood rather than purified PBMCs is likely 
to detect frequencies of DCs accurately in vivo. 
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3.3.2 Evidence for impaired B cell activation or maturation in HTLV-1 infection 
B cells play an important role in the adaptive immune response as they produce antibodies 
against pathogens but can also function as antigen-presenting cells. Upon activation, naïve B 
cells up-regulate CD27 and undergo an antibody class switch, which is characterised by the 
loss of IgD surface expression. Surprisingly, we detected significantly decreased frequencies 
of unswitched memory B cells in HTLV-1-positive individuals (Figure 13). This suggests that 
HTLV-1 either directly or indirectly impairs the activation or the maturation of B cells. 
Until recently, unswitched memory B cells (CD27
+
IgD
+
) had been considered to represent B 
cells which are committed to develop into terminally differentiated memory B cells 
(CD27
+
IgD
-
) (Klein et al, 1998). While this may still be the case, the unswitched memory B 
cell population has also been demonstrated to rapidly produce large quantities of IgM 
antibodies upon stimulation and could therefore serve a crucial function in secondary immune 
responses (Shi et al, 2003). Indeed, IgM antibodies were detected in ~50% of HTLV-1 
carriers (Nagasato et al, 1991; Ishihara et al, 1994). Inhibition of antibody production 
contributes to viral immune evasion; however, the potential benefit for HTLV-1 propagation 
due to a decreased IgM but not IgG-antibody production is not known.  
So far, studies have only confirmed the presence of anti-HTLV-1 antibodies in serum from 
HAM/TSP patients; however, no systematic analysis of B cell function has been performed 
(Jacobson et al, 1990a; Nagasato et al, 1991). Thus, future studies are required to investigate 
whether HTLV-1 infection is associated with a defect in B cell maturation and subsequently 
impaired antibody production. 
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3.3.3 Expansion of CD56-negative NK cells in patients with HAM/TSP 
NK cells are critical in the first-line defence of the immune system against viral infections. 
Three functionally distinct NK cell subsets can be identified by their expression levels of 
CD56 and CD16 (Cooper et al, 2001): CD56
+
CD16
+
 NK cells represent highly cytotoxic NK 
cells and we found this to be the dominant NK cell subtype in ACs. These double-positive 
NK cells have been shown to down-regulate CD16 expression after target cell encounter 
(Grzywacz et al, 2007). However, in patients with HAM/TSP the frequencies of such CD16-
negative NK cells (CD56
+
CD16
-
) were even lower than in uninfected subjects and might 
indicate a diminished lytic activity of NK cells in the context of HAM/TSP.  
In contrast, HAM/TSP was associated with high frequencies of CD56
-
CD16
+
 NK cells, which 
were only present at moderate levels in uninfected individuals and ACs. An expansion of this 
CD56-negative NK cell subset has also been observed in HIV and HCV infection where this 
subset was associated with an impaired lytic function and decreased production of cytokines 
(Hu et al, 1995; Alter et al, 2005; Mavilio et al, 2005; Gonzalez et al, 2009). Importantly, the 
expansion of the CD56-negative NK cells was of clinical relevance as high frequencies were 
indicative of high HIV viral load and predicted failure of treatment with pegylated-IFN-α in 
chronic HCV infection (Mavilio et al, 2005; Gonzalez et al, 2009).  
So far only a few studies have been conducted on NK cell responses to HTLV-1 infection but 
differences in flow cytometric NK cell definition make it difficult to compare our 
observations directly with previous findings (Fujihara et al, 1991; Yu et al, 1991b; Saito et al, 
2003). However, a common feature of all studies was that low activity of NK cell-like 
responses was associated with the presence of HAM/TSP. Based on our findings and 
evidence in the literature, we hypothesise that in HTLV-1 infection the reported reduced NK 
cell activity is due to the expansion of a functionally skewed CD56-negative NK cell subset. 
Furthermore, our finding that the frequency of this subset negatively correlated with proviral 
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in ACs suggests that the expansion of these NK cells does not passively follow proviral load 
but may play a role in HAM/TSP pathogenesis.  
 
3.3.4 High frequencies of terminally differentiated cytotoxic CD8+ T cells increase 
the probability of HAM/TSP 
 
CD8
+
 T cells contribute to the clearance of viral infections by killing infected target cells and 
producing pro-inflammatory cytokines. In HTLV-1 infection, cytotoxic T cell activity was 
found to be an important determinant of HTLV-1 proviral load (Bangham et al, 1996; Asquith 
& Bangham, 2000). The presence of double-negative (DN) T cells, which comprise γδ T cells 
has been reported in patients with HAM/TSP but their role in HTLV-1 infection is not known 
(Jacobson et al, 1990a; Yasukawa et al, 1992; Horiuchi et al, 1999).  
We found that in patients with the inflammatory disease a large proportion of CD8
+
 and DN T 
cells were terminally differentiated (~15% above healthy baseline levels) and comprised high 
levels of perforin and granzyme B (~40% Per
+
 and 30% GrzB
+
 above healthy baseline levels). 
Thus, both T cell populations were activated and matured at some point during HTLV-1 
infection; however, this strong immune response did not translate into a reduction of HTLV-1 
proviral load. Quite the contrary, in a mathematical model we found that high frequencies of 
circulating granzyme B and perforin-positive CD8
+
 T cells significantly increased the 
probability of HAM/TSP.  
In this respect, our observations echo previous studies which demonstrated that HTLV-1-
specific CTLs are highly abundant in patients with HAM/TSP but apparently fail to eradicate 
the virus and instead may be responsible for the tissue damage and lesions observed in 
HAM/TSP (Parker et al, 1994; Kubota et al, 2000a; Wodarz et al, 2001; Jacobson, 2002). The 
frequency of HTLV-1-specifc CTLs has been shown to range between 1 and 10% of all 
circulating CD8
+
 T cells (Jeffery et al, 1999). It is thus likely that a significant percentage of 
the observed highly mature and granzyme-rich CD8
+
 T cells do not recognize HTLV-1-
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antigens but represent bystander T cells with various specificities, which could then in turn 
further augment or even cause the tissue damage associated with HAM/TSP disease.  
However, it has to be noted that the actual cytotoxic capability of these CTLs is not clear as 
we detected increased granzyme and perforin protein levels but total blood mRNA levels of 
cytotoxic molecules were unchanged or significantly down-regulated (Figure 16). In 
peripheral blood granzyme B is produced in T cells as well as NK cells but the kinetics of this 
process are poorly understood and a discrepancy between cytolytic enzyme mRNA and 
protein levels has been observed before (Morissette et al, 2007; Gaafar et al, 2009). 
Moreover, the interpretation of immunostained CTL granzyme content is not straight forward 
as detection of cytolytic proteins in CTLs could either represent truly increased granzyme 
production and cytotoxic activity or an accumulation of cytolytic proteins due to impaired 
granule secretion.  
In contrast, cytolytic enzyme mRNA levels have been shown to accurately predict acute 
allograft rejection (Strehlau et al, 1997; Li et al, 2001; Simon et al, 2003) and thus may be a 
better predictor of CTL activity. In this case low mRNA levels would suggest a reduced 
cytolytic activity of CTLs in patients with HAM/TSP. This could explain their inability to 
effectively reduce HTLV-1 proviral load but questions the models of HAM/TSP pathogenesis 
that presume a high cytotoxic activity of CTLs.  
To date, discharge of granzyme B by CD8
+
 T cells from HTLV-1-positive subjects has not 
been measured directly but the rate of target cell lysis per CD8
+
 T cell was found to be lower 
in patients with HAM/TSP than ACs (Asquith et al, 2005). Thus, functional experiments are 
required to determine whether granzyme B and perforin are efficiently released by HTLV-1-
specific T cells or T cells of other specificities in ACs and patients with HAM/TSP.  
An important characteristic of HTLV-1 infection is the chronic stimulation of the immune 
system. There is accumulating evidence that suggests crucial differences between acute and 
chronic immune responses. For example, in the acute phase of infection granzymes are 
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rapidly produced and discharged by activated CTLs upon antigen encounter. In chronic viral 
infections, however, repeated antigen exposure eventually leads to decreased levels of 
cytolytic enzymes, possibly to prevent autoimmune reactions to self-antigen (Zhang et al, 
2003). Therefore the cytolytic capability of virus-specific T cells might differ from that of 
CTLs with other specificities. For example, in chronic HIV infection a large proportion of 
circulating CD8
+
 T cells was positive for perforin but tetramer-stained HIV-specific CD8
+
 T 
cells generally lacked perforin expression (Appay et al, 2000; Chen et al, 2001). Thus, future 
tetramer staining for HTLV-1-specific T cells will be required to investigate to what extend 
the here observed CD8
+
 T cell phenotypes are representative of HTLV-1-specific CTLs. 
 
3.3.5 The potential role of granzyme A-positive CD4+ T cells in HAM/TSP 
pathogenesis 
 
In addition to CD8
+
 T cells it is also likely that CD4
+
 T cells play a role in bystander tissue 
damage in HAM/TSP pathogenesis. Indeed, CD4
+
 T cells are found in early lesions in the 
CNS of patients with HAM/TSP (Iwasaki et al, 1992a). Intriguingly, CD4
+
 T cells were the 
only T cells in which granzyme A expression was significantly up-regulated and frequencies 
of CD4
+
GrzA
+
 T cells doubled in patients with HAM/TSP. We investigated whether HTLV-
1-Tax expression induces the production of granzyme A in infected CD4
+ 
T
 
cells; however, 
we found that increased granzyme A production was not limited to infected cells but a general 
hallmark of HAM/TSP. 
Emerging evidence suggests a pro-inflammatory rather than cytotoxic role of granzyme A in 
infection (Pardo et al, 2009a; Pardo et al, 2009b). At physiological quantities purified 
granzyme A has been demonstrated to stimulate IL-1β, IL-6 and TNF-α secretion by 
macrophages (Sower et al, 1996a; Sower et al, 1996b; Metkar et al, 2008). Moreover, 
increased serum granzyme A levels have been reported in a variety of diseases that are 
characterised by an exacerbated pro-inflammatory cytokine profile (Spaeny-Dekking et al, 
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1998; Lauw et al, 2000). We therefore hypothesise that granzyme A secreting CD4
+
 T cells 
contribute to HAM/TSP pathology by stimulating infiltrating or resident cells in the CNS to 
secrete pro-inflammatory cytokines which then cause bystander tissue damage. 
 
 
3.3.6 Summary of the Chapter 
In this chapter we measured the frequencies of peripheral blood leukocyte populations and 
characterised their activation and maturation status by flow cytometry. We found that while 
there were no significant differences in the overall frequencies of leukcoyte populations, 
alterations in cell activation were apparent in B cell, T cell and NK cell populations but not 
DCs, monocytes and neutrophils. Frequencies of matured B cells and T cells were increased 
in HTLV-1 carriers, particularly in HAM/TSP. Granzyme- and perforin-rich CD8
+
 T cells 
were highly abundant in patients with HAM/TSP; however, their actual cytolytic capacity 
remains unknown. Importantly, we found that in patients with HAM/TSP NK cell subsets 
were skewed towards the expansion of an NK cell type that has been associated with reduced 
cytolytic activity in other chronic viral infections.  
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Chapter 4 
 
Identification of an IFN-inducible 
transcriptional signature in HAM/TSP 
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4.1 Introduction 
4.1.1 Insights into pathogenic mechanisms through blood transcriptomics  
High-throughput microarrays provide high-quality information on the expression of thousands 
of genes within a single sample. These gene expression profiles reflect ongoing molecular 
processes and changes in the transcription pattern can be linked to biological functions or 
pathological processes (Chaussabel et al, 2010). Analysis of gene expression profiles for 
clinical biomarker discovery was pioneered in the field of cancer research (Alizadeh et al, 
2000; Bittner et al, 2000). Here, screening of cancerous tissue led to the identification of 
tumour subtypes and allowed the prediction of treatment responses.  
In the past decade transcriptome analysis has been extended to complex, autoimmune and 
infectious diseases to investigate their molecular pathology and to uncover mechanisms of 
pathogenesis (Jenner & Young, 2005; Chaussabel et al, 2010; Pascual et al, 2010). However, 
availability of relevant tissues is often limited due to restricted access to the site of injury, e.g. 
the brain in multiple sclerosis or the joints in rheumatoid arthritis. Analysis of transcriptional 
patterns in peripheral blood cells has been shown to be a viable alternative: gene expression is 
a highly dynamic process that is largely influenced by environmental factors such as the 
surrounding cytokine milieu or stimulation of pattern recognition receptors by pathogens 
(Chaussabel et al, 2010). During their migration to and from sites of injury blood leukocytes 
are exposed to injury site-specific as well as systemically released factors. Thus, circulating 
immune cells are an easily accessible source of immunophenotypic information and their 
gene expression profiles provide a ‘snapshot’ of the state of the immune system.  
In infectious diseases, transcriptional changes in the blood reflect the immune response 
mounted against the pathogen as well as pathological changes in the immune system. In 2007 
Ramilo and colleagues hypothesised that because each pathogen comprises a distinct 
combination of molecular patterns that are differentially recognized by receptors on immune 
cells (Medzhitov & Janeway, 2000; Ruland & Mak, 2003), each pathogen encounter will 
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result in a unique gene expression profile in host cells. They compared transcription patterns 
generated from PBMCs from patients with Influenza A, Escherichia coli or Streptococcus 
pneumoniae infection and demonstrated that their ‘transcriptional fingerprints’ were indeed 
highly distinct (Ramilo et al, 2007). Ramilo et al. concluded that patients with different 
infections and diseases can be discriminated by their gene expression profiles in peripheral 
blood immune cells. Thus, blood transcriptome analysis can aid the development of novel 
diagnostic tools and therapeutic strategies whilst circumventing the need for highly invasive 
tissue sampling from sites of inflammation (Pascual et al, 2008).  
 
4.1.2 Gene expression profiling in HTLV-1 infection  
A number of studies have investigated altered gene expression in the context of HTLV-1 
infection. The aim of these experiments was to identify cellular target genes of HTLV-1 
proteins within infected cells by studying in vitro transformed cell lines expressing the full 
length virus or single viral proteins such as Tax, HBZ or p30 (summarised in Table 6). 
HTLV-1 proteins were found to affect the expression of genes involved in transcription, 
nuclear shuttling of cellular mRNA transcripts, cell cycle, cell migration and innate immune 
signalling. These studies indicate potential pathways for the proliferation and survival of 
HTLV-1 infected cells; however, it is not clear to which extent they reflect the mechanisms 
utilised by the virus in vivo. 
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Table 6. HTLV-1 target genes identified in previous microarray studies.  
Viral component 
expressed in vitro 
      Genes and biological pathways targeted 
Tax   Altered expression of genes involved in apoptosis, cell cycle,  
DNA repair, cytokines, adhesion molecules               (Ng et al, 2001) 
 Up-regulation of Fascin                                          (Kress et al, 2011) 
 Regulation of STAT5 mediated gene expression    (Fung et al, 2005) 
 Regulation of genes involved in IFN signaling    (Suzuki et al, 2010) 
HBZ  Up-regulation of Dkk1 which plays a role    (Polakowski et al, 2010) 
in the development of bone lesions                                          
p30  Altered expression of genes for                           (Taylor et al, 2009) 
shuttling of nuclear mRNA  
Full length virus  Up-regulation of CD70 expression                          (Baba et al, 2008) 
 Up-regulation of P21CIP expression          (de La Fuente et al, 2000) 
 Up-regulation of IFN-stimulated genes                (Refaat et al, 2011)     
And down-regulation of chemokines                 (Rahman et al, 2011) 
 
Two studies have examined gene expression profiles in fresh T lymphocytes from patients 
with HAM/TSP. Vine and colleagues isolated CD8
+
 T cells from healthy HTLV-1 carriers 
and patients with HAM/TSP to investigate factors that determine an individual’s set point of 
HTLV-1 proviral load (Vine et al, 2004). They found that a strong CTL-mediated immune 
response, i.e. over-expression of genes associated with cytotoxicity and antigen recognition, 
was associated with a low HTLV-1 proviral load. However, their experimental design did not 
allow inferences on factors relevant to HAM/TSP pathology.  
A recent study by Oliere et al. investigated mRNA profiles of primary CD4
+
 T cells isolated 
from ACs and patients with HAM/TSP to identify expression patterns characteristic of 
HTLV-1 infection and disease status (Oliere et al, 2010). They found that HTLV-1 infected 
cells significantly over-expressed the suppressor of cytokine signalling 1 (SOCS1). SOCS1 is 
a member of the STAT-induced STAT inhibitor family and attenuates IFN signalling 
downstream of the IFN receptor by inhibition of the JAK/STAT3 pathway. In addition, 
SOCS1 inhibits the production of IFN- thus enabling infected cells not only to evade the 
existing type 1 IFN-mediated immune response but also to abrogate a future response.. 
Furthermore Oliere et al. reported a set of seven genes that were differentially expressed in 
CD4
+
 T cells from patients with HAM/TSP but not ACs: RABL4, IKBKG, PHC2, BMP4, 
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MKL1, CBLC and IFNG. However, the biological consequences of this HAM/TSP signature 
are not known. 
In contrast to these previous studies, whole blood studies integrate gene expression profiles of 
HTLV-1-infected CD4
+
 T cells as well as uninfected immune cells that respond to the virus. 
Thus, the resulting transcriptional profiles provide a comprehensive overview of the global 
status of the immune system and associated pathological changes. Therefore, the whole blood 
approach overcomes the limitations of previous HTLV-1-related microarrays: (i) processing 
of whole blood samples avoids any bias that derives from focusing on specific blood cell 
types; (ii) the use of ex vivo patient samples reflects the in vivo situation more accurately than 
analysis of in vitro transformed T cell clones or cell lines. 
While whole blood microarrays have the advantage that they provide an overview of the 
general direction of the immune response against a pathogen, their interpretation is limited 
when attempting to associate expression levels of individual genes with a particular cell type. 
Three strategies can be implemented to lessen this problem: (i) a bioinformatic data analysis 
approach developed by Chaussabel et al. assigns transcriptional changes in objectively 
identified gene clusters to different cell types (Chaussabel et al, 2008); (ii) simultaneously 
acquired flow cytometric information on frequencies, activation and maturation stages of 
peripheral blood immune cell populations can be correlated with mRNA levels; (iii) 
quantitative real-time PCR can be performed to measure expression levels in candidate cell 
types.  
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4.1.3 Aim 
The aim of this Chapter was to identify and quantify differences in the blood gene expression 
profiles of patients with HAM/TSP, asymptomatic HTLV-1 carriers and seronegative controls 
to determine the biological pathways that are deregulated in HTLV-1 infection and 
HAM/TSP pathology. 
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4.2 Results 
4.2.1 Demographic characteristics of the patient cohort 
Over a period of 2 years we collected blood samples from 57 HTLV-1-positive and 17 
seronegative control subjects who attended the National Centre for Human Retrovirology at 
St Mary’s Hospital, London, UK (Figure 2). Patients had previously tested negative for co-
infections with HCV, HBV and HIV and had not received pharmaceutical treatment for 
HTLV-1-related diseases for at least 6 months. HAM/TSP in HTLV-1 carriers was diagnosed 
according to the criteria specified in the WHO guidelines (Osame, 1990) and medical records 
documented patients’ performance in the 10-metre timed walk (Martin et al, 2010) on the day 
of blood sampling. 
Eligible individuals were classified according to their HTLV-1 status and clinical profile as 
uninfected (control), asymptomatic HTLV-1 carrier (AC) or patient with HAM/TSP. We 
employed a staged study design, to determine whether any identified patterns of gene 
expression in a first (training) set of patients were reproducible in an independent second 
(test) set of patients. For this we grouped participants into two cohorts and their samples were 
processed and analysed independently from each other (microarray training and test set).  
The demographic data and clinical characteristics of all study participants are summarised in 
Table 7. The majority of individuals who attended the HTLV-1 clinic were females of 
African Caribbean descent, which is reflected in all study groups. The median age of patients 
with HAM/TSP was 60 (training set) and 63 years (test set); in comparison control subjects 
and ACs who were eligible for the study were on average 10-20 years younger. 
The median proviral load differs between ACs and patients with HAM/TSP by more than ten-
fold (Nagai et al, 1998); thus, to identify changes in gene expression due to disease 
manifestation rather than those arising from differences in HTLV-1 proviral load, we further 
subdivided ACs into two groups: those with high proviral load (≥ 1% PBMCs) or low proviral 
load (< 1% PBMCs). 
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As expected, the proviral load varied significantly among HTLV-1 carriers in the study 
cohorts (Figure 19); however, both microarray training and test sets included a subset of ACs 
whose high proviral loads that overlapped with those from patients with HAM/TSP. 
Table 7. Demographics characteristics of uninfected and HTLV-1-positive individuals in 
the microarray training and test set. 
 Controls Asymptomatic Carriers HAM/TSP 
  
PVL <1% 
(low) 
PVL >1% 
(high) 
 
Training set     
Number of samples 9 11 9 10 
Age (median/quartiles, 
years) 
41 (39-43) 59  (52-63) 50  (34-53) 56  (53-68) 
PVL (median/quartiles, %) -- 0.3 (0.1-0.4) 2.6 (1.4-6.2) 5.9 (3.3-
11.2) 
Gender 
Male 1 (11%) 2 (18%) 1 (11%) 1 (10%) 
Female 8 (89%) 9 (82%) 8 (89%) 9 (90%) 
Ethnicity 
African 0 (0%) 0 (0%) 2 (22%) 1 (10%) 
Afro-Caribbean 4 (44%) 7 (63%) 6 (67%) 7 (70%) 
Caucasian 5 (56%) 4 (37%) 1 (11%) 2 (20%) 
Test set  
    
Number of samples 8 4 13 10 
Age (median/quartiles, years) 49 (46-71) 47 (38-62) 54 (49-62) 63 (44-74) 
PVL (median/quartiles, %) -- 0.6 (0.4-0.9) 3.9 (3.4-6.7) 10.1 (6.7-17.8) 
Gender  
Male  4 (50%) 0 (0%) 0 (0%) 3 (30%) 
Female  4 (50%) 4 (100%) 13 (100%) 7 (70%) 
 
African  0 (0%) 1 (25%) 0 (0%) 0 (0%) 
Ethnicity Afro-Caribbean  5 (62%) 2 (50%) 10 (77%) 9 (90%) 
 Caucasian  3 (38%) 1 (25%) 3 (23%) 1 (10%) 
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Figure 19. Proviral load distribution in the microarray patient cohorts.   
The HTLV-1 proviral load (PVL) was measured by quantitative real-time PCR (Nagai et al, 1998) and 
expressed as log10(copies/100 PBMCs). In both (A) microarray training and (B) test set cohorts the 
proviral load ranges of a subset of ACs and patients with HAM/TSP overlapped (denoted as area in-
between the dotted lines). Training set: AC low PVL: n=11, AC high PVL: n=9, HAM/TSP: n=10; test 
set: AC low PVL: n=4, AC high PVL: n=13, HAM/TSP: n=10. 
 
4.2.2 The blood transcriptional signature of HTLV-1 infection 
4.2.2.1 Identification of a gene expression signature in HTLV-1 carriers 
To identify a blood transcriptional signature that was associated with HTLV-1 infection, we 
generated gene expression profiles from uninfected controls, patients with HAM/TSP and 
ACs with low and high HTLV-1 proviral loads (Table 7). The Illumina Human HT12 
BeadChip array comprises 48,804 probes that target ~ 27,000 coding transcripts with well-
established annotations (Table 3).  Gene lists were identified in the microarray training set 
cohort and then validated on the test set cohort. We positively detected more than 14,300 
different transcripts in blood samples of at least 10% of study participants in the training set 
(Figure 8). Of those the abundance of 7,205 transcripts differed greater than 2-fold relative to 
the median gene expression value across all patients.  
Starting with this pre-filtered list of 7,205 genes we conducted a supervised non-parametric 
class comparison analysis and identified a pattern of 542 transcripts whose expression 
differed significantly between at least two of the four study groups (Appendix –I: Genes 
Suppl. Table 1).  
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Figure 20. A 542-gene whole blood transcriptional signature in HTLV-1 infection.   
Non-parametric group comparison of blood transcriptional profiles of the study participants identified 
542 genes whose expression value differed between HTLV-1 carriers and seronegative controls. (A) 
Microarray training and (B) test set gene expression profiles. Participants were clustered in hierarchical 
condition trees (Spearman correlation with average linkage). Each row denotes a gene and each column 
a single patient. Subclusters are identified as regions (R). Colour scale indicates normalized expression 
values and coloured boxes below the trees indicate patient characteristics.  
Training set: Ctr n=9, AC n=20, HAM/TSP n=10; test set: Ctr n=8, AC n=17, HAM/TSP n=10. 
 
 103 
The list of 542 transcripts was used in a hierarchical clustering analysis that grouped 
transcripts horizontally and study participants vertically based on similarities in their 
expression patterns (Figure 20). The resulting heatmaps samples from both training and test 
set revealed two main clusters that branched into several smaller subclusters (identified in 
Figure 20 as regions, R) independently of participant gender (two-tailed Fisher’s exact test: 
training set P=1; test set P=0.2) or ethnicity (two-tailed Fisher’s exact test: training set 
P=0.06; test set P=0.4). We then compared the known clinical phenotype of the participants 
with the molecular classification obtained from hierarchical clustering. In the training set 
eight out of nine uninfected controls were grouped together a cluster (cluster I, R 1 and 3) 
which was distinct from that of patients with HAM/TSP (cluster II, R 5 and 6; Figure 20 A). 
In the test set changes in the expression of the 542 transcripts were less pronounced, and 
uninfected controls did not form a distinct subcluster; however, seven out of ten patients with 
HAM/TSP clustered in regions 5 and 7 (Figure 20 B).  
To test whether the observed transcriptional changes in these 542 genes distinguished 
uninfected from HTLV-1-positive individuals, we calculated the Weighted Molecular 
Distance to Health (WMDH) for each study participant (see methods). The WMDH is a 
metric that quantifies global transcriptional changes in a given sample over a baseline value 
determined from uninfected control subjects (Pankla et al, 2009). The WMDH score was 
higher in HTLV-1-positive individuals and peaked in patients with HAM/TSP compared to 
uninfected controls, suggesting that accumulation of transcriptional changes in these 542 
genes are associated with the viral infection (Figure 21 A, D).  
Differential expression of these 542 genes was independent of HTLV-1 proviral load (Figure 
21 B, E) and age (Figure 21 C, F) of the study participants. However, in the test set the 
WMDH varied greatly among AC and did not differ significantly from uninfected controls 
(Figure 21 A, D).  In contrast, k-nearest neighbour class prediction based on the expression 
levels of the 542 genes correctly classified 74% of ACs in the test set as HTLV-1 positive. 
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Thus, the 542-gene transcriptional signature accurately identified the majority of healthy 
HTLV-1 carriers.  
 
 
Figure 21. Quantification of the 542-gene blood transcriptional signature in HTLV-1 infection. 
Transcriptional changes in the 542-gene blood signature were quantified using the Weighted Molecular 
Distance to Health (WMDH) score which accounts for the number and the variance of genes that differ 
greater than 2-fold relative to the median gene expression value of uninfected, healthy controls. (A) 
The WMDH was higher in HTLV-1-positive individuals and discriminated HTLV-1 carriers in the 
training set and (D) patients with HAM/TSP in the test set from uninfected controls. Box plots 
represent median ± 1.5 IQR Graphs represent median P-values were calculated using a two-tailed 
Mann-Whitney test. Transcriptional changes in the 542 genes as quantified by the WMDH score were 
independent of (B, E) HTLV-1 proviral load and (C, F) age in both training and test set participant 
cohorts. Proviral load is expressed as log10(copies/100 PBMCs). Correlation was tested by Spearman’s 
rank order.  
Training set: Ctr n=9, AC n=20, HAM/TSP n=10; test set: Ctr n=8, AC n=17, HAM/TSP n=10. 
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4.2.2.3 HTLV-1 infection is associated with perturbations in the p53 signaling pathway 
To better characterise the biological significance of transcriptional changes in these 542 
genes, we performed a pathway-focused analysis using the web-based Ingenuity Pathway 
Analysis tool (Ingenuity Systems Inc., http://www.ingenuity.com/). The majority of the gene 
products were involved in more than one of the reported pathways and affected mainly cell 
cycle control, cell proliferation and anti-viral immune responses (Figure 22). The strongest 
association was predicted for the p53 pathway (P=0.000186, two-tailed Fisher’s exact test 
with Benjamini-Hochberg correction for multiple comparisons). 
Cell stress such as DNA damage and hypoxia results in the activation of the p53 protein 
which induces cell cycle arrest and apoptosis by transcriptional activation of its target genes 
(Meek, 2009). Immune cells of patients with HAM/TSP had markedly decreased mRNA 
levels of proteins involved in responses to DNA damage (ATM, PRKDC; Figure 23 A) but 
up-regulated the expression of genes mediating cell cycle arrest and survival (GADD45; 
Figure 23 B) as well as pro-apoptotic processes (CD95, SCO2; Figure 23 C).  
 
Figure 22. Canonical pathway analysis of the 542-gene blood transcriptional HTLV-1 signature. 
The biological pathway affiliation of the genes was identified using Ingenuity Pathway Analysis 
software (Ingenuity Systems Inc.). The graph displays the top 10 identified pathways. The 542 genes 
were strongly associated with p53-mediated signalling (P =0.000186). Orange squares indicate the ratio 
of the number of genes from the dataset that map to the canonical pathway. The solid blue bars 
correspond to the P-value representing the probability that the association between the genes and the 
identified pathway occurs by chance alone (calculated by two-tailed Fisher’s exact test with Benjamini-
Hochberg multiple testing correction, given as a log P-value). 
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The expression levels of most genes were only significantly altered in patients with 
HAM/TSP. In contrast, up-regulation of P21CIP mRNA, which promotes cell cycle arrest, 
was a general hallmark of HTLV-1 infection (Figure 23 B). Except for the expression levels 
of the DNA-dependent protein kinase (gene: PRKDC) no other transcript correlated by trend 
with HTLV-1 proviral load (Spearman correlation P=0.0681). Thus, the altered expression of 
these genes cannot be explained by changes in proviral load alone, but may also be 
exacerbated by the presence of the inflammatory disease.   
 
 
 
Figure 23. Blood mRNA expression levels of p53 up-stream and down-stream target molecules of 
HTLV-1 carriers and uninfected controls.  
The involvement of the p53 signaling pathway was statistically significant even at the level of 
individual genes. The mRNA levels of genes mediating (A) cellular DNA damage responses, (B) cell 
cycle arrest and (C) apoptosis were significantly altered in patients with HAM/TSP. Box plot represent 
median ± 1.5 IQR. P-values were calculated using a two-tailed Mann-Whitney test.  
Ctr n=9, AC n=20, HAM/TSP n=10.  
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Perturbation of the p53 signalling pathway can result from direct actions of viral proteins in 
infected cells or alternatively, can reflect active proliferation of immune cells in response to a 
pathogen. To test whether differential expression of molecules of the p53 signalling pathway 
was limited to CD4
+
 T cells, the major HTLV-1 reservoir in vivo, we quantified mRNA levels 
of P53, P21CIP and CD95 in peripheral blood leukocyte populations by qRT-PCR. HTLV-1 
infection did not directly alter transcript levels of the P53 (Figure 24 A); however, in 
agreement with our observations from the microarray mRNA levels of P21CIP and CD95 
were increased in HTLV-1 carriers (Figure 24 B, C). Up-regulation of P21CIP and CD95 in 
patients with HAM/TSP was apparent in monocytes and CD4
+
 T cells or neutrophils and 
CD8
+
 T cells respectively. These findings suggest that the observed blood transcriptional 
signature of the p53 signalling pathway originates from actively proliferating immune cells in 
response to HTLV-1. 
 
Figure 24.Transcript abundance of genes of the p53-signalling pathway in leukocyte populations.  
Leukocyte populations were isolated from fresh whole blood using antibody-coupled magnetic beads 
and mRNA levels of (A) P53, (B) CD95 and (C) P21CIP were quantified by real-time PCR. P-values 
were calculated using a two-tailed Mann-Whitney test with *P <0.05 versus controls. Data represent 
mean ± SEM, Ctrl n=4, AC n=4, HAM/TSP n=4. 
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4.2.3. The blood transcriptional signature of HAM/TSP pathology 
4.2.3.1 Identification of a gene expression signature in patients with HAM/TSP 
Differential gene expression in HTLV-1 infection reflects both the degree of infection 
(proviral load) and the presence or absence of HAM/TSP. The transcriptional changes in the 
542 core genes discriminated between controls and HTLV-1-infected subjects, but these 
changes also varied with proviral load and did not distinguish between diseased and healthy 
HTLV-1 carriers. To identify genes that were associated with the inflammatory disease rather 
than HTLV-1 infection per se, we performed statistical group comparisons between ACs and 
patients with HAM/TSP (two-tailed Mann Whitney test, P<0.05). Out of 542 genes we 
identified a total of 80 genes that were significantly different expressed between patients with 
the HAM/TSP and ACs  (Figure 25, Suppl. Table 2). Expression levels of these 80 genes did 
not discriminate between ACs low and high HTLV-1 proviral; we therefore hypothesised that 
their expression was associated with the presence of HAM/TSP independently of proviral 
load.  
Figure 25. Venn diagram 
showing the number of 
genes that were 
differentially expressed 
between ACs and patients 
with HAM/TSP.   
Based on the previously 
derived list of 542 genes, 
non-parametric group 
comparisons were 
performed between patients 
with HAM/TSP and 
asymptomatic HTLV-1 
carriers with different 
proviral loads. Numbers in 
brackets depict the number 
of genes that were 
significantly different 
expressed between the tested 
study groups (two-tailed 
Mann Whitney test, P<0.05). 
A set of 80 genes 
discriminated patients with 
HAM/TSP from both groups 
of ACs but not AC with low 
from ACs with high proviral loads. AC low PVL n=11, AC high PVL n-9, HAM/TSP n=10.  
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To visualise differences in the 80-gene transcriptional profile between healthy individuals and 
patients with HAM/TSP, we performed a hierarchical clustering analysis based on similarities 
in gene expression patterns. In the resulting heatmaps, the study participants were grouped 
into two clusters depending on the presence or absence of the inflammatory disease (Figure 
26; two-tailed Fisher’s exact test: training set P < 0.0001, test set P=0.0258) independently of 
participant gender (training set P=0.3, test set P=0.4) or ethnicity (training set P=0.2, test set 
P=0.1). Quantification of transcriptional changes in the 80-gene signature confirmed the 
association with disease status: the WMDH was significantly higher in patients with 
HAM/TSP than in ACs or controls (Figure 27 A, D) and was independent of HTLV-1 
proviral load (Figure 27 B, E) and participant age (Figure 27 C, F). 
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Figure 26. Presence of an 80-gene blood transcriptional signature in HAM/TSP.  
The blood expression levels of 80 genes differed between patients with HAM/TSP and clinically 
asymptomatic HTLV-1 carriers and uninfected individuals. (A) Microarray training and (B) test set 
gene expression profiles. Participants were clustered in hierarchical condition trees (Spearman 
correlation with average linkage) with each row representing a single gene and each column an 
individual subject. Colour scale indicates normalized expression values and coloured boxes below the 
trees indicate the individual’s clinical classification (study group). ACs with high or low proviral loads 
were not distinguished by colour because their results did not differ significantly either in hierarchical 
clustering or WMDH analysis. Filled triangle (▲) and empty square (□) identify patients with 
HAM/TSP who clustered with healthy individuals.  
Training set: Ctr n=9, AC n=20, HAM/TSP n=10; test set: Ctr n=8, AC n=17, HAM/TSP n=10. 
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Figure 27. Quantification of the  80-gene blood transcriptional signature in HAM/TSP. 
Transcriptional changes in the 80-gene blood signature were quantified using the Weighted Molecular 
Distance to Health (WMDH) score (see methods). The WMDH peaked in patients with HAM/TSP, 
discriminating them from ACs and controls in the (A) training and (D) test set.  Box plots represent 
median ± 1.5 IQR Graphs represent median P-values were calculated using a two-tailed Mann-Whitney 
test. Transcriptional changes in the 80genes as quantified by the WMDH score were independent of (B, 
E) HTLV-1 proviral load and (C, F) age in both training and test set participant cohorts. Red dot 
depicts outlier in the test set of low PVL ACs. Proviral load is expressed as log10(copies/100 PBMCs). 
Correlation was tested by Spearman’s rank order.  
Training set: Ctr n=9, AC low PVL n=11, AC high PVL n=9, HAM/TSP n=10; test set: Ctr n=8, AC 
low PVL n=4, AC high PVL n=13, HAM/TSP n=10. 
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4.2.3.2 The 80-gene transcriptional signature is an independent correlate of disease status 
The strongest correlate of the risk of HAM/TSP to date has been a high HTLV-1 proviral 
load. To test whether the identified 80-gene blood transcriptional signature adds an 
independent value to the prediction of risk of HAM/TSP, we incorporated both HTLV-1 
proviral load and the WMDH of the 80 genes as parameters in a generalized linear model:  
P[HAM/TSP] ~ [proviral load] + [WMDH_80 genes]  P= Probability 
We then used the model to categorize HTLV-1-positive participants of the training and test 
set cohorts as either AC (n=37) or HAM/TSP (n=20) based on proviral load and gene 
expression profiles. As expected the proviral load was a strong predictor of HAM/TSP 
(P=0.00514); however, the 80-gene expression signature significantly strengthened the 
association with HAM/TSP (P=0.01960). Thus, the 80-gene blood transcriptional signature is 
an independent correlate of disease status. 
Based on the expression levels of these 80 genes, k-nearest neighbour class prediction 
identified patients with HAM/TSP in the test set with a sensitivity of 70% and specificity of 
92%; a support vector machine approach gave similar results (Table 8). 
Two ACs in the training set and three in the test set were misclassified as HAM/TSP, 
representing 10% and 17% of the respective asymptomatic cohorts. However, three of these 
five individuals had previously presented with urticaria and urinary urgency, which are 
associated with the onset of HAM/TSP, and with episodes of uveitis, and other inflammatory 
conditions associated with HTLV-1 (Mochizuki et al, 1994). These observations further 
support our finding that the transcriptional signature is specifically associated with HTLV-1-
associated inflammatory disease, rather than viral infection alone.   
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Table 8. Class prediction analysis of the 80-gene HAM/TSP transcriptional signature. 
 K-nearest neighbour Support vector machine 
 Training set Test set Training set Test set 
Accuracy 0.92 0.86 0.87 0.77 
Sensitivity 0.90 0.70 0.80 0.70 
Specificity 0.93 0.92 0.90 0.80 
Area under the ROC
a
 curve 0.92 0.81 0.85 0.75 
a
ROC=receiver operating characteristic 
 
4.2.3.3 The 80-gene transcriptional signature correlates with the severity of HAM/TSP 
Two patients diagnosed with HAM/TSP clustered with uninfected and asymptomatic 
individuals in the test set (Figure 26 B: filled triangle, empty square). To test whether this 
observation reflected heterogeneity in disease severity, we grouped patients according to their 
performance in the 10-meter timed walk, a test of the patient’s mobility, on the day the blood 
sample was taken (Figure 2 D).  Indeed, the two outlier patients had only mild or moderate 
impairment of mobility. In the whole cohort, the WMDH was significantly greater in patients 
who took >30 s to walk 10 m or required wheelchairs compared with less disabled HAM/TSP 
patients (healthy controls < 8 s). Thus, the degree of molecular perturbation of the 
transcriptional signature reflected the clinical severity of HAM/TSP (Figure 2 D). 
 
Figure 28. The 80-gene HAM/TSP blood 
transcriptional signature correlates with 
clinical severity of HAM/TSP. 
Extent of impaired mobility was assessed by 
patients’ performance in the 10-meter timed 
walk, i.e. time taken to walk 10 m with or 
without a walking aid (healthy < 8 s). The extent 
of deterioration was categorized as ‘mild’ (8-15 
s; n=5), ‘moderate’ (16-30 s; n=6) or ‘severe’ 
(>30 s or use of a wheelchair; n=6). Graphs 
comprise data of the training and test set. Box 
plot represent median ± 1.5 IQR. The P-values 
were calculated using a two-tailed Mann-
Whitney test. 
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4.2.3.4 The gene expression profiles of HAM/TSP and multiple sclerosis are distinct 
Clinically, HAM/TSP closely resembles certain forms of multiple sclerosis; both diseases 
show neurological abnormalities due to axonal lesions in the spinal cord and brain (Nagai & 
Osame, 2003; Hauser & Oksenberg, 2006). We therefore compared the present data with the 
recently reported whole blood gene-expression profiles from 99 patients with multiple 
sclerosis (Gandhi et al, 2010). Employing the k-nearest neighbour class prediction approach, 
using the 80-gene list, none of the multiple sclerosis patients were classified as having 
HAM/TSP. Thus, the signature distinguished HAM/TSP from the clinically similar condition 
multiple sclerosis (Figure 29).  
 
 
 
 
Figure 29. The 80-gene transcriptional signature discovered in HAM/TSP is not present in 
patients with multiple sclerosis. 
The transcriptional profiles of the 80-gene HAM/TSP signature were compared between patients with 
HAM/TSP and patients with multiple sclerosis (Gandhi et al, 2010).  Datasets were generated 
normalized to their own controls. Training set: HAM/TSP n=10, Ctrl n=9; test set: HAM/TSP n=10, 
Ctrl n=8; multiple sclerosis data set: patients n=99, Ctrl n=45. 
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4.2.3.5 Over-expression of IFN-stimulated genes in patients with HAM/TSP 
We then wished to test whether the observed changes in gene expression occurred in genes 
that encode proteins in a number of identifiable metabolic or immunological pathways. A 
pathway-focused analysis, using Ingenuity Pathway Analysis software, revealed that the 
products of the 80 genes were significantly associated with the interferon (IFN) signalling 
pathway (Figure 30 A; p=0.00859, Fisher’s exact test). A detailed description of IFNs and 
associated signalling pathways can be found in the introduction to Chapter 5. 
We subsequently inspected the list of 80 genes for the presence of well characterised IFN-
stimulated proteins using the INTERFEROME database (Samarajiwa et al, 2009). We found 
that of 23 out of 80 genes were inducible by type 1 (IFN-/) and/or type 2 (IFN-) IFNs; the 
majority (87%) of these transcripts were over-expressed (Figure 30 B).  
 
Figure 30. The HAM/TSP transcriptional signature comprises IFN-stimulated genes. 
(A) Canonical pathway analysis of the 80-gene HAM/TSP signature (Ingenuity Pathway Analysis 
software). Orange squares represent the ratio of the number of genes present in the transcriptional 
signature versus all genes in the pathway. Solid blue bars correspond to the P-value representing the 
probability that the association between the genes and the identified pathway due to chance alone 
(Fisher’s exact test with Benjamini-Hochberg multiple testing correction, given as log P-value). (B) 
The IFN-regulated genes in the 80-gene HAM/TSP signature were identified using the 
INTERFEROME database. Categories indicate the number of transcripts that are induced by a 
particular type or types of IFN. Colours indicate the proportion of IFN-regulated genes that are over-
expressed (red) or under-expressed (blue) in the HAM/TSP transcriptional signature. 
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A second, independent analysis approach was applied to the microarray data set to confirm 
and expand the conclusions derived from the canonical pathway analysis. The modular 
framework analysis compares transcript abundance between patients and healthy control 
subjects in 28 groups (“modules”) of co-regulated genes, the majority of which have been 
shown to reflect specific cell populations or biological processes (Chaussabel et al, 2008). 
The raw, i.e. non-normalized gene expression values were compared between patients and 
healthy control subjects on a module-by-module basis. Within each module the percentage of 
genes whose expression intensity changed significantly (Mann Whitney, P<0.05) was 
calculated and graphically displayed on a module map, with over-expressed genes depicted in 
red and under-expressed genes in blue (Figure 31 A).  
 
The modular blood signature revealed an over-expression of IFN-stimulated genes in 
HAM/TSP that was absent in asymptomatic virus carriers (module M3.1). Differentially 
expressed genes included key proteins of IFN signalling (STAT1, STAT2), genes associated 
with antigen processing (TAP-1), cell migration (CXCL10) and the innate antiviral response 
(IFI35). Transcriptional changes in the IFN-stimulated genes were reproduced in the test set 
(Figure 31 B) and distinguished patients with HAM/TSP from controls and ACs (Figure 31 
C). Moreover, expression of these genes did not correlate with proviral load in patients with 
HAM/TSP; suggesting that their over-expression did not relate to viral load but to the 
presence of the inflammatory disease itself (Figure 31 D).  
 
Differential gene expression in other modules, e.g. platelets (M1.2), T cells (M2.8) and B 
cells (M1.3) were consistent within but not reproducible across training and test data sets.  
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Figure 31. Module maps confirm the over-expression of IFN-stimulated genes in HAN/TSP.  
Modular analysis approach on microarray (A) training and (B) test set. Gene expression levels were 
compared between HTLV-1-positive study groups and healthy control subjects on a module-by-module 
basis.(Chaussabel et al, 2008) Modules correspond to previously identified co-regulated gene clusters 
that were assigned biological functions by unbiased literature profiling (see legend grid on the right). 
Over-abundance of transcripts in a module is depicted in red, under-abundance in blue. The intensity of 
the dot corresponds to the percentage of genes in the respective module that are significantly 
differentially expressed between the study groups. (C) Transcriptional changes for all 76 IFN-
stimulated genes comprised in the IFN module (M3.1) were calculated using the WMDH metric and 
compared between asymptomatic HTLV-1 carriers with low or high HTLV-1 proviral loads (AC low 
and high PVL), patients with HAM/TSP. P-values were calculated using a two-tailed  Mann-Whitney 
test, Box plot represent median  ± 1.5 IQR. (D) Transcriptional changes in the IFN module were 
independent of HTLV-1 proviral load in patients with HAM/TSP (Spearman correlation). 
Ctrl n=17, AC low PVL n=15, AC high PVL n=21, HAM/TSP n=20. 
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4.2.3.6 Over-expression of a distinct subset of IFN-stimulated genes is specific to HAM/TSP  
IFNs are a family of secreted autocrine and paracrine proteins that modulate immune 
responses by induction of IFN-stimulated genes. Expression of IFN-stimulated genes has 
been reported in the context of infectious and autoimmune diseases (Randall & Goodbourn, 
2008; Hall & Rosen, 2010). To test whether the expression of the distinct subset of 23 IFN-
stimulated genes in the 80-gene blood transcriptional signature reflects more common 
immune responses evoked in several diseases, we quantified expression of these genes in 
bacterial and other inflammatory diseases (Figure 32 A). No significant transcriptional 
changes in the 23 IFN-stimulated genes were detected in patients with multiple sclerosis, 
Still’s disease or individuals infected with Staphylococcus or group A Streptococcus. 
However, expression levels in adults or children with systemic lupus erythematosus (SLE) 
were similar to those observed in patients with HAM/TSP.  
 
Figure 32. Expression of a distinct subset of IFN-stimulated genes distinguishes HAM/TSP from 
other diseases.  
(A) Transcriptional changes for all IFN-stimulated genes comprised in the 80-gene blood 
transcriptional signature were calculated using the WMDH metric and compared between patients with 
HAM/TSP (patients n=20, control n=17), multiple sclerosis (MS; n=99, control n=45), Still’s disease 
(Still’s; n=31, control n=22), individuals infected with Staphylococcus (n=40, control n=12) or group A 
Streptococcus (n=23, control n=12) and patients with adult (ASLE; n=28, control=15) or paediatric 
systemic lupus erythematosus (PSLE; n=82, control=18). P-values were calculated using a two-tailed 
Mann-Whitney test; box plots represent median  ± 1.5 IQR. (B) In contrast to patients with SLE, 
transcriptional changes in patients with HAM/TSP were limited to a small subset of IFN-stimulated 
genes. Based on list of 76 IFN-stimulated genes in module M3.1, non-parametric group comparisons 
were performed between patients with HAM/TSP and adult or paediatric systemic lupus erythematosus 
(ASLE and PSLE). Numbers in brackets depict the number of genes that were significantly different 
expressed between patients with the disease and their respective healthy controls (two-tailed Mann 
Whitney test, P<0.05).  
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There are more than 300 IFN-stimulated genes, the actions of the majority of which are not 
known. To estimate the size of the IFN-mediated immune response in HAM/TSP and SLE, 
we determined the number of differentially expressed genes between diseased individuals and 
healthy control subjects in module M3.1, which comprises a total of 76 well-known IFN-
stimulated genes (Figure 32 B). Whilst both adult and paediatric SLE differentially expressed 
92-95% of IFN-stimulated genes in the module, the IFN response in patients with HAM/TSP 
was limited to a small subset. We conclude that in contrast to the broad pattern in SLE, the 
IFN-mediated immune response in patients with HAM/TSP is restricted to a distinct subset to 
IFN-stimulated genes.  
. 
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4.3 Discussion 
4.3.1 Deregulation of the p53 signalling pathway is a hallmark of HTLV-1 infection 
HTLV-1 infection was characterised by the differential expression of genes involved in p53-
mediated signaling cascades (Figure 22). The tumour suppressor p53 is central to cellular 
defence systems controlling cancer suppression and immunity: it acts as a transcription factor 
for genes mediating cell cycle arrest, senescence and apoptosis (Meek, 2009). We found that 
perturbations of the p53 signalling pathway were evident in all peripheral leukocyte 
populations (Figure 24). It is therefore likely that the HTLV-1 signature reflects a highly 
active immune response, i.e. rapid cell turnover and clonal expansion of viral antigen-
stimulated, uninfected leukocyte populations. However, deregulation of the p53 pathway was 
also observed in CD4
+
 T cells, the major reservoir for HTLV-1 in vivo (Richardson et al, 
1990).  
In infected cells abnormal p53 signalling has been implicated in HTLV-1-mediated 
leukaemogenesis (Grassmann et al, 2005). The p53 protein itself is usually intact in HTLV-1-
leukaemic cells, but there is evidence that the virus inhibits p53-induced anti-viral responses 
by targeting other components of the signalling pathway (Cereseto et al, 1996; Akagi et al, 
1997; Tabakin-Fix et al, 2006; Boxus et al, 2008). This hypothesis is supported by our finding 
that p53 mRNA levels remained unchanged (Figure 24) but HTLV-1-positivity was 
associated with low mRNA levels of molecules involved in the detection of DNA damage, i.e. 
the ataxia telangiectasia mutated protein (ATM) and the DNA-dependent protein kinase 
(PRKDC; Figure 23 A). The protein products of these genes sense double strand DNA breaks 
arising from viral integration into the cell’s genome and induce cell cycle arrest and/or 
apoptosis (Meek, 2009). Decreased expression of ATM and PRKDC could therefore facilitate 
the survival of genomically unstable HTLV-1-infected cells and allow premature DNA 
replication in the presence of genomic lesions, thus contributing to the oncogenic potential of 
HTLV-1. Previous studies have focussed on Tax-dependent inhibition of ATM protein 
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function in cell lines transfected with HTLV-1 in vitro (Van et al, 2001; Chandhasin et al, 
2008). The in vivo down-regulation of ATM and PRKDC mRNAs reported here could 
represent an alternative route by which HTLV-1 impairs the function of the p53 pathway.  
Having down-regulated sensors of DNA damage, it seems paradoxical that HTLV-1 infection 
is also associated with increased mRNA levels of other DNA damage responders such as the 
cyclin-dependent inhibitor 1A (P21CIP) and the growth-arrest and DNA damage-inducible 
gene alpha (GADD45A).  However, in contrast to ATM and PRKDC, which activate p53 and 
may induce apoptosis, P21CIP and GADD45A proteins  are downstream targets of p53 and 
mediate cell cycle arrest and inhibition of DNA synthesis (Eldeiry et al, 1993; Smith et al, 
1994; Waldman et al, 1995; Sherr & Roberts, 1999; Gartel & Radhakrishnan, 2005). Previous 
studies have demonstrated that HTLV-1-Tax can directly elevate P21CIP mRNA and protein 
levels by inducing its transcription and enhancing mRNA stability (Kuo & Giam, 2006; 
Zhang et al, 2009). Manipulation of cell cycle progression can be advantageous to HTLV-1 
replication as it focuses the cellular protein synthesis machinery on the production of viral 
proteins instead of DNA repair. 
A role for GADD45A in HTLV-1 infection has not been reported in the literature. 
Interestingly, in addition to its role in mediating cell cycle arrest, GADD45A has been shown 
to relieve epigenetic gene silencing by promoting DNA repair, which erases methylation 
marks (Barreto et al, 2007). Hypomethylation of transcriptional control sequences is prevalent 
in cancer cells (Ehrlich, 2002); increased GADD45A protein may therefore contribute to the 
development of ATLL in HTLV-1 infection. 
Another effect of DNA damage-mediated activation of p53 is the induction of CD95 (Fas) 
transcription (Muller et al, 1998). Stimulation of surface-bound CD95 by Fas-ligand (FasL), 
which is typically expressed on activated lymphocytes or NK cells, induces a caspase-
dependent signalling cascade which results in apoptosis of the CD95-expressing cell (Strasser 
et al, 2009). It is intriguing that at a given proviral load CD95 mRNA levels were 
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significantly higher in patients with HAM/TSP than in ACs (Figure 23 B). The CD95 mRNA 
levels are particularly up-regulated in CD8
+
 T cells of HTLV-1 carriers (Figure 24 B). This 
observation could reflect an increase in activation induced cell death triggered by viral 
antigen stimulation. In HTLV-1 infected cells it has been shown that even in the presence of 
CD95-FasL stimulation Tax can counteract pro-apoptotic signals by inducing the expression 
of the cellular anti-apoptotic protein c-FLIP (cellular FLICE/caspase-8-inhibitory protein) 
(Irmler et al, 1997; Okamoto et al, 2006).  
The biological consequences of the increased levels of SCO2 mRNA in patients with 
HAM/TSP are the subject of speculation (Figure 23 C). SCO2 (Synthesis of Cytochrome C 
Oxidase 2) protein is required for the assembly of the mitochondria DNA-encoded COX II 
subunit into the COX complex and its expression has been shown to increases cellular oxygen 
consumption (Pel et al, 1992). The synthesis of cytochrome c oxidase 2 gene (SCO2) is 
initiated by activated p53 and somehow inhibits the switch to glycolysis that is observed in 
cancers with p53 protein mutations (Matoba et al, 2006). However, no function for SCO2 in 
HTLV-1 infection has been reported in the literature and the beneficial or detrimental effect 
of increased oxygen consumption on viral replication remains unclear.   
 
4.3.2 HAM/TSP pathology is characterised by on over-expression of IFN-stimulated 
genes 
 
We found that the presence of HAM/TSP was associated with over-expression of a distinct 
subset of IFN-stimulated genes in blood from HTLV-1 carriers. The finding that 
transcriptional changes in these genes were independent of HTLV-1 proviral suggests that the 
expression of these genes was not a direct result of viral replication and may not be limited to 
HTLV-1-infected cells. However, to clarify the relationship between HTLV-1 and IFN-
stimulated gene expression in infected and responder cell populations, it will be necessary to 
identify the cell types that bear the IFN-inducible transcriptional signature. 
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IFN-stimulated genes have been shown to mediate potent antiviral and neuroprotective effects 
(Randall & Goodbourn, 2008; Li et al, 2011). Thus, one would expect an IFN response to be 
present in asymptomatic virus carriers who efficiently control the infection. However, the 
IFN-inducible transcriptional signature was absent in healthy HTLV-1 carriers and 
independent of HTLV-1 proviral load. We conclude that expression of IFN-stimulated genes 
is a hallmark of the inflammatory disease and not a trivial consequence of a viral infection.  
The strength of the IFN-inducible signature correlated positively with the clinical severity of 
HAM/TSP. While this confirms that the transcriptional signature is clinically relevant, the 
causality between expression of IFN-stimulated genes and HAM/TSP is not clear: do IFN-
stimulated genes contribute to the pathogenesis of HAM/TSP or are they merely a 
consequence of the inflammatory condition?  
Due to the lack of a suitable animal model for HAM/TSP formal proof for either of these 
hypotheses remains currently unattainable. However, two observations suggest a pathogenic 
role of IFNs in HAM/TSP:  
(i) Despite similarities in clinical presentation, the gene expression profiles of HAM/TSP and 
multiple sclerosis were distinct (Figure 29). Similar to HAM/TSP, multiple sclerosis is 
characterised by axonal damage in the CNS; thus, the inflammatory profiles of the conditions 
are comparable. However, the IFN-inducible signature present in HAM/TSP was absent in 
patients with multiple sclerosis suggesting that over-expression of IFN-stimulated genes does 
not reflect inflammation in the CNS per se but instead indicates that pathogenic mechanisms 
differ between the two diseases. Interestingly, a recent study reported the expression of a 
subset of type I IFN-stimulated genes in 50% of patients with a particular clinical subtype of 
multiple sclerosis (relapsing-remitting) (van Baarsen et al, 2006). However, in agreement 
with our finding there is little overlap between the IFN-stimulated genes identified in 
HAM/TSP and the ones reported in multiple sclerosis.  
 124 
(ii) Several recent studies have implicated IFNs in the pathogenesis of autoimmune disorders 
such as rheumatoid arthritis (Kraan et al, 2007), systemic lupus erythematosus (Baechler et al, 
2003), systemic sclerosis (Assassi et al, 2010) and Sjögren’s syndrome (Emamian et al, 
2009). It has been hypothesised that IFNs trigger autoimmunity by promoting the activation 
and survival of autoreactive T and B cells in genetically predisposed individuals (Conrad, 
2003). There is little evidence for the presence of autoreactive molecules in HAM/TSP (Levin 
et al, 2002); instead, the risk of disease is linked to high frequencies of poor quality antiviral 
cytotoxic T cells (Kattan et al, 2009); i.e. low avidity of HTLV-1 antigen recognition and 
reduced lytic efficiency. However, IFNs may contribute to immunopathological processes in 
the CNS by stimulating and propagating a detrimental immune response to HTLV-1. 
We found that different subsets of IFN-stimulated genes are actively expressed in diseases 
with IFN-inducible signatures (Figure 32). There are more than 300 known IFN-stimulated 
genes, the individual actions of many of which are largely uncharacterized (Schoggins et al, 
2011). Thus, it is conceivable that there are cell-type-, pathogen- and disease-specific patterns 
of IFN-stimulated gene expression that contribute to a beneficial or detrimental outcome of 
immunological processes.  
4.3.3 Limitations 
Blood is a complex tissue, hence a caveat of whole blood microarrays is that the observed 
transcriptional profiles can be the result of differential transcriptional regulation at the single 
cell level or differences in cell composition, i.e. reduced frequencies of a particular cell 
population. Previously we had quantified leukocyte subsets by flow cytometry. No significant 
differences in the abundance of antigen-presenting or major effector cell populations were 
observed between the study groups (Figure 9). We therefore conclude that the observed 
transcriptional signatures of HTLV-1 infection and HAM/TSP pathology arise from 
differential gene expression in single cells. 
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4.3.4 Summary of Chapter 
In this chapter, we identified blood transcriptional signatures characteristic of HTLV-1 
infection and HAM/TSP. We found that perturbations of the p53 signalling pathway were a 
hallmark of HTLV-1 infection and most likely reflect an active immune response against 
HTLV-1. Presence of HAM/TSP was associated with over-expression of a specific subset of 
IFN-stimulated genes and the strength of this IFN-inducible signature correlated positively 
with the clinical severity of HAM/TSP.   
 
Publication arising from this chapter 
Tattermusch, S., Skinner, J.A., Chaussabel, D., Banchereau, J., Berry, M.P., MacNab, F.W., 
O’Garra, A., Taylor, G.P., Bangham, C.R.M. (2011) Systems biology approaches reveal a 
specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8: 
e1002480 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
 
 
  
 127 
 
 
 
 
 
Chapter 5 
 
Investigating the molecular origin and 
consequences of the IFN-inducible 
transcriptional signature in HAM/TSP 
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5.1 Introduction 
5.1.1 Classification of the IFN family 
Originally described by Isaacs and Lindemann, IFNs are a family of conserved cytokines that 
mediate potent antiviral, antiproliferative and immunomodulatory effects (Isaacs & 
Lindenmann, 1957; Isaacs et al, 1957).  The members of the IFN family are classified as type 
I, II or type III IFNs based on their protein structures, chromosomal location of the genes, 
receptor usage and biological activities (Pestka et al, 2004).  
Type I IFNs comprise at least 13 different IFN- isoforms (IFN-1, -2, -4, -5, -6, -7, -
8, -10, -13, -14, -16, -17 and -21), and single IFN-, IFN-, IFN- and IFN- 
isotypes (reviewed in (Platanias, 2005; Randall & Goodbourn, 2008)). The best characterised 
amongst the type I IFNs are INF- and IFN-, both of which are produced by cells in 
response to viral infection. Whilst all type I IFNs signal through a common cell surface 
receptor the biological purpose of the different IFN- isoforms remains speculative, i.e. 
whether they are produced by different cell types, in response to particular viruses or whether 
they mediate distinct cellular responses (Brideau-Andersen et al, 2007). 
In contrast the term type II IFN refers to only a single gene, IFN-, which is structurally 
different from the other types of IFNs and binds to a distinct cell surface receptor (Platanias, 
2005). Unlike type I IFNs, IFN- is not secreted directly by virally infected cells but is 
produced by proliferating T cells and activated NK cells in response to a number of 
immunological stimuli e.g. T cell-specific antigens, staphylococcal enterotoxins, and phorbol 
esters (reviewed in (Jonasch & Haluska, 2001)). 
The type III IFN family comprises three highly related proteins: IFN-1, -2 and -3, which 
are also known as interleukin (IL)-29, IL-28A and IL-28B (Kotenko et al, 2003; Sheppard et 
al, 2003). Similarly to type I IFNs, type III IFNs are produced in viral infection. Indeed, IFN-
/ and IFN- share many biological properties because although they bind to distinct cell 
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surface receptors, they activate the same signaling pathway (reviewed in (Donnelly & 
Kotenko, 2010)). However, whilst the type I IFN receptor is ubiquitously expressed on all 
cells including leukocytes, expression of the IFN- receptor at physiologically significant 
levels is mostly restricted to cells of epithelial origin (Witte et al, 2009). 
5.1.2 Induction of IFN production 
 All cells are able to produce type I IFNs in response to viral infection; however, pDCs 
secrete 200-1000-fold more type I IFN than any other blood cell type and are thus the main 
producers of INF- and IFN- in vivo (Siegal et al, 1999).  
There are two main classes of innate sensors that detect viral nucleic acids within infected 
cells (McCartney & Colonna, 2009): cytosolic retinoic acid-inducible gene I (RIG-I)-like 
receptors that are activated by double-stranded RNA (dsRNA), which is a by-product of viral 
replication in the cytosol or the genome of some viruses; and endosomal Toll-like receptors 
(TLRs) which recognise viral single-stranded RNA (ssRNA) or unmethylated CpG-
containing DNA, which is present in some pathogens but not host genomic DNA. Thus, there 
are several routes by which host cells can recognize viral pathogen-associated molecular 
patterns (PAMPs) and induce production of type I IFNs (reviewed in (Randall & Goodbourn, 
2008)): 
(i) The endosomal TLR7/TLR8/TLR9–MyD88 signaling pathway (Figure 33 A) 
Following endocytosis of extracellular virus, uncoating of viral particles or degradation of 
engulfed apoptotic cells, viral nucleic acids are processed in endosomes. In pDCs TLR7 and 
TLR8 are expressed in endosomes where they recognise ssRNA (Diebold et al, 2004) and 
imidazolequinilone compounds (e.g. resiquimod R-848) (Hemmi et al, 2002). In addition, the 
endosomal membranes of pDCs and certain PBMCs contain TLR9, which recognises the 
unmethylated CpG-containing DNA found in certain viruses. Activation of either TLR results 
in recruitment of the adaptor protein myeloid differentiation factor 88 (Myd88) which 
subsequently recruits interleukin-1 receptor-associated kinases 1 and 4 (IRAK1 and IRAK4) 
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as well as TNF receptor associated factor 6 (TRAF6) and BTK (Bruton's tyrosine kinase) 
(reviewed in (Akira & Takeda, 2004; Kaisho & Akira, 2006)). In PBMCs this signaling 
complex induces type I IFN production through the NF-B signaling pathway. However, in 
pDCs constitutively high levels of interferon regulatory factor 7 (IRF7) provide an additional 
route for type I IFN induction. 
(ii) The endosomal TLR3–TRIF signaling pathway (Figure 33 B) 
Dendritic cells internalize extracellular dsRNA, which is recognized by endosomal TLR3 
(Alexopoulou et al, 2001). Induction of type I IFN production via TRL3 is MyD88-
independent and instead requires the adaptor TRIF (Toll/IL-1R (TIR) domain-containing 
adaptor protein inducing IFN-). TRIF engagement promotes the assembly of the TRAF6, 
TRAF-associated NF-κB activator binding kinase 1 (TBK1) and IkappaB kinase epsilon 
(IKK) signaling complex, which then induces IFN- transcription via IRF3 (Yamamoto et 
al, 2002; Yamamoto et al, 2003). 
(iii) The RIG-I-like-receptor signaling pathway (Figure 33 C) 
All nucleated cells possess TLR-independent pathways that enable them to detect viral 
double-stranded or 5’-triphospho-RNA in the cytosol (Yoneyama et al, 2005; Pichlmair et al, 
2006). Activated RIG-I-like receptors (RLRs) - RIG-I and melanoma differentiation 
associated gene 5 (MDA5) – recruit the mitochondrion-associated adaptor termed CARD 
adaptor inducing IFN- (Cardif)/virus-induced signaling adaptor (VISA)/mitochondrial 
antiviral signaling protein (MAVS)/IFN- promotor stimulator protein (IPS-1). The 
Cardif/VISA/MAVS/IPS-1 complex acts via the TRAF3 pathway, which promotes 
translocation of IRF7 and IRF3 to the nucleus (Kawai et al, 2005; Meylan et al, 2005). In 
contrast, the third member of the RIG-I-like receptors, laboratory of genetics and physiology 
2 (LGP2), lacks a CARD domain and is therefore unable to induce the assembly of the 
Cardif/VISA/MAVS/IPS-1 complex. Instead it is thought to act as a co-receptor for RIG-I 
and MDA5 (Satoh et al, 2010). 
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Figure 33. Schematic of intracellular pathways for nucleic acid sensing type I IFNs. 
transcription. 
(A) Binding of ssRNA (TLR7, TLR8) or unmethylated CpG-rich DNA (TLR9) activates endosomal 
Toll-like receptors (TLRs). Activated TLRs recruit the adaptor protein MyD88 (myeloid differentiation 
primary-response gene 88), which in turn promotes the assembly of a signaling complex comprising 
TRAF6 (tumour-necrosis factor (TNF)-receptor-associated factor 6), BTK (Bruton's tyrosine kinase), 
IRAK4 (interleukin-1-receptor (IL-1R)-associated kinase 4) and IRAK1. Subsequent activation of the 
interferon regulatory factor 7 (IRF7) or the Nuclear factor-kappaB (NF-B) pathway initiates the 
transcription of type I IFNs. (B) Endosomal TLR3 binds dsRNA, which recruits the adaptor protein 
TRIF (Toll/IL-1R (TIR) domain-containing adaptor protein inducing IFN-). TRIF acts as a scaffold 
and promotes the assembly of a signaling complex that activates IFN- transcription via IRF3. (C) 
Cytosolic sensors of dsRNA and 5’-triphosphoRNA –RIG-I (retinoic acid-inducible gene I) and MDA5 
(melanoma differentiation associated gene 5) – bind to an adaptor molecule IPS-1 (IFN- promotor 
stimulator protein) located on mitochondria. Engagement of the TRAF3 signaling complex induces 
type I IFN production via IRF3 and IRF7. Figure adapted from (Gilliet et al, 2008). 
 
Type III IFNs are expressed in response to stimulation with type I IFNs and a variety of TLR 
agonists (Coccia et al, 2004; Ank et al, 2006). Analysis of the type III IFN promotor revealed 
putative binding sites for IRFs and NF-B, which also regulate the transcription of type I 
IFNs (Onoguchi et al, 2007; Osterlund et al, 2007). Thus, it has been hypothesised that 
transcription of IFN- genes is controlled by the same signaling pathways that govern type I 
IFN production. 
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In contrast to type I and type III IFNs, IFN- is produced predominantly by CD8+ T cells and 
to a lesser extent by TH1-polarised CD4
+
 T cells, NK cells and macrophages (Schroder et al, 
2004; Schoenborn & Wilson, 2007). The promotor of the IFN- gene comprises binding sites 
for a plethora of transcription factors: Nuclear factor of activated T-cells (NFAT), Activating 
transcription factor 2 (ATF2), Activator protein 1 (AP-1), NF-B, T-bet and Signal transducer 
and activator of transcription 4 (STAT4) (Nakanishi, 2001). In principle, IFN- production 
can be stimulated via two pathways (Figure 34): (i) the ‘acquired pathway’ which requires T 
cell receptor (TCR) engagement in addition to IL-12 stimulation (Zhang et al, 1999); and (ii) 
the ‘innate pathway’ where IL-12 and IL18 act synergistically to induce sustained p38 
Mitogen-activated protein kinase (MAPK) activation which results in TCR-independent 
transcription of the IFN- gene (Yang et al, 2001; Nakahira et al, 2002).  
 
 
Figure 34.  Simplified schematic of the principle signaling pathways leading to IFN-γ production. 
Pathway I, acquired T cell activation pathway: naïve T cells are primed by TCR engagement and IL-12 
to produce IFN- upon further antigen i.e. TCR stimulation. This pathway is requires transcription 
factor NFAT that can be inhibited by Cyclosporin A (CsA). Pathway II, innate type T cell activation 
pathway: IL-12 and IL-18 act synergistically to induce IFN-γ production via many transcription 
factors. This pathway is TCR-independent, not sensitive to CsA and requires the activation of P38 
MAPK via GADD45.  Figure from (Nakanishi, 2001). 
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5.1.3 The IFN signaling pathways 
IFNs signal through heterodimeric receptor complexes located at the cell surface. Whilst IFN 
I and II receptors are ubiquitously expressed, the expression of the type III IFN receptor is 
limited to cells of epithelial origin (Witte et al, 2009). 
All type I IFNs bind to the IFN I receptor, which consists of an IFN-R1 (IFNAR1) and IFN-
R2 (IFNAR2) subunit. Similarly, the IFN II receptor is composed of unique IFN-R1 
(IFNGR1) and IFN-R2 (IFNGR2) chains (reviewed in (Platanias, 2005)). In contrast, the 
IFN III receptor complex contains only one unique IFN-R1 chain and a shared IL-10R2 
chain, which also participates in IL10, IL-22 and IL-26-mediated signaling (Kotenko et al, 
2003). 
All receptor complexes are associated with members of the Janus activated kinase (JAK) 
family: JAK1, JAK2 or the tyrosine kinase 2 (TYK2) (see Figure 35). Binding of the 
respective IFN triggers conformational rearrangement and dimerisation of the receptor 
subunits, which results in autophosphorylation and activation of the associated JAKs. In turn, 
activated JAKs phosphorylate tyrosines located on the IFN receptors (IFNAR1, IFNGR1 or 
IFNLR1 chain), thereby creating a docking site for cytosolic STATs (Platanias, 2005; 
Donnelly & Kotenko, 2010).  
Type I and III IFN receptors phosphorylate tyrosines on STAT1 and STAT2, which then form 
a stable heterodimer that translocates into the nucleus. In the nucleus, the STAT1-STAT2 
complex recruits IRF9 to form the ISGF3 (Interferon stimulated gene (ISG) factor 3). This 
heterotrimeric complex activates the transcription of genes which contain the IFN-stimulated 
response element (ISRE) DNA motif in their promotor sequences (Zhou et al, 2007). 
In contrast, the phosphorylated IFN II receptor recruits and phosphorylates only STAT1, 
which then forms STAT1-STAT1 homodimers that also translocate to the nucleus. Dimerised 
STAT1 then binds to a distinct DNA sequence in the promotor of ISGs termed gamma-
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activated sequence (GAS) (Platanias, 2005). To a lesser extent IFN-/-mediated signaling 
can also result in the formation of STAT1 homodimers and induce the transcription of some 
genes. 
 
 
 
Figure 35. Schematic of type I, II and type III IFN signaling pathways. 
IFNs are recognised by heterodimeric receptors located on the cell surface. Binding of extracellular 
IFN to its respective IFN receptor trigger conformational changes and subsequent activation of the 
receptor associated tyrosine kinases (IFN I and III: TYK2 and JAK1; IFN II receptor: JAK1 and 
JAK2). Activated kinases phosphorylate the respective IFN receptor, which creates a binding site for 
STATs. IFN-/ and IFN-- mediated signaling result in phosphorylation of STAT1 on tyrosine 701 
and STAT 2 on tyrosine 690. The STAT1-STAT2 heterodimer then translocates to the nucleus where it 
associates with IRF9 to form the ISGF3 complex. Binding of the ISGF3 complex to the IFN-stimulated 
response element (ISRE) DNA motif induces transcription of IFN-responsive genes. In contrast, 
activation of the IFN II receptor and associated kinases results in STAT1 phosphorylation and 
formation of STAT1 homodimers. STAT1 homodimers do not recruit IRF9 but instead directly target 
promotors of IFN responsive genes containing the gamma-activated sequence (GAS) DNA motif. 
Figure from (Sadler & Williams, 2008). 
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5.1.4 Biological effects of IFNs 
IFNs exert their biological function by inducing the expression of more than 300 genes that 
interfere with various cellular processes (Figure 36) and establish an ‘antiviral-state’ in host 
cells (reviewed in (Randall & Goodbourn, 2008)). Although several of these genes are 
expressed constitutively they are particularly up-regulated in response to IFN stimulation. The 
functions of many of these genes are not yet characterised; however, their biological effects 
broadly fall into four categories: 
(i) Restriction of viral replication by inhibition of the host cell’s mRNA processing machinery 
The protein products of several IFN-stimulated genes counteract viral replication by 
interfering with components of the host cell’s mRNA processing machinery. For example 
cytosolic dsRNA, a by-product of viral replication, is recognised by the IFN-inducible protein 
kinase R (PKR) (reviewed in (Williams, 1999)). Activated PKR then shuts down translation 
of host and viral mRNA by inhibiting the recycling of eIF2 (elongation initiation factor 2 
subunit ), a host cell factor that is essential to the initiation of mRNA translation.  
(ii) Blocking of viral protein function  
A variety of IFN-stimulated cellular proteins are able to interact directly with viral proteins, 
thereby restricting their function in the viral life cycle (reviewed in (Sadler & Williams, 
2008)). For instance, MxA, a member of the dynamin superfamily of large GTPases, is able to 
physically bind to the nucleoprotein component of viral nucleocapsids to inhibit the 
translocation of virus to the nucleus (Kochs & Haller, 1999).  
(iii) Induction of apoptosis 
IFNs contribute to the clearance of viral infections by promoting apoptosis of infected cells 
(reviewed in (Chawla-Sarkar et al, 2003)). Apoptosis is triggered by the activation of caspase 
cascades either by stimulation of death receptors on the surface of cells or release of 
cytochrome c from mitochondria. Several cellular procaspase genes are IFN-inducible and 
IFNs have been demonstrated to activate distinct apoptotic pathways, one of which involving 
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activation of PKR and the P53 signaling pathway in response to viral dsRNA (Cuddihy et al, 
1999a; Cuddihy et al, 1999b). 
(i) Modulation of adaptive immune responses 
Type I and II IFNs have profound immunomodulatory effects that promote the development 
of adaptive immune responses against viruses (reviewed in (Le Bon & Tough, 2002)). For 
example, IFNs enhance viral antigen presentation by increasing surface expression levels of 
the class I major histocompatibility complex (MHC) and augmenting the expression of 
components of the antigen processing machinery, e.g. the transport associated with antigen 
processing 1 (TAP1) (Epperson et al, 1992). Furthermore, type I IFNs have been 
demonstrated to promote the maturation of DCs (Luft et al, 1998) and to promote the survival 
of antigen-specific T cells by preventing their activation-induced cell death (Marrack et al, 
1999). 
 
 
Figure 36. Schematic of IFN-stimulated gene function. 
IFNs exert their biological function by inducing the expression of more than 300 genes. Figure from 
(de Veer et al, 2001), numbers in brackets indicate the number of IFN-stimulated genes identified by 
microarray in the respective category. 
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5.1.5 Aim 
The aim of this chapter was to investigate the cellular origin and the biological consequences 
of the IFN-inducible transcriptional signature in HAM/TSP.  
In particular we wished to investigate (i) whether the IFN-inducible blood transcriptional 
signature was also present on the protein level; (ii) whether the over-abundance of IFN-
stimulated gene transcripts in blood was a result of direct induction by HTLV-1 of an IFN-
mediated response in infected cells or reflected systemic exposure to IFNs that affected all 
peripheral leukocyte populations; and (iii) whether IFN-mediated immune responses affected 
viral mRNA and expression.  
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5.2 Results 
5.2.1 Validation of the IFN-inducible signature on the protein level 
Previous studies have suggested a poor correlation between cellular mRNA and protein levels 
(de Sousa Abreu et al, 2009; Maier et al, 2009). To confirm that the IFN-inducible 
transcriptional signature discovered in HAM/TSP was also present on the protein level, we 
quantified mRNA and corresponding protein levels of four representative IFN-stimulated 
genes: 1) STAT1, which is expressed in all peripheral leukocyte populations; 2) CD64 
(FCGRB1), which is expressed on monocytes; 3) CD95, which is expressed on T-
lymphocytes; and 4) CXCL10 (IP-10), which is secreted into the plasma (Figure 37).  
We found that protein levels as measured by flow cytometry and Luminex assays correlated 
well with mRNA abundance either in blood or individual cell populations (Figure 37 C). This 
finding supports a recent study by Schwanhausser et al. which reported that mRNA levels 
correlate better with protein levels than assumed previously: Schwanhausser and colleagues 
quantified the transcript abundance and absolute protein levels of more than 5,000 
mammalian cells and found that mRNA levels explained 40% of variation in protein levels 
(Schwanhausser et al, 2011). We conclude that the observed over-expression of IFN-
stimulated transcripts reflected an increased abundance of the corresponding proteins in 
patients with HAM/TSP.  
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Figure 37. Validation of the IFN-inducible mRNA signature in HAM/TSP on the protein level.  
The mRNA and protein levels of the IFN-stimulated genes (A, B) STAT1, (C, D) CD64 and (E, F) 
FAS were quantified by real-time PCR and flow cytometry on peripheral leukocyte populations. Data 
represents mean ± SEM; P-values were calculated using a two-tailed Mann-Whitney test with*P < 
0.05; mRNA: Ctrl: n=4, HAM/TSP: n=4; protein: Ctrl: n=10, HAM/TSP: n=10.  (G) Blood mRNA 
levels of CXCL10 correlated well with CXCL10 protein levels in plasma (Spearman correlation P-
value = 0.0011). AC: n= 13, HAM/TSP: n=13. 
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5.2.1 The HAM/TSP IFN-inducible transcriptional signature is present in monocytes 
and neutrophils 
 
In the blood CD4
+
 T cells constitute the main reservoir for HTLV-1 in vivo (Richardson et al, 
1990). To test whether the observed IFN-inducible signature was restricted to HTLV-1-
infected CD4
+
 T cells we selected genes with the strongest association with HAM/TSP (11 
genes; see Methods) and quantified their expression levels in separated blood leukocyte 
populations by quantitative RT-PCR (Figure 38 A). The IFN-inducible signature was present 
in neutrophils and monocytes (Fisher’s method of combining probabilities: P = 0.0271 and P 
= 0.0260 respectively) but not in CD4
+
 or CD8
+
 T cells (P= 0.3 and P=0.1, respectively, 
Figure 38 A).  
Furthermore, increased protein levels of STAT1, a key molecule in IFN signalling, were 
detected by flow cytometry in all peripheral blood effector cell populations from patients with 
HAM/TSP, but not in ACs or uninfected controls (Figure 38 B). These results suggest that the 
observed IFN-stimulated transcriptional signature in whole blood did not result from direct 
activation of IFN-mediated anti-viral pathways in infected CD4
+
 T cells but rather that all cell 
types had been systemically exposed to IFNs in vivo. 
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Figure 38. Expression of IFN-stimulated genes in blood leukocytes from patients with HAM/TSP.  
(A) The mRNA levels of the 11 genes most strongly associated with presence of HAM/TSP in whole 
blood and separated peripheral blood immune cell populations as quantified by real-time PCR (P-value: 
Fisher’s method of combining probabilities). Ctrl: n=4, HAM/TSP: n=4. (B) STAT1 protein levels in 
blood leukocyte populations. Whole blood samples were stained for markers of leukocyte populations; 
intracellular expression of STAT1 was assessed by flow cytometry. P-values were calculated using a 
two-tailed Mann-Whitney test with P <0.05 HAM/TSP versus 
*
controls or 
$
AC. Data represent mean ± 
SEM, Ctrl: n=6, AC: n=6, HAM/TSP: n=6.  
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5.2.3 Plasma protein levels of type I, II and III IFNs in HTLV-1 infection 
Over-expression of IFN-stimulated genes in peripheral blood leukocytes must result from 
exposure to IFNs in vivo. To identify the molecular basis of the IFN-inducible transcriptional 
signature we tested for elevated levels of IFNs in fresh plasma samples from patients with 
HAM/TSP. We did not detect significant differences in IFN-2, IFN-β, IFN-λ and IFN- 
plasma protein levels from HTLV-1 carriers and seronegative control subjects (Figure 39 A-
D).  
The family of type I IFNs comprises at least 13 different IFN- isoforms, and single IFN-, 
IFN-, IFN- and IFN- isotypes (Platanias, 2005). To avoid biasing our results towards 
subtypes IFN-2, IFN-β and IFN-, we tested patient plasma for general type I IFN 
bioactivity. For this we used a quantitative reporter gene assay: plasma samples were 
incubated with a macrophage cell line that carried the luciferase gene under the control of the 
type I IFN promotor. If type I IFN is present in patient plasma, luciferase protein is produced 
and subsequently generates measurable quantities of bioluminescence. We did not detect type 
I IFN bioactivity in plasma samples from HTLV-1 carriers or uninfected controls (data not 
shown). 
However, in agreement with previous reports (Narikawa et al, 2005; Guerreiro et al, 2006) 
plasma levels of the IFN--inducible chemokine CXCL10 were significantly increased in 
patients with HAM/TSP compared to ACs (Figure 39 E).   
 
 143 
 
 
 
 
Figure 39. Plasma concentrations of Type I, II and Type III IFNs and CXCL10.  
Plasma was cleared of blood cells by spin centrifugation and analyzed by luminex for concentrations of 
IFN and the IFN--inducible chemokine CXCL10. P-values were calculated using a two-tailed Mann-
Whitney test. No type I IFN bioactivity was detected in plasma samples (data not shown). Ctrl: n=12, 
AC: n=13, HAM/TSP: n=13. 
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5.2.3 Production of IFN- and IFN- in HTLV-1 infection 
Next, we tested for abnormal production of IFNs in patients with HAM/TSP compared to 
ACs and uninfected control subjects. Secretion of IFN- by pDCs in response to TLR7/8 
stimulation was quantified in short-term whole-blood ex vivo assays. We detected no 
significant differences in the production of IFN- by stimulated pDCs between HTLV-1 
carriers and uninfected controls (Figure 40 A).  
Next, we compared the capacities of CD8
+ 
T cells from HTLV-1 carriers and uninfected 
controls to produce IFN-T cells in fresh blood were activated with PMA and calcimycin in 
the presence of the golgi inhibitor monensin. We found that although the frequency of CD8
+
 
T cells producing IFN- in patients with HAM/TSP was greater than that in uninfected 
controls, it did not differ significantly from the frequency observed in ACs (Figure 40 B).  
 
Figure 40. Production of IFN- and IFN- in HTLV-1 carriers. 
(A) IFN- secretion by plasmacytoid dendritic cells (pDCs) in whole blood in response to stimulation 
of TLR7 and TLR8. Fresh blood was stimulated with 10 M R-848 for 3 h at 37C. Secreted IFN- 
was captured on the surface of pDCs and quantified by flow cytometry. (B) Intracellular production of 
IFN- in CD8+ T cells after PMA/calcimycin stimulation. Fresh blood was stimulated with 10 ng/ml 
PMA and 0.5 g/ml calcimycin in the presence of monensin for 4 h at 37C. Intracellular production of 
IFN- in CD8+ T cells was analyzed by flow cytometry. Histograms are gated on (A) pDCs or (B) 
CD8
+
 T cells; unstimulated controls are indicated as grey shaded area, stimulated samples are indicated 
by a solid black line. Data represents mean ± SEM; P-values were calculated using a two-tailed Mann-
Whitney test; Ctrl: n=6, AC: n=6, HAM/TSP: n=6. 
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5.2.4 Increased responsiveness to IFNs in HAM/TSP 
Next we analysed molecules of the IFN signalling pathway that are involved in IFN-
responsiveness. We measured the surface expression levels of the heterodimeric IFN-α and 
IFN-γ receptors on peripheral leukocyte populations by flow cytometry. We found that the 
expression levels of all receptor pairs were similar among the study groups (Figure 41).  
 
 
 
 
 
Figure 41. Surface expression of IFN receptors in HTLV-1 carriers and uninfected controls. 
Heparinised blood samples were analysed by flow cytometry after staining with monoclonal antibodies 
corresponding to leukocyte populations and (A) IFN-α receptor 1 (IFNAR1), (B) IFN-α receptor 2 
(IFNAR2), (C) IFN-γ receptor 1 (IFNGR1) or (D) IFN-γ receptor 2 (IFNGR2). No significant changes 
in IFN receptor abundance were detected between the study groups. Data represents mean ± SEM; P-
values were calculated using a two-tailed Mann-Whitney test; Ctrl: n=6, AC: n=5, HAM/TSP: n=4.  
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We then measured phosphorylated STAT1 (p-STAT1) by flow cytometry as a marker of 
activation of the IFN signalling pathway on a single-cell level. Stimulation with recombinant 
IFNs (particularly IFN-) led to an increase of p-STAT1 levels in all study groups (Figure 42 
A-B). Patients with HAM/TSP had higher STAT1 protein baseline levels, which, after IFN 
stimulation, resulted in significantly higher p-STAT1 levels compared to ACs or uninfected 
controls. Expression of STAT1 itself is up-regulated by IFNs (Hall & Rosen, 2010); it is 
likely that exposure to IFNs in vivo induces higher STAT1 protein and thus p-STAT1 levels 
which makes leukocytes from patients with HAM/TSP more sensitive to IFNs.  
 
 
Figure 42. Cellular responses to IFN stimulation in HTLV-1 carriers.  
STAT1-P(Y701) phosphorylation in response to (A) IFN- and (B) IFN- was quantified in whole 
blood by flow cytometry. Bar graphs represent the mean ± SEM, p-values were calculated using a two-
tailed Mann-Whitney test with *P <0.05 versus controls, 
$
P <0.05 versus AC; Ctrl: n=6, AC: n=6, 
HAM/TSP: n=6.  
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5.2.5 Effect of IFN-α and IFN-γ on HTLV-1 Tax, Gag and HBZ expression 
IFNs activate several intracellular antiviral responses and are typically associated with a 
beneficial effect on the outcome of viral infection (Randall & Goodbourn, 2008). To examine 
the effect of IFNs on HTLV-1 expression, we quantified protein expression of HTLV-1 Tax 
and Gag after treatment with exogenous IFN-α and IFN-γ. Interestingly, whilst IFN-α 
treatment partially inhibited the expression of the HTLV-1 protein Gag, it could not suppress 
production of the viral pleiotropic transcriptional transactivator Tax (Figure 43 A, B). In 
contrast, IFN-γ treatment did not alter the expression of either Gag or Tax proteins in infected 
CD4
+
 T cells (Figure 43 C, D).   
 
 
Figure 43. Effect of IFN- and IFN- on HTLV-1 Tax and Gag protein expression.  
CD8
+
 T cell depleted PBMCs were incubated for 16 h in the absence or presence of exogenous IFN-α 
or IFN-. Protein expression of the viral transactivator (A, C) Tax and the structural protein (B, D) 
were assessed by flow cytometry. P-values were calculated using a paired Wilcoxon signed-rank test; 
HAM/TSP: n=11. 
 
 148 
HBZ mRNA is consistently expressed in ATL cells, ACs and patients with HAM/TSP (Satou 
et al, 2006; Saito et al, 2009).  It is not known what proportion of HBZ mRNA is translated 
into protein and only recently a monoclonal antibody against HBZ protein has been 
developed. Using this antibody, Saito et al. provided some preliminary evidence for 
suppression of HBZ protein expression in vivo but confirmed a correlation between HBZ 
mRNA and the severity of HAM/TSP (Saito et al, 2011).  
We quantified HBZ and Tax mRNA after stimulation with exogenous IFN-α and IFN-γ. 
Expression of Tax mRNA was strongly induced during incubation of non-stimulated cells in 
vitro and treatment with IFNs neither enhanced nor suppressed this effect. In contrast, HBZ 
mRNA was detected in fresh cells from HTLV-1 carriers and its levels increased with IFN 
treatment; however, this observation did not reach statistical significance (Figure 44). 
 
 
Figure 44. Effect of IFNs on Tax and HBZ mRNA expression. 
Fresh PBMCs were depleted of CD8
+
 T cells and incubated in the absence or presence of 100 IU/ml 
IFN- or IFN-. (A) Tax and (C) HBZ mRNA levels were quantified by real-time PCR after 0, 2, 4, 8 
and (B) 16 h. All graphs depict mean ± SEM. (D) Table depicts the average Tax and HBZ mRNA fold 
change after 16 h incubation with IFNs. P-values were calculated using a Wilcoxon signed-rank test. 
AC: n=2, HAM/TSP: n=7. 
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5.3 Discussion 
5.3.1 The HAM/TSP blood transcriptional signature is likely to result from exposure 
of peripheral leukocyte populations to IFNs in vivo 
 
Expression of IFN-stimulated genes was evident in neutrophils and monocytes, but not in T 
cells, which are the main cellular reservoir of HTLV-1 in vivo (Richardson et al, 1990). It is 
therefore likely that the HAM/TSP-specific transcriptional profile originated from exposure to 
IFNs in vivo rather than direct activation of the IFN-response pathway by HTLV-1 in infected 
cells. The IFN-stimulated genes identified in HAM/TSP can be induced by both type I and 
type II IFNs (Figure 30 B); however we did not detect abnormal plasma levels of any type of 
IFN in patients with HAM/TSP. This may be due to their short half-life in blood (Harris & 
Chess, 2003) or because production of IFNs in HAM/TSP is increased locally rather than 
systemically. Indeed, it has been shown that in response to retroviral infection activated pDCs 
migrate to the lymph nodes where they produce large amounts of type I IFNs (Diop et al, 
2008). Furthermore, IFN- could be produced locally by antigen-stimulated T cell populations 
in inflamed tissues, thus affecting the gene expression pattern in blood cells that are recruited 
to or circulate through these areas. 
Previous studies on monocyte-derived or isolated blood DCs from HTLV-1 carriers reported 
a diminished capacity of these cells to produce IFN- after in vitro stimulation with TLR 
agonists (Makino et al, 2000; Al-Dahoodi et al, 2003; Hishizawa et al, 2004). In contrast, we 
did not obtain evidence for abnormal production of IFN- by pDCs in a short term ex vivo 
whole blood assay. Based on the previous in vitro findings, the authors hypothesized that 
direct infection of DCs with HTLV-1 impairs the cells’ function to efficiently stimulate anti-
viral adaptive immune responses leading to immune suppression and pathogenesis in HTLV-1 
infection. However, whilst it has been shown that DC can be infected with HTLV-1 in vitro 
(Ali et al, 1993; Jones et al, 2008) and there is some evidence for the presence of HTLV-1-
infected blood DCs in patients with HAM/TSP (Macatonia et al, 1992), the overall infection 
rate of blood DCs in HTLV-1 infection is low. 
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A recent finding by Tilton and colleagues in patients infected with HIV could reconcile our in 
vivo observations with the reports on DC dysfunction in vitro (Tilton et al, 2008). In HIV 
infection, Tilton et al. observed the same discrepancy between the expression of IFN-
stimulated genes in vivo but reduced IFN- production by pDCs in vitro. They found that 
restimulation of pDCs with TLR agonists in vitro initiated a negative feedback loop that 
resulted in inhibition of IFN- production. They concluded that low production of type I IFNs 
by pDCs in vitro does not necessarily reflect diminished IFN- production in vivo.  
Previous studies have documented elevated IFN- levels in plasma and cerebrospinal fluid 
(CSF) of some but not all HTLV-1 carriers and patients with HAM/TSP (Kuroda & Matsui, 
1993; Furuya et al, 1999; Inagaki et al, 2006). Whilst we did not detect increased plasma IFN-
 levels in our patient cohort, we found that CD8+ T cells from patients with HAM/TSP 
produced high levels of IFN-γ in response to a non-specific stimulus ex vivo. Furthermore, we 
confirmed the presence of increased plasma levels of the IFN--inducible chemokine 
CXCL10. Taken together these findings may reflect higher local production of IFN-γ in vivo.  
Elevated plasma levels of the chemokine CXCL10 have been reported previously (Narikawa 
et al, 2005). CXCL10 is produced and secreted by monocytes, neutrophils and epithelial cells 
in response to stimulation with IFN-γ (reviewed in (Liu et al, 2011)). The CXCL10 receptor, 
CXCR3, is expressed on activated but not on resting T cell and NK cell populations 
(Bonecchi et al, 1998; Inngjerdingen et al, 2001). In addition to its chemotactic activity, 
CXCL10 promotes apoptosis and regulates cell proliferation and growth (Liu et al, 2011). 
Elevated plasma levels of CXCL10 have been reported in chronic HCV infection where they 
correlated with negative treatment outcome (Butera et al, 2005). However, a recent study by 
Casrouge et al. was able to attribute this effect to a dominant negative version of CXCL10 
(Casrouge et al, 2011): a truncated form of the protein binds but does not activate the CXCR3 
receptor, thus inhibiting the recruitment of activated responder cell populations to the site of 
inflammation. Current CXCL10 assays are not able to discriminate between the full length 
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and truncated form of CXCL10; thus, it is not clear whether the situation in HTLV-1 infection 
resembles that in HCV. 
5.3.2 Evidence for the self-amplifying nature of the IFN-inducible signature 
We found that STAT1, a key molecule of the IFN signaling pathway, was up-regulated in 
patients with HAM/TSP. Indeed, many of the receptors, signal transduction molecules and 
transcription factors that are involved in IFN production and signaling are themselves 
inducible by IFNs (Sato et al, 1998; Miettinen et al, 2001). This generates a powerful feed-
forward loop that promotes the rapid amplification of IFN responses. Thus, increased STAT1 
levels in leukocytes from patients with HAM/TSP heightened the cells’ responsiveness to 
IFNs.  
However, a possible consequence of the heightened sensitivity to IFNs is that comparably low 
levels of IFN can maintain the expression of the IFN-inducible transcriptional signature. 
Thus, it is likely that even transient production of IFNs could prolong the potentially 
pathogenic effects of the transcriptional signature in patients.  
 
5.3.3 IFNs only partially inhibit HTLV-1 protein expression 
IFNs activate several intracellular pathways that ultimately lead to the inhibition of viral 
protein expression and replication (Randall & Goodbourn, 2008). We found that in the 
absence of CD8
+
 T cells, exogenous IFN- did not alter HTLV-1 mRNA or protein expression 
patterns. In contrast, treatment with IFN- reduced the expression of the structural viral 
protein Gag; however, it did not affect the expression of the viral transactivator protein Tax. 
Furthermore, IFN treatment increased HBZ expression but this observation did not reach 
statistical significance. 
 152 
There are few studies that examined the effect of IFN treatment on HTLV-1 replication and 
none of them assessed the impact on Tax or HBZ expression. However, our finding that IFN-
 suppresses expression of Gag protein is consistent with a recent report by Kinpara and 
colleagues who found that co-cultivation of type I IFN-producing cells with HTLV-1-infected 
cell lines inhibited transcription of viral Gag mRNA and subsequently reduced Gag protein 
levels (Kinpara et al, 2009). 
Whilst Gag is required for the formation of HTLV-1 capsids, HTLV-1 Tax is essential to the 
viral life cycle: it has been shown to drive viral replication, promote host cell proliferation 
and viral cell-to-cell spread (Grassmann et al, 2005; Matsuoka & Jeang, 2007). HBZ has been 
shown to down-modulate Tax function (Basbous et al, 2003; Matsumoto et al, 2005) whilst 
promoting infectivity and viral persistence (Arnold et al, 2006), and a recent study has linked 
elevated HBZ mRNA levels to increased clinical severity of HAM/TSP (Saito et al, 2009).  
We conclude that although type I IFN treatment may decrease the production of viral 
structural complexes, i.e. capsids, it does not completely abrogate viral activity and 
proliferation of infected cells.  
Indeed, a previous study by Smith et al. demonstrated that HTLV-1-infected cells are resistant 
to type I IFN-mediated cell cycle arrest and continue to proliferate in the presence of IFN- 
(Smith et al, 1999). This suggests that HTLV-1 interferes with type I IFN signaling cascades, 
which blocks the transcription of IFN-stimulated genes and may explain the absence of the 
IFN-inducible transcriptional signature in CD4
+
 T cells.  
HTLV-1-infected cells express normal levels of the IFN I receptor on the cell surface (Smith 
et al, 1999; Feng & Ratner, 2008); suggesting that perturbations occur downstream of the 
receptor. Feng et al. reported low levels of phosphorylated Tyk2 and STAT2 in HTLV-1-
infected cells in response to IFN- and IFN- stimulation (Feng & Ratner, 2008). The 
unphosphorylated forms of the proteins are unable to form the ISGF3 complex that initiates 
the transcription of genes containing an ISRE motif in their promotor sequence (see section 
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5.1.3). The authors found that this effect was independent of HTLV-1 envelope and 
polymerase as well as Tax-mediated activation of the NF-B pathway and suggested that the 
effect may be mediated by Gag.  
Furthermore, a recent study by Olière and colleagues found that a cellular inhibitor of IFN 
signaling, SOCS1, was over-expressed in CD4
+
 T cells from patients with HAM/TSP (Oliere 
et al, 2010). SOCS1 abrogates IFN signaling by dephosphorylating activated STAT1 
molecules. In a subsequent publication Charoenthongtrakul et al. were able to demonstrate 
that HTLV-1 Tax can induce SOCS1 expression and that SOCS1 expression levels correlate 
with proviral load in CD4
+ 
T cells from patients with HAM/TSP (Charoenthongtrakul et al, 
2011).   
In addition to blocking IFN-mediated phosphorylation of signaling molecules, HTLV-1 Tax 
interferes with the JAK-STAT signaling pathway by competing with the ISGF3 complex for 
binding to the cellular coactivators p300 and CBP (cyclic AMP-responsive element-binding 
factor (CREB)-binding protein) (Zhang et al, 2008). The CBP/p300 complex acts as an 
adaptor that connects transcription factors to the cellular transcription machinery: thus, 
HTLV-1 inhibits ISGF3-mediated activation of IFN-stimulated gene transcription. 
It should be noted that the majority of experiments investigating IFN signaling in HTLV-1 
infection were performed on HTLV-1-transformed or Tax-expressing cell lines. Thus, the 
actual in vivo significance of these experiments is not clear as depending on the experimental 
setting HTLV-1 Tax for example either to down-regulate or up-regulate the expression of 
IFN-stimulated genes (Suzuki et al, 2010).  
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5.3.4 Limitations 
We were not able to explore the effect of IFNs on Gag mRNA because of technical 
limitations: the gag gene does not contain a splice site that allows the design of intron-
spanning primers. Therefore, detection of Gag mRNA during real-time PCR can be 
confounded by genomic proviral DNA. As we were not able to eliminate all traces of 
genomic DNA from RNA preparations the accurate detection of Gag mRNA was technically 
not possible. 
 
5.3.5 Summary of the Chapter 
In this chapter, we confirmed that the IFN-inducible transcriptional signature discovered in 
HAM/TSP was also present on the protein level. Expression of IFN-stimulated genes was 
evident in all peripheral leukocyte populations, suggesting that the transcriptional profile 
originated from exposure to IFNs in vivo rather than direct activation of the IFN-response 
pathway by HTLV-1 in infected cells. The source of IFN in vivo remains unknown, as there 
were no differences in IFN production or plasma protein levels between ACs and patients 
with HAM/TSP.  However, cells from patients with HAM/TSP responded strongly to IFN 
treatment, suggesting that they were primed by IFNs in vivo. Furthermore, we found that 
whilst IFN- had no effect on viral protein expression, IFN- treatment suppressed expression 
of the viral structural protein Gag, but not Tax or HBZ. 
 
Publication arising from this chapter 
Tattermusch, S., Skinner, J.A., Chaussabel, D., Banchereau, J., Berry, M.P., MacNab, F.W., 
O’Garra, A., Taylor, G.P., Bangham, C.R.M. (2011) Systems biology approaches reveal a 
specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8: 
e1002480 
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Chapter 6 
 
Discussion 
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Despite our growing understanding of HTLV-1 persistence, very little is known about the 
pathogenesis of HAM/TSP and, importantly, what distinguishes hosts who develop the 
disease from those who remain asymptomatic. The aim of this study was to identify cell 
populations, pathways and molecules in whole blood gene expression profiles of HTLV-1 
carriers that fuel new hypotheses as to the mechanisms of viral persistence and HAM/TSP 
pathology.  
Here, we present 3 major findings: 
(i) HAM/TSP was associated with an over-expression of a distinct subset of IFN-stimulated 
genes in peripheral leukocytes; 
(ii) HTLV-1 infection was associated with differential expression of molecules involved in 
p53 signalling cascades; 
(iii) HTLV-1 carriers had skewed ratios of B cell and NK cell subsets, and high frequencies of 
granzyme and perforin-rich CD8
+
 and DN T cells were present in patients with HAM/TSP. 
Taken together these findings provide evidence for differential innate and adaptive immune 
responses between ACs and patients with HAM/TSP that are likely to be the underlying basis 
of disease development in HTLV-1 infection.  
The observed over-expression of IFN-stimulated genes in patients with HAM/TSP could be 
cause or consequence of the disease. However, we argue that the latter is more likely based on 
the findings that (i) the expression of these genes was independent of HTLV-1 proviral load 
and thus does not passively follow or directly arise from increased viral replication; and (ii) 
the IFN-inducible signature was absent in multiple sclerosis and therefore does not merely 
reflect inflammation of the central nervous system per se.   
The majority of studies have reported immunomodulatory effects of IFNs that are beneficial 
for the host. Indeed, type I IFN therapy is effective in controlling certain persistent viral 
infections (Pearlman & Traub, 2011), and there is evidence that it can slow down disease 
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progression in multiple sclerosis (Dhib-Jalbut & Marks, 2010). However, clinical trials 
assessing the benefit of IFN- and IFN- therapy in the treatment of HAM/TSP have been 
less successful (reviewed in (Martin & Taylor, 2011)); few patients showed any improvement 
and the overall clinical benefit was limited.  
Although a beneficial net effect of systemically administered IFN cannot be excluded, two 
findings in the present study support the clinical observation that IFNs do not effectively 
control HTLV-1 infection: (i) over-expression of IFN-stimulated genes was not observed in 
healthy HTLV-1 carriers who efficiently control the infection; (ii) while IFN- reduced the 
expression of the structural viral protein Gag as reported previously (Kinpara et al, 2009), we 
found that IFN treatment did not affect the expression of the viral transactivator protein Tax 
or HBZ mRNA.  
An increasing body of evidence suggests an immunomodulatory effect of IFNs on T cell 
activity that enhances clearance of acute infections but can have detrimental effects in 
persistent infections. For example, in a murine model repeated triggering of TLR7 and TLR9 
signalling cascades and subsequent type I IFN production resulted in immunocompromised 
phenotypes: animals presented with lymphopenia, elevated proinflammatory cytokine and 
IgG levels, splenomegaly as well as altered morphology and function of lymphoid organs 
(Heikenwalder et al, 2004; Baenziger et al, 2009).  
A relationship between chronic production of type I IFNs and immunopathogenesis has also 
been established in simian immunodeficiency virus (SIV) infection. Non-pathogenic SIV 
infection in sooty mangabeys and African green monkeys is characterised by significant 
induction of IFN-stimulated gene expression, which abates at the end of the acute phase 
(Bosinger et al, 2009; Jacquelin et al, 2009). In contrast, rhesus macaques that chronically 
produce high levels of type I IFNs rapidly progress to AIDS (acquired immunodeficiency 
syndrome) (Durudas et al, 2009).  
Current research has predominantly focussed on the direct interactions between IFN-
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stimulated genes and viral proteins and much less is known about their role in uninfected cells 
or about changes in immune functions due to chronic IFN exposure. Chronically high levels 
of IFNs and IFN-stimulated genes have been implicated in the immunopathology observed in 
several autoimmune diseases such as lupus erythematosus and dermatomyositis (Baechler et 
al, 2003; Baechler et al, 2007; Li et al, 2010). Although it is not fully understood how 
sustained IFN signalling leads to immunopathology, several studies have documented the 
deleterious effects of long-term IFN exposure in viral infections.  
Herbeuval and colleagues demonstrated that type I IFN controls TRAIL (TNF-related 
apoptosis-inducing ligand)-dependent apoptosis of CD4
+
 T cells in HIV infection (Herbeuval 
et al, 2005). Additional studies in HIV infection showed that IFN--mediated MHC I up-
regulation on thymic epithelial cells resulted in the selection of CD3
+
CD8
low
 T cells that were 
less responsive to antigen stimulation (Keir et al, 2002a; Keir et al, 2002b). Thus, type I IFNs 
can compromise anti-viral immune responses by reducing the frequencies of CD4
+ 
T cells and 
promoting the selection of dysfunctional CD8
+
 T cells, at least in HIV infection. 
IFNs have also been recognised as important players in neuroinflammation. IFN- production 
in the CNS has been associated with demyelination and disease exacerbation in multiple 
sclerosis (Panitch et al, 1987; Renno et al, 1998). Furthermore, IFN- has been suggested to 
allow for CTLs and other peripheral to cross the blood-brain-barrier (BBB) (Wong et al, 
2004). The BBB is formed by specialised endothelial cells connected by tight junctions, 
which limits the exchange of fluids, molecules and cells between the CNS and the peripheral 
blood circulation. In an in vitro model of the human BBB, IFN- has been demonstrated to 
disrupt the tight junctions that connect the cells, thus compromising the integrity of the BBB 
(Wong et al, 2004). 
If chronic over-expression of IFN-stimulated genes is indeed the cause of HAM/TSP, then 
what could cause this over-expression? This question was addressed by Boasso et al. who 
suggested a double-threshold model of DC activation and associated type I IFN responses 
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during viral infections (Figure 45) (Boasso et al, 2011).  According to this model, minimal 
antigen stimulation results in moderate activation of antigen presenting cells characterised by 
up-regulation of co-stimulatory molecules (1
st
 threshold). In contrast, a strong stimulus is 
required to initiate production of type I IFNs and associated innate antiviral immune 
responses (2
nd
 threshold). High-level DC activation is prominent during the acute phase of 
viral infections where it promotes T helper cell responses that eventually limit viral 
replication. However, DC activation is only transient and falls below the second threshold 
during the contraction of the innate responses. Here, low activation of DCs controls the newly 
developed cytotoxic T cell responses. However, in some chronic viral infections DCs are 
consistently over-activated, causing acute immune responses to continue into the chronic 
phase. This results in persistent stimulation of innate and adaptive immune responses, which 
can contribute to immunopathogenesis. 
Indeed, the two-threshold model could explain the differential immune responses between 
ACs and patients with HAM/TSP in HTLV-1 infection. In ACs efficient lysis of infected cells 
by highly cytotoxic NK cells and HTLV-1-specific-T cells results in low HTLV-1 antigen 
abundance and thus low activation of DCs, which then promote moderate T cell responses. In 
contrast, low lytic efficiency of CTLs and NK cells results in increased HTLV-1-antigen 
abundance, which leads to over-activation of DCs in some HTLV-1 carriers (patients who 
develop HAM/TSP) but not all (ACs with high proviral loads). IFN production by persistently 
over-activated DCs can then promote immunopathogenic processes.  
We did not detect increased frequencies of mature DCs or elevated levels of type I IFNs in the 
peripheral blood of patients with HAM/TSP. Nevertheless, Boasso’s model may apply to 
HTLV-1 infection: activated DCs preferentially migrate to the lymph nodes, and it is possible 
that the production of excessive type I IFNs occurs in the lymph nodes. To confirm this it 
would be necessary to examine DC phenotypes and type I IFN levels in lymph nodes from 
ACs and patients with HAM/TSP. 
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Figure 45. Double-threshold model of DC activation and differential outcome in viral infections. 
(A) During the acute phase of infection DCs are strongly activated (above the 2
nd
 threshold) but this 
activation is rapidly controlled to promote the contraction of immune responses and allow for 
maintenance of moderate memory T cell responses. (B) DC stimulation is not controlled and continues 
throughout the chronic phase of the infection. This promotes the continuous development of new 
primary innate and adaptive immune responses while memory T cell responses are suppressed. Figure 
from (Boasso et al, 2011). 
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An alternative concept for the induction of IFN responses has been proposed by several 
groups who investigated individual-specific variances in gene-expression profiles of healthy 
subjects. These studies revealed differences in baseline expression levels of IFN-stimulated 
genes that were consistent over time (Whitney et al, 2003; Radich et al, 2004; Eady et al, 
2005). Elevated baseline levels of IFN-stimulated genes were detected in ~18% of healthy 
individuals and upon stimulation with IFN-α, individuals with high baseline levels had a > 2-
fold higher maximal expression level of IFN-stimulated genes than subjects with low baseline 
levels. Furthermore, donor-specific differences in expression of IFN-responsive genes were a 
prominent feature of gene expression in PBMCs challenged with bacteria in vitro (Boldrick et 
al, 2002). 
If indeed there is a substantial variation in IFN-stimulated gene expression in the normal 
population, it is intriguing to consider the possibility that the response to IFNs might be 
‘preset’, and so might predetermine the outcome of infections with viruses such as HTLV-1. 
In that case, it is likely that an individual’s genetic background will determine the base line 
level of IFN-stimulated gene expression. To confirm this potential relationship between host 
genotype and outcome of HTLV-1 infection, it will be necessary to test for an association 
between single nucleotide polymorphisms in interferon-associated genes and the presence of 
HAM/TSP. 
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Appendix –I: Genes 
Suppl. Table 1. List of the 542 transcripts deregulated in HTLV-1 infection. 
Illumina HT12 v3 ID Gene Symbol Genbank 
ILMN_1776157 SEPT4 NM_080415.1 
ILMN_1789627 SEPT5 NM_002688.4 
ILMN_2061446 AADACL1 NM_020792.3 
ILMN_2094875 ABCB1 NM_000927.3 
ILMN_1812070 ABCB1 NM_000927.3 
ILMN_1677814 ABCC3 NM_003786.2 
ILMN_2396672 ABLIM1 NM_001003407.1 
ILMN_1785424 ABLIM1 NM_006720.3 
ILMN_1656940 ABLIM3 NM_014945.2 
ILMN_1740265 ACOT7 NM_181864.2 
ILMN_1784203 ACRBP NM_032489.2 
ILMN_2148360 ADAM10 NM_001110.2 
ILMN_1664236 ADAM28 NM_021777.3 
ILMN_1730504 AGPAT4 NM_020133.2 
ILMN_2307656 AGTRAP NM_001040194.1 
ILMN_1752159 AHNAK NM_024060.2 
ILMN_1681301 AIM2 NM_004833.1 
ILMN_1670282 AIRE NM_000658.1 
ILMN_1712530 AKAP1 NM_003488.3 
ILMN_1713124 AKR1C3 NM_003739.4 
ILMN_1687757 AKR1C4 NM_001818.2 
ILMN_1670870 ALCAM NM_001627.2 
ILMN_1690252 ALKBH2 NM_001001655.1 
ILMN_1713731 ALOX12 NM_000697.2 
ILMN_1793894 ANAPC13 NM_015391.2 
ILMN_2132599 ANKRD22 NM_144590.1 
ILMN_1799848 ANKRD22 NM_144590.2 
ILMN_2214278 ANKRD32 NM_032290.2 
ILMN_1798006 ANKRD35 NM_144698.2 
ILMN_1711408 ANXA4 NM_001153.2 
ILMN_2325338 APOL2 NM_145637.1 
ILMN_1736112 ARHGAP10 NM_024605.3 
ILMN_1660544 ARRDC4 NM_183376.1 
ILMN_2184064 ARRDC4 NM_183376.1 
ILMN_1769013 ASGR1 NM_001671.2 
ILMN_1815184 ASPM NM_018136.3 
ILMN_2374865 ATF3 NM_001040619.1 
ILMN_1779214 ATM NM_000051.3 
ILMN_1730291 ATP1B1 NM_001677.3 
ILMN_2407824 ATP1B1 NM_001001787.1 
ILMN_2376771 ATR NM_001184.2 
ILMN_2271627 ATXN2L NM_007245.2 
ILMN_1749081 AUTS2 NM_015570.1 
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ILMN_1724480 AXIN2 NM_004655.2 
ILMN_1761093 B3GAT1 NM_018644.3 
ILMN_1669323 BACE2 NM_138992.1 
ILMN_1690241 BATF2 NM_138456.3 
ILMN_1763207 BATF3 NM_018664.1 
ILMN_1704452 BCL9 NM_004326.2 
ILMN_2351638 BEX4 NM_001080425.1 
ILMN_1806473 BEX5 NM_001012978.1 
ILMN_1747650 BMP6 NM_001718.4 
ILMN_1724658 BNIP3 NM_004052.2 
ILMN_1697546 BRCC3 NM_024332.2 
ILMN_1800619 BRI3BP NM_080626.5 
ILMN_1770161 BST1 NM_004334.1 
ILMN_1802708 BTN3A1 NM_007048.4 
ILMN_1749868 C10ORF38 NM_001010924.1 
ILMN_1790100 C11ORF82 NM_145018.2 
ILMN_1730523 C16ORF14 NM_138418.2 
ILMN_1693630 C16ORF7 NM_004913.2 
ILMN_1702526 C17ORF48 NM_020233.4 
ILMN_1717793 C19ORF33 NM_033520.1 
ILMN_1692834 C1ORF26 NM_017673.5 
ILMN_1796409 C1QB NM_000491.3 
ILMN_1662640 C20ORF127 NM_080757.1 
ILMN_1791248 C20ORF175 NM_080829.1 
ILMN_1785644 C20ORF29 NM_018347.1 
ILMN_1712386 C21ORF45 NM_018944.2 
ILMN_2224486 C3ORF14 NM_020685.3 
ILMN_1672124 C4ORF18 NM_016613.4 
ILMN_1672605 C7ORF41 NM_152793.2 
ILMN_1714278 C9ORF30 NM_080655.1 
ILMN_1762508 C9ORF72 NM_145005.3 
ILMN_1783598 CAB39L NM_001079670.1 
ILMN_1676973 CABP5 NM_019855.3 
ILMN_1671263 CACNA1H NM_021098.2 
ILMN_1754076 CACNA2D3 NM_018398.2 
ILMN_1730487 CALD1 NM_033140.2 
ILMN_1743021 CAMKK2 NM_153500.1 
ILMN_1792660 CAMSAP1L1 NM_203459.1 
ILMN_1722158 CASP5 NM_004347.1 
ILMN_2373763 CASP7 NM_033339.3 
ILMN_1686920 CCDC58 NM_001017928.2 
ILMN_2228845 CCL28 NM_148672.2 
ILMN_2374425 CCNE1 NM_001238.1 
ILMN_1715131 CCR7 NM_001838.2 
ILMN_1722622 CD163 NM_203416.2 
ILMN_2379599 CD163 NM_203416.1 
ILMN_1733270 CD163 NM_004244.4 
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ILMN_2174805 CD300LG NM_145273.2 
ILMN_2070940 CD302 NM_014880.3 
ILMN_1716797 CD302 NM_014880.3 
ILMN_1792538 CD7 NM_006137.6 
ILMN_1704730 CD93 NM_012072.3 
ILMN_2379560 CDC14B NM_033331.2 
ILMN_1737184 CDCA7 NM_031942.4 
ILMN_1784602 CDKN1A NM_000389.2 
ILMN_2371724 CEACAM1 NM_001024912.1 
ILMN_1795933 CHMP7 NM_152272.2 
ILMN_1732831 CHST7 NM_019886.2 
ILMN_1653166 CLEC10A NM_006344.2 
ILMN_1796423 CLIC3 NM_004669.2 
ILMN_1682501 CNOT1 NM_206999.1 
ILMN_1711514 COCH NM_004086.1 
ILMN_1698621 COG5 NM_006348.2 
ILMN_1721535 COG5 NM_006348.2 
ILMN_1726591 COP1 NM_052889.2 
ILMN_1720484 CRTAP NM_006371.3 
ILMN_2392189 CTDSPL NM_005808.2 
ILMN_1665655 CTDSPL2 NM_016396.1 
ILMN_1792885 CTSC NM_001814.2 
ILMN_2387224 CTSE NM_148964.1 
ILMN_1758895 CTSK NM_000396.2 
ILMN_1744912 CTTN NM_005231.2 
ILMN_2393712 CTTN NM_138565.1 
ILMN_1752562 CXCL5 NM_002994.3 
ILMN_2171384 CXCL5 NM_002994.3 
ILMN_1779234 CXCL6 NM_002993.2 
ILMN_1745256 CXXC5 NM_016463.5 
ILMN_1708303 CYP4F22 NM_173483.2 
ILMN_1772627 D4S234E NM_001040101.1 
ILMN_2209671 DCDC5 NM_198462.2 
ILMN_1805696 DFFA NM_213566.1 
ILMN_2384181 DHRS9 NM_005771.3 
ILMN_1733998 DHRS9 NM_005771.3 
ILMN_1727150 DHRS9 NM_199204.1 
ILMN_2285618 DIP2A NM_015151.2 
ILMN_1767651 DKFZP434B0335 NM_015395.1 
ILMN_1892638 DKFZP564C152 AL049980 
ILMN_2049184 DNASE1L3 NM_004944.2 
ILMN_1700822 DPP3 NM_005700.3 
ILMN_1692535 DPP4 NM_001935.3 
ILMN_1811328 DPP7 NM_013379.2 
ILMN_2402640 DSC1 NM_004948.2 
ILMN_2401873 DUSP10 NM_144729.1 
ILMN_1690939 ECGF1 NM_001953.2 
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ILMN_1767322 EDAR NM_022336.2 
ILMN_2371055 EFNA1 NM_004428.2 
ILMN_1805902 ELA1 NM_001971.4 
ILMN_1737965 ELOVL4 NM_022726.2 
ILMN_1780601 EMR1 NM_001974.3 
ILMN_1664265 EPHA1 NM_005232.3 
ILMN_2388547 EPSTI1 NM_033255.2 
ILMN_2352131 ERBB2 NM_004448.2 
ILMN_1668092 ESAM NM_138961.1 
ILMN_1788625 EXOC5 NM_006544.3 
ILMN_2364529 EZH2 NM_152998.1 
ILMN_1717163 F13A1 NM_000129.3 
ILMN_2102951 FAHD2A NM_016044.1 
ILMN_1714418 FAM101B NM_182705.2 
ILMN_2291455 FAM102A NM_001035254.1 
ILMN_1788416 FAM108C1 NM_021214.1 
ILMN_2319077 FAS NM_152877.1 
ILMN_1808132 FAS NM_152872.1 
ILMN_1700232 FBXO30 NM_032145.4 
ILMN_1701455 FBXO6 NM_018438.4 
ILMN_2176063 FCGR1A NM_000566.2 
ILMN_2391051 FCGR1B NM_001004340.1 
ILMN_2261600 FCGR1B NM_001017986.1 
ILMN_1782015 FCRLB NM_001002901.2 
ILMN_2370976 FER1L3 NM_013451.2 
ILMN_1810289 FER1L3 NM_133337.1 
ILMN_1795865 FGFRL1 NM_021923.3 
ILMN_2355831 FHL2 NM_201555.1 
ILMN_1668411 FHL2 NM_201557.2 
ILMN_2303955 FKBP1B NM_054033.1 
ILMN_1778444 FKBP5 NM_004117.2 
ILMN_1733947 FKBP8 NM_012181.3 
ILMN_1707286 FLJ22662 NM_024829.4 
ILMN_1693471 FLJ33790 NM_001039548.1 
ILMN_1687335 FLNA NM_001456.2 
ILMN_1789400 FOXD2 NM_004474.3 
ILMN_1682495 FOXP1 NM_032682.4 
ILMN_1811692 FTSJ3 NM_017647.2 
ILMN_1724236 FUT7 NM_004479.2 
ILMN_1781045 FXYD2 NM_021603.2 
ILMN_1768812 FXYD6 NM_022003.1 
ILMN_2052208 GADD45A NM_001924.2 
ILMN_1657475 GALT NM_000155.2 
ILMN_1794595 GAMT NM_000156.4 
ILMN_1756469 GAMT NM_000156.4 
ILMN_1784749 GAS6 NM_000820.1 
ILMN_1741837 GBAP NR_002188.1 
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ILMN_1701114 GBP1 NM_002053.1 
ILMN_2148785 GBP1 NM_002053.1 
ILMN_1725314 GBP3 NM_018284.2 
ILMN_2114568 GBP5 NM_052942.2 
ILMN_1725471 GK NM_000167.3 
ILMN_2217513 GLB1L NM_024506.3 
ILMN_1782419 GNG11 NM_004126.3 
ILMN_2401033 GOSR1 NM_001007024.1 
ILMN_1753575 GP1BA NM_000173.4 
ILMN_1732269 GP6 NM_001083899.1 
ILMN_1743290 GP9 NM_000174.2 
ILMN_2283325 GPR177 NM_024911.4 
ILMN_1805973 GPR19 NM_006143.1 
ILMN_1701947 GPR34 NM_005300.3 
ILMN_1778143 GRAP2 NM_004810.2 
ILMN_1713162 GSTM2 NM_000848.2 
ILMN_2157957 GTF2H1 NM_005316.2 
ILMN_1731233 GZMH NM_033423.3 
ILMN_1694268 HES6 NM_018645.3 
ILMN_1686478 HIST1H2AG NM_021064.3 
ILMN_1651496 HIST1H2BD NM_138720.1 
ILMN_1758623 HIST1H2BD NM_138720.1 
ILMN_1732071 HIST2H2BE NM_003528.2 
ILMN_2115340 HIST2H4A NM_003548.2 
ILMN_2066060 HLA-DRB6 NR_001298.1 
ILMN_1720059 HMBOX1 NM_024567.2 
ILMN_1705984 HNMT NM_006895.2 
ILMN_1671486 HOMER2 NM_199331.2 
ILMN_1741406 HOOK1 NM_015888.4 
ILMN_1768101 HOXB6 NM_018952.4 
ILMN_1867588 HS.103173 BX100504 
ILMN_1851599 HS.130245 BX110640 
ILMN_1911047 HS.14706 AY358510 
ILMN_1915777 HS.202313 BQ189294 
ILMN_1914343 HS.211821 BX090817 
ILMN_1836309 HS.326560 XM_498568 
ILMN_1915076 HS.355933 AK123915 
ILMN_1864558 HS.382309 BC034632 
ILMN_1906423 HS.390407 BX097705 
ILMN_1847870 HS.445121 BM545878 
ILMN_1866389 HS.446266 BQ182905 
ILMN_1868047 HS.537779 BP398340 
ILMN_1865639 HS.548213 AI630987 
ILMN_1859863 HS.555181 BM458075 
ILMN_1856991 HS.557339 AA080911 
ILMN_1818632 HS.561844 BX101194 
ILMN_1886769 HS.572538 CF454561 
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ILMN_1911428 HS.573549 BG190571 
ILMN_1851535 HS.578214 DA957648 
ILMN_1842582 HS.579530 CD522953 
ILMN_1832508 HS.583642 BG190619 
ILMN_1910908 HS.72010 BG205162 
ILMN_1654566 HSPA1L NM_005527.3 
ILMN_1901198 HSPC157 BC071749 
ILMN_1671913 HTF9C NM_022727.4 
ILMN_1732296 ID3 NM_002167.2 
ILMN_1707695 IFIT1 NM_001548.3 
ILMN_1739428 IFIT2 NM_001547.4 
ILMN_1701789 IFIT3 NM_001031683.1 
ILMN_1664543 IFIT3 NM_001031683.1 
ILMN_1805750 IFITM3 NM_021034.2 
ILMN_1807423 IGF2BP3 NM_006547.2 
ILMN_2369221 IL15 NM_172174.1 
ILMN_1724181 IL15 NM_000585.2 
ILMN_1813572 IL16 NM_172217.2 
ILMN_1715603 IL23A NM_016584.2 
ILMN_1683774 IL2RA NM_000417.1 
ILMN_2342579 IL7R NM_002185.2 
ILMN_1691507 IL8RBP XR_001023.1 
ILMN_1707979 INCA NM_001007232.1 
ILMN_2054019 ISG15 NM_005101.1 
ILMN_1747934 ISYNA1 NM_016368.3 
ILMN_1733324 ITGB3 NM_000212.2 
ILMN_1668374 ITGB5 NM_002213.3 
ILMN_1661519 KIAA0408 NM_014702.3 
ILMN_1690139 KIAA0748 XM_934138.1 
ILMN_2058975 KIAA0776 NM_015323.2 
ILMN_2143155 KIF11 NM_004523.2 
ILMN_1803018 KIFC2 NM_145754.2 
ILMN_1693207 KIR2DL4 NM_002255.5 
ILMN_2229379 KIT NM_000222.1 
ILMN_2386790 KLRC3 NM_002261.2 
ILMN_1672120 KRT73 NM_175068.2 
ILMN_1660635 LACTB2 NM_016027.1 
ILMN_1683792 LAP3 NM_015907.2 
ILMN_1763537 LCTL NM_207338.2 
ILMN_1809040 LDLRAP1 NM_015627.2 
ILMN_1679185 LEF1 NM_016269.2 
ILMN_1698019 LGMN NM_001008530.1 
ILMN_1747744 LHFPL2 NM_005779.1 
ILMN_2355953 LILRB4 NM_001081438.1 
ILMN_2184708 LIN7C NM_018362.2 
ILMN_2343105 LIPT1 NM_015929.2 
ILMN_1671372 LOC137107 XM_940214.1 
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ILMN_1716468 LOC152195 NM_194289.1 
ILMN_1798557 LOC202134 XM_371783.3 
ILMN_1709326 LOC23117 XM_933864.1 
ILMN_2089752 LOC285016 NM_001002919.1 
ILMN_1915188 LOC286440 AK123807 
ILMN_1734149 LOC388122 XM_370865.4 
ILMN_1782487 LOC400759 NR_003133.1 
ILMN_1761281 LOC441019 XM_498969.2 
ILMN_1719579 LOC441081 XR_017029.1 
ILMN_1707904 LOC641518 XR_017788.1 
ILMN_1657996 LOC642035 XM_936105.1 
ILMN_1690970 LOC642233 XM_942795.1 
ILMN_1678568 LOC643913 XM_931913.1 
ILMN_1701753 LOC644063 XR_016547.1 
ILMN_1710458 LOC646990 XM_929962.1 
ILMN_1672687 LOC648099 XM_937154.1 
ILMN_1689876 LOC648189 XM_937239.2 
ILMN_1682968 LOC648196 XM_937246.1 
ILMN_1711087 LOC648526 XM_937579.1 
ILMN_1804601 LOC649923 XM_939003.1 
ILMN_1664398 LOC651621 XM_940809.1 
ILMN_1733983 LOC653316 XM_933119.1 
ILMN_1813950 LOC653486 XM_927639.1 
ILMN_1719149 LOC653663 XM_371511.4 
ILMN_1652459 LOC654161 XM_944884.1 
ILMN_1692072 LOC728006 XM_001128698.1 
ILMN_1785919 LOC728229 XM_001128450.1 
ILMN_1654389 LOC728744 XM_001128342.1 
ILMN_1704014 LOC730256 XM_001134398.1 
ILMN_1728999 LOC730273 XM_001124203.1 
ILMN_1651610 LOC730525 XM_001126202.1 
ILMN_1732278 LOC730996 XM_001128017.1 
ILMN_1703102 LOC731777 XR_015950.1 
ILMN_1701441 LPAR1 NM_057159.2 
ILMN_1796335 LPCAT2 NM_017839.3 
ILMN_1813175 LPHN1 NM_014921.3 
ILMN_2128795 LRIG1 NM_015541.2 
ILMN_1718633 LRP5L NM_182492.1 
ILMN_2048591 LRRN3 NM_018334.3 
ILMN_1773650 LRRN3 NM_001099660.1 
ILMN_1795464 LTA NM_000595.2 
ILMN_1684984 MAGED2 NM_177433.1 
ILMN_1713807 MAN1C1 NM_020379.2 
ILMN_2303170 MBNL3 NM_133486.1 
ILMN_1660462 MCOLN2 NM_153259.2 
ILMN_1705685 MEIS1 NM_002398.2 
ILMN_1688775 METRNL XM_941466.2 
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ILMN_1815190 METTL1 NM_005371.4 
ILMN_1756071 MFGE8 NM_005928.1 
ILMN_1657708 MGLL NM_007283.5 
ILMN_1738589 MGLL NM_007283.5 
ILMN_1781952 MGST1 NM_020300.3 
ILMN_1864900 MIAT NR_003491.1 
ILMN_2344988 MLL5 NM_182931.2 
ILMN_1803005 MMACHC NM_015506.2 
ILMN_2399016 MMP28 NM_001032278.1 
ILMN_1717046 MOBKL2B NM_024761.3 
ILMN_2247988 MOCS1 NM_001075098.1 
ILMN_1721337 MRPS18B NM_014046.2 
ILMN_1741404 MSC NM_005098.3 
ILMN_1691156 MT1A NM_005946.2 
ILMN_2173611 MT1E NM_175617.3 
ILMN_1715401 MT1G NM_005950.1 
ILMN_1686664 MT2A NM_005953.2 
ILMN_2136089 MTE NM_175621.2 
ILMN_1756992 MUC1 NM_001044391.1 
ILMN_1680618 MYC NM_002467.3 
ILMN_1738523 MYD88 NM_002468.3 
ILMN_1688417 MYL2 NM_000432.1 
ILMN_1675062 MYL9 NM_006097.3 
ILMN_1691476 MYLK NM_053032.2 
ILMN_2364768 MYLK NM_053026.3 
ILMN_2315569 N6AMT1 NM_182749.2 
ILMN_1691264 NAT8B NM_016347.2 
ILMN_1676289 NCAM1 NM_000615.5 
ILMN_1751444 NCAPG NM_022346.3 
ILMN_2335198 NCOA1 NM_147233.2 
ILMN_2044471 NCR3 NM_147130.1 
ILMN_1677396 NDFIP2 NM_019080.1 
ILMN_1758548 NEK7 NM_133494.1 
ILMN_1758311 NET1 NM_001047160.1 
ILMN_1783276 NEXN NM_144573.3 
ILMN_1778991 NFIB NM_005596.2 
ILMN_2310896 NLRP3 NM_004895.3 
ILMN_2347592 NMB NM_021077.3 
ILMN_1657884 NME2 NM_002512.2 
ILMN_1692413 NMNAT1 NM_022787.2 
ILMN_1684210 NPAL3 NM_020448.3 
ILMN_1704206 NPSR1 NM_207172.1 
ILMN_1661777 NR3C2 NM_000901.2 
ILMN_2210934 NR3C2 NM_000901.1 
ILMN_1705686 NRGN NM_006176.1 
ILMN_1769734 NT5C3 NM_001002010.1 
ILMN_2410826 OAS1 NM_001032409.1 
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ILMN_1745397 OAS3 NM_006187.2 
ILMN_1681721 OASL NM_003733.2 
ILMN_1674811 OASL NM_198213.1 
ILMN_2382121 OCRL NM_001587.3 
ILMN_1671288 ODF2 NM_002540.3 
ILMN_1742025 OLFM1 NM_014279.4 
ILMN_2045975 ORMDL1 NM_016467.3 
ILMN_1765061 OXER1 NM_148962.4 
ILMN_2342835 P2RY14 NM_014879.3 
ILMN_1723535 P2RY2 NM_176071.1 
ILMN_1718558 PARP12 NM_022750.2 
ILMN_2053527 PARP9 NM_031458.1 
ILMN_1731224 PARP9 NM_031458.1 
ILMN_1701644 PCDHGB6 NM_018926.2 
ILMN_1767934 PCSK5 NM_006200.2 
ILMN_2113535 PCYOX1 NM_016297.2 
ILMN_1810836 PDE5A NM_001083.3 
ILMN_2306540 PDE9A NM_001001567.1 
ILMN_2394305 PDGFB NM_033016.1 
ILMN_2376859 PDGFD NM_025208.4 
ILMN_1803094 PDGFD NM_033135.3 
ILMN_1684982 PDK4 NM_002612.3 
ILMN_1660232 PEX5 NM_000319.3 
ILMN_1687978 PHLDA1 NM_007350.3 
ILMN_1766264 PI16 NM_153370.2 
ILMN_1671891 PID1 NM_017933.3 
ILMN_2117323 PIK3C2B NM_002646.2 
ILMN_1687896 PIK3C3 NM_002647.2 
ILMN_2391400 PITX2 NM_153427.1 
ILMN_1720034 PKHD1 NM_138694.3 
ILMN_2406169 PKIG NM_007066.3 
ILMN_1810191 PLA2G4C NM_003706.1 
ILMN_1696270 PLAG1 NM_002655.1 
ILMN_1718852 PLCL1 NM_006226.1 
ILMN_2206953 PLCL1 NM_006226.1 
ILMN_2394250 PLEKHA1 NM_021622.3 
ILMN_1770850 PNMA1 NM_006029.4 
ILMN_1751773 POLD3 NM_006591.1 
ILMN_1690077 PPM1A NM_177951.1 
ILMN_1713846 PPM1H NM_020700.1 
ILMN_1761968 PPP1R14A NM_033256.1 
ILMN_2044226 PPP3CA NM_000944.2 
ILMN_1809818 PRCC NM_005973.4 
ILMN_1725188 PRKCI NM_002740.5 
ILMN_2334121 PRKDC NM_006904.6 
ILMN_1677509 PRR7 NM_030567.3 
ILMN_1658243 PSD3 NM_206909.2 
 203 
Illumina HT12 v3 ID Gene Symbol Genbank 
ILMN_1798233 PSMB9 NM_002800.4 
ILMN_1713058 PSTPIP2 NM_024430.2 
ILMN_2051867 PTCD2 NM_024754.3 
ILMN_1763723 PTDSS2 NM_030783.1 
ILMN_2339835 PTGS1 NM_080591.1 
ILMN_1721046 PTMS NM_002824.4 
ILMN_1744146 PTTG2 NM_006607.2 
ILMN_2346997 RAB23 NM_016277.3 
ILMN_1837428 RAB27B AF131784 
ILMN_2221006 RAD21 NM_006265.1 
ILMN_2398474 RAP1B NM_015646.4 
ILMN_2120210 RCAN2 NM_005822.2 
ILMN_1773395 RDH5 NM_002905.2 
ILMN_1751886 REC8 NM_005132.2 
ILMN_2317751 REC8 NM_005132.2 
ILMN_1757537 RGAG4 NM_001024455.2 
ILMN_1746138 RLTPR NM_001013838.1 
ILMN_1706266 RNF157 NM_052916.1 
ILMN_1792389 RNF165 NM_152470.2 
ILMN_2357777 RNF214 NM_207343.2 
ILMN_1734366 RORC NM_001001523.1 
ILMN_1771126 RORC NM_001001523.1 
ILMN_1665425 RPRM NM_019845.2 
ILMN_2411781 RYR1 NM_001042723.1 
ILMN_1740842 SALL2 NM_005407.1 
ILMN_1658821 SAMD1 NM_138352.1 
ILMN_1799467 SAMD9L NM_152703.2 
ILMN_1700896 SAP30 NM_003864.3 
ILMN_1655663 SC65 NM_006455.2 
ILMN_2340908 SCML1 NM_001037540.1 
ILMN_1701621 SCO2 NM_005138.1 
ILMN_1756439 SCRN1 NM_014766.3 
ILMN_1715991 SDPR NM_004657.4 
ILMN_1742947 SEC14L4 NM_174977.2 
ILMN_1687268 SEC14L5 NM_014692.1 
ILMN_1655595 SERPINE2 NM_006216.2 
ILMN_1670305 SERPING1 NM_001032295.1 
ILMN_2205935 SFXN1 NM_022754.4 
ILMN_1701237 SH2D1B NM_053282.4 
ILMN_1794780 SHARPIN NM_030974.2 
ILMN_2380566 SIAH1 NM_001006610.1 
ILMN_1782938 SLC16A10 NM_018593.3 
ILMN_1729691 SLC16A6 NM_004694.3 
ILMN_1752639 SLC25A24 NM_013386.3 
ILMN_1659894 SLC25A26 NM_001009938.1 
ILMN_2350801 SLC25A29 NM_001039355.1 
ILMN_1767717 SLC2A11 NM_001024939.1 
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ILMN_2067852 SLC30A1 NM_021194.2 
ILMN_2203896 SMAD7 NM_005904.2 
ILMN_2408987 SMARCD3 NM_001003802.1 
ILMN_1690262 SNAI3 NM_178310.1 
ILMN_1682354 SNORD33 NR_000020.1 
ILMN_1740180 SNX3 NM_003795.3 
ILMN_1707077 SORT1 NM_002959.4 
ILMN_1789244 SOX8 NM_014587.2 
ILMN_2367681 SPAG1 NM_003114.3 
ILMN_2381476 SPG3A NM_181598.2 
ILMN_1729987 SRC NM_198291.1 
ILMN_2328986 SREBF1 NM_004176.3 
ILMN_1726626 SSR2 XM_945427.1 
ILMN_1699887 ST14 NM_021978.2 
ILMN_1781135 STAM2 NM_005843.3 
ILMN_1777325 STAT1 NM_007315.2 
ILMN_1690105 STAT1 NM_007315.2 
ILMN_1691364 STAT1 NM_139266.1 
ILMN_2215119 SYNJ2 NM_003898.2 
ILMN_1719599 SYTL4 NM_080737.1 
ILMN_1739001 TACSTD2 NM_002353.1 
ILMN_1668351 TAF6 NM_139315.1 
ILMN_1688098 TBC1D4 NM_014832.2 
ILMN_1703891 TBC1D9 NM_015130.2 
ILMN_1726928 TCEA3 NM_003196.1 
ILMN_1676470 TCF7 NM_213648.1 
ILMN_2367141 TCF7 NM_201632.1 
ILMN_1740572 TCN2 NM_000355.2 
ILMN_1685124 TCTN1 NM_001082538.1 
ILMN_2389876 TGFB1I1 NM_015927.3 
ILMN_1686116 THBS1 NM_003246.2 
ILMN_1659610 TJP3 NM_014428.1 
ILMN_1766814 TK2 NM_004614.3 
ILMN_1674009 TKTL1 NM_012253.2 
ILMN_1814917 TLE2 NM_003260.3 
ILMN_1736585 TMED10 NM_006827.5 
ILMN_2067607 TMEM106B NM_018374.2 
ILMN_2194229 TMEM128 NM_032927.2 
ILMN_1663033 TMEM129 NM_138385.2 
ILMN_1792455 TMEM158 NM_015444.2 
ILMN_1773935 TMEM165 NM_018475.2 
ILMN_1725387 TMEM200A NM_052913.2 
ILMN_1785732 TNFAIP6 NM_007115.2 
ILMN_2299661 TNFRSF25 NM_001039664.1 
ILMN_1765109 TNFRSF25 NM_148973.1 
ILMN_2399190 TNFSF13 NM_172087.1 
ILMN_1784264 TNFSF13 NM_172088.1 
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ILMN_2168933 TNIP2 NM_024309.2 
ILMN_1653180 TPM4 NM_003290.1 
ILMN_1843100 TRA AY375451 
ILMN_1690783 TREML1 NM_178174.2 
ILMN_1770865 TRIM46 NM_025058.3 
ILMN_1719254 TRIM9 NM_015163.4 
ILMN_2352380 TRPM2 NM_001001188.3 
ILMN_1787567 TSC22D1 NM_006022.2 
ILMN_1692177 TSC22D1 NM_006022.2 
ILMN_1729453 TSPAN9 NM_006675.3 
ILMN_1710280 TUBB1 NM_030773.2 
ILMN_1741143 TXK NM_003328.2 
ILMN_1670764 USP25 NM_013396.3 
ILMN_1809467 VAMP5 NM_006634.2 
ILMN_1687301 VCAN NM_004385.2 
ILMN_1795429 VCL NM_014000.2 
ILMN_2413527 VCL NM_003373.3 
ILMN_1727271 WARS NM_173701.1 
ILMN_2337655 WARS NM_004184.3 
ILMN_1805863 WDR81 NM_152348.1 
ILMN_1734544 WTAP NM_004906.3 
ILMN_1742618 XAF1 NM_199139.1 
ILMN_2188374 XPOT NM_007235.3 
ILMN_1743456 ZCCHC14 NM_015144.2 
ILMN_1663858 ZNF286A NM_020652.1 
ILMN_1901934 ZNF33B BI258188 
ILMN_1658094 ZNF365 NM_014951.2 
ILMN_1654946 ZSCAN18 NM_023926.3 
ILMN_1789410 ZSCAN21 NM_145914.2 
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ILMN_2094875 ABCB1 NM_000927.3 
ILMN_1812070 ABCB1 NM_000927.3 
ILMN_1670282 AIRE NM_000658.1 
ILMN_1687757 AKR1C4 NM_001818.2 
ILMN_1799848 ANKRD22 NM_144590.2 
ILMN_2132599 ANKRD22 NM_144590.1 
ILMN_2184064 ARRDC4 NM_183376.1 
ILMN_1749081 AUTS2 NM_015570.1 
ILMN_1669323 BACE2 NM_138992.1 
ILMN_1802708 BTN3A1 NM_007048.4 
ILMN_1796409 C1QB NM_000491.3 
ILMN_1722158 CASP5 NM_004347.1 
ILMN_2228845 CCL28 NM_148672.2 
ILMN_1732831 CHST7 NM_019886.2 
ILMN_1711514 COCH NM_004086.1 
ILMN_2387224 CTSE NM_148964.1 
ILMN_1745256 CXXC5 NM_016463.5 
ILMN_1772627 D4S234E NM_001040101.1 
ILMN_1805696 DFFA NM_213566.1 
ILMN_1727150 DHRS9 NM_199204.1 
ILMN_1892638 DKFZP564C152 AL049980 
ILMN_2049184 DNASE1L3 NM_004944.2 
ILMN_1737965 ELOVL4 NM_022726.2 
ILMN_2388547 EPSTI1 NM_033255.2 
ILMN_1788416 FAM108C1 NM_021214.1 
ILMN_1808132 FAS NM_152872.1 
ILMN_2176063 FCGR1A NM_000566.2 
ILMN_2391051 FCGR1B NM_001004340.1 
ILMN_2261600 FCGR1B NM_001017986.1 
ILMN_1810289 FER1L3 NM_133337.1 
ILMN_2148785 GBP1 NM_002053.1 
ILMN_1701114 GBP1 NM_002053.1 
ILMN_2114568 GBP5 NM_052942.2 
ILMN_1725471 GK NM_000167.3 
ILMN_1851599 HS.130245 BX110640 
ILMN_1915777 HS.202313 BQ189294 
ILMN_1914343 HS.211821 BX090817 
ILMN_1910908 HS.72010 BG205162 
ILMN_1654566 HSPA1L NM_005527.3 
ILMN_1707695 IFIT1 NM_001548.3 
ILMN_1701789 IFIT3 NM_001031683.1 
ILMN_1664543 IFIT3 NM_001031683.1 
ILMN_1805750 IFITM3 NM_021034.2 
ILMN_1707979 INCA NM_001007232.1 
ILMN_1690139 KIAA0748 XM_934138.1 
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ILMN_1709326 LOC23117 XM_933864.1 
ILMN_2089752 LOC285016 NM_001002919.1 
ILMN_1782487 LOC400759 NR_003133.1 
ILMN_1804601 LOC649923 XM_939003.1 
ILMN_1652459 LOC654161 XM_944884.1 
ILMN_1654389 LOC728744 XM_001128342.1 
ILMN_1676289 NCAM1 NM_000615.5 
ILMN_1657884 NME2 NM_002512.2 
ILMN_2342835 P2RY14 NM_014879.3 
ILMN_1718558 PARP12 NM_022750.2 
ILMN_1731224 PARP9 NM_031458.1 
ILMN_2053527 PARP9 NM_031458.1 
ILMN_1767934 PCSK5 NM_006200.2 
ILMN_2206953 PLCL1 NM_006226.1 
ILMN_2394250 PLEKHA1 NM_021622.3 
ILMN_1658243 PSD3 NM_206909.2 
ILMN_2120210 RCAN2 NM_005822.2 
ILMN_1751886 REC8 NM_005132.2 
ILMN_2317751 REC8 NM_005132.2 
ILMN_1792389 RNF165 NM_152470.2 
ILMN_1734366 RORC NM_001001523.1 
ILMN_1771126 RORC NM_001001523.1 
ILMN_1799467 SAMD9L NM_152703.2 
ILMN_1701621 SCO2 NM_005138.1 
ILMN_1701237 SH2D1B NM_053282.4 
ILMN_2203896 SMAD7 NM_005904.2 
ILMN_1690262 SNAI3 NM_178310.1 
ILMN_1691364 STAT1 NM_139266.1 
ILMN_1690105 STAT1 NM_007315.2 
ILMN_1668351 TAF6 NM_139315.1 
ILMN_1674009 TKTL1 NM_012253.2 
ILMN_2194229 TMEM128 NM_032927.2 
ILMN_1725387 TMEM200A NM_052913.2 
ILMN_1727271 WARS NM_173701.1 
ILMN_2337655 WARS NM_004184.3 
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Tattermusch, S., Skinner, J.A., Chaussabel, D., Banchereau, J., Berry, M.P., MacNab, F.W., 
O’Garra, A., Taylor, G.P., Bangham, C.R.M. (2011) Systems biology approaches reveal a 
specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8: 
e1002480 
 
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that persists lifelong in the host. 
In ,4% of infected people, HTLV-1 causes a chronic disabling neuroinflammatory disease 
known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The 
pathogenesis of HAM/TSP is unknown and treatment remains ineffective. We used gene 
expression microarrays followed by flow cytometric and functional assays to investigate 
global changes in blood transcriptional profiles of HTLV-1-infected and seronegative 
individuals. We found that perturbations of the p53 signaling pathway were a hallmark of 
HTLV-1 infection. In contrast, a subset of interferon (IFN)-stimulated genes was over-
expressed in patients with HAM/TSP but not in asymptomatic HTLV-1 carriers or patients 
with the clinically similar disease multiple sclerosis. The IFN-inducible signature was present 
in all circulating leukocytes and its intensity correlated with the clinical severity of 
HAM/TSP. Leukocytes from patients with HAM/TSP were primed to respond strongly to 
stimulation with exogenous IFN. However, while type I IFN suppressed expression of the 
HTLV-1 structural protein Gag it failed to suppress the highly immunogenic viral 
transcriptional transactivator Tax. We conclude that over-expression of a subset of IFN- 
stimulated genes in chronic HTLV-1 infection does not constitute an efficient host response 
but instead contributes to the development of HAM/TSP. 
 
